

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
12 August 2004 (12.08.2004)

PCT

(10) International Publication Number  
**WO 2004/067707 A3**

(51) International Patent Classification<sup>7</sup>: **C12N 15/00**,  
15/63, C12P 21/00, A01K 67/027

70810 (US). **FIORETTI, William, C.** [US/US]; 2225 Lak-  
eridge Road Drive, Grapevine, TX 76051 (US). **CADD,**  
**Gary, G.** [US/US]; 501 Turner Road, Apartment 1111,  
Grapevine, TX 76051 (US).

(21) International Application Number:  
PCT/US2003/041335

(74) Agent: **PRATT, John, S.**; Kilpatrick Stockton LLP, Suite  
2800, 1100 Peachtree Street, Atlanta, GA 30309 (US).

(22) International Filing Date:  
24 December 2003 (24.12.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,  
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,  
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/441,377 21 January 2003 (21.01.2003) US  
60/441,381 21 January 2003 (21.01.2003) US  
60/441,392 21 January 2003 (21.01.2003) US  
60/441,405 21 January 2003 (21.01.2003) US  
60/441,447 21 January 2003 (21.01.2003) US  
60/441,502 21 January 2003 (21.01.2003) US  
10/609,019 26 June 2003 (26.06.2003) US

(84) Designated States (*regional*): ARIPO patent (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*): **TRANS-**  
**GENRES, LLC** [US/US]; 1750 Valley View Lane, Suite  
100, Dallas, TX 75243 (US). **THE BOARD OF SUPER-**  
**VISORS OF LOUISIANA STATE UNIVERSITY AND**  
**AGRICULTURAL AND MECHANICAL COLLEGE**  
[US/US]; P.O. Box 25055, Baton Rouge, LA 70894 (US).

Published:  
— with international search report

(88) Date of publication of the international search report:  
27 January 2005

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **COOPER, Richard,**  
**K.** [US/US]; 111 Pecan Meadow Drive, Baton Rouge, LA

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: ADMINISTRATION OF TRANSPOSON-BASED VECTORS TO REPRODUCTIVE ORGANS

(57) Abstract: Methods and compositions for the administration of transposon-based vectors to the reproductive organs of animals and the creation of transgenic animals. Preferred methods involve administration of the transposon-based vectors to the lumen of the oviduct of an avian, expression of a vector derived transgene in the avian, and deposition of the resultant polypeptide in an egg. This invention allows for large amounts of protein to be deposited in the egg.



WO 2004/067707 A3

5

1

10           **ADMINISTRATION OF TRANSPOSON-BASED VECTORS TO**  
                  **REPRODUCTIVE ORGANS**

                  The U.S. Government has certain rights in this invention. The development of  
this invention was partially funded by the United States Government under a HATCH  
grant from the United States Department of Agriculture, partially funded by the  
15   United States Government with Formula 1433 funds from the United States  
Department of Agriculture and partially funded by the United States Government  
under contract DAAD 19-02016 awarded by the Army.

                  FIELD OF THE INVENTION

20           The present invention relates generally to administration of a transposon-based  
vector to the reproductive tract in an animal. The reproductive tract includes an  
ovary, ova within an ovary, and an oviduct. Such administration results in  
incorporation of a gene of interest contained in the vector in the ovary, the oviduct or  
an ovum of the animal. In some embodiments, the present invention further includes  
25   production of a protein encoded by the gene in an egg produced by the animal.

                  BACKGROUND OF THE INVENTION

                  Transgenic animals are desirable for a variety of reasons, including their  
potential as biological factories to produce desired molecules for pharmaceutical,  
30   diagnostic and industrial uses. This potential is attractive to the industry due to the  
inadequate capacity in facilities used for recombinant production of desired molecules  
and the increasing demand by the pharmaceutical industry for use of these facilities.  
Numerous attempts to produce transgenic animals have met several problems,  
including low rates of gene incorporation and unstable gene incorporation.  
35   Accordingly, improved gene technologies are needed for the development of  
transgenic animals for the production of desired molecules.

Improved gene delivery technologies are also needed for the treatment of disease in animals and humans. Many diseases and conditions can be treated with gene-delivery technologies, which provide a gene of interest to a patient suffering from the disease or the condition. An example of such disease is Type 1 diabetes.

5 Type 1 diabetes is an autoimmune disease that ultimately results in destruction of the insulin producing  $\beta$ -cells in the pancreas. Although patients with Type 1 diabetes may be treated adequately with insulin injections or insulin pumps, these therapies are only partially effective. Insulin replacement, such as via insulin injection or pump administration, cannot fully reverse the defect in the vascular endothelium found in

10 the hyperglycemic state (Pieper et al., 1996. Diabetes Res. Clin. Pract. Suppl. S157-S162). In addition, hyper- and hypoglycemia occurs frequently despite intensive home blood glucose monitoring. Finally, careful dietary constraints are needed to maintain an adequate ratio of calories consumed. This often causes major psychosocial stress for many diabetic patients. Development of gene therapies

15 providing delivery of the insulin gene into the pancreas of diabetic patients could overcome many of these problems and result in improved life expectancy and quality of life.

Several of the prior art gene delivery technologies employed viruses that are associated with potentially undesirable side effects and safety concerns. The majority

20 of current gene-delivery technologies useful for gene therapy rely on virus-based delivery vectors, such as adeno and adeno-associated viruses, retroviruses, and other viruses, which have been attenuated to no longer replicate. (Kay, M.A., et al. 2001. Nature Medicine 7:33-40).

There are multiple problems associated with the use of viral vectors. Firstly,

25 they are not tissue-specific. In fact, a gene therapy trial using adenovirus was recently halted because the vector was present in the patient's sperm (Gene trial to proceed despite fears that therapy could change child's genetic makeup. The New York Times, December 23, 2001). Secondly, viral vectors are likely to be transiently incorporated, which necessitates re-treating a patient at specified time intervals. (Kay, M.A., et al. 2001. Nature Medicine 7:33-40). Thirdly, there is a concern that a viral-

30 based vector could revert to its virulent form and cause disease. Fourthly, viral-based vectors require a dividing cell for stable integration. Fifthly, viral-based vectors indiscriminately integrate into various cells, which can result in undesirable germline integration. Sixthly, the required high titers needed to achieve the desired effect have

35 resulted in the death of one patient and they are believed to be responsible for induction of cancer in a separate study. (Science, News of the Week, October 4, 2002).

Accordingly, what is needed is a new method to produce transgenic animals and humans with stably incorporated genes, in which the vector containing those genes does not cause disease or other unwanted side effects. There is also a need for DNA constructs that would be stably incorporated into the tissues and cells of animals and humans, including cells in the resting state that are not replicating. There is a further recognized need in the art for DNA constructs capable of delivering genes to specific tissues and cells of animals and humans.

When incorporating a gene of interest into an animal for the production of a desired protein or when incorporating a gene of interest in an animal or human for the treatment of a disease, it is often desirable to selectively activate incorporated genes using inducible promoters. These inducible promoters are regulated by substances either produced or recognized by the transcription control elements within the cell in which the gene is incorporated. In many instances, control of gene expression is desired in transgenic animals or humans so that incorporated genes are selectively activated at desired times and/or under the influence of specific substances. Accordingly, what is needed is a means to selectively activate genes introduced into the genome of cells of a transgenic animal or human. This can be taken a step further to cause incorporation to be tissue-specific, which prevents widespread gene incorporation throughout a patient's body (animal or human). This decreases the amount of DNA needed for a treatment, decreases the chance of incorporation in gametes, and targets gene delivery, incorporation, and expression to the desired tissue where the gene is needed to function. What is also needed is a rapid expression method for rapidly producing a protein or peptide of interest in eggs and milk of transgenic animals.

## SUMMARY OF THE INVENTION

The present invention addresses the problems described above by providing new, effective and efficient compositions for producing transgenic animals and for treating disease in animals or humans. Transgenic animals include all egg-laying animals and milk-producing animals. Transgenic animals further include but are not limited to avians, fish, amphibians, reptiles, insects, mammals and humans. In another preferred embodiment, the animal is a milk-producing animal, including but not limited to bovine, porcine, ovine and equine animals. In a preferred embodiment, the animal is an avian animal. In another preferred embodiment, the animal is a mammal. Animals are made transgenic through administration of a composition comprising a transposon-based vector designed for incorporation of a gene of interest for production of a desired protein, together with an acceptable carrier. The



compositions of the present invention are introduced into the reproductive system of an animal. The compositions of the present invention are administered to a reproductive organ including, but not limited to, an oviduct, an ovary, or into the duct system of the mammary gland. The compositions of the present invention are may be  
5 administered to a reproductive organ of an animal through the cloaca. The compositions of the present invention may be directly administered to a reproductive organ or can be administered to an artery leading to the reproductive organ. In a preferred embodiment, the compositions of the present invention are introduced into the the reproductive system of an avian animal. In another preferred embodiment, the  
10 compositions of the present invention are introduced into the the intramammary duct system of a mammal. A transfection reagent is optionally added to the composition before administration.

The transposon-based vectors of the present invention include a transposase, operably-linked to a first promoter, and a coding sequence for a protein or peptide of  
15 interest operably-linked to a second promoter, wherein the coding sequence for the protein or peptide of interest and its operably-linked promoter are flanked by transposase insertion sequences recognized by the transposase. The transposon-based vector also includes the following characteristics: a) one or more modified Kozak sequences at the 3' end of the first promoter to enhance expression of the transposase;  
20 b) modifications of the codons for the first several N-terminal amino acids of the transposase, wherein the nucleotide at the third base position of each codon is changed to an A or a T without changing the corresponding amino acid; c) addition of one or more stop codons to enhance the termination of transposase synthesis; and/or,  
d) addition of an effective polyA sequence operably-linked to the transposase to  
25 further enhance expression of the transposase gene. In some embodiments, the effective polyA sequence is an avian optimized polyA sequence.

The present invention also provides for tissue-specific incorporation and/or expression of a gene of interest. Tissue-specific incorporation of a gene of interest may be achieved by placing the transposase gene under the control of a tissue-specific  
30 promoter, whereas tissue-specific expression of a gene of interest may be achieved by placing the gene of interest under the control of a tissue-specific promoter. In some embodiments, the gene of interest is transcribed under the influence of an ovalbumin, or other oviduct specific, promoter. Linking the gene of interest to an oviduct specific

promoter in an egg-laying animal results in synthesis of a desired molecule and deposition of the desired molecule in a developing egg.

The present invention advantageously produces a high number of transgenic animals having a gene of interest stably incorporated. In some embodiments wherein  
5 the transposon-based vector is administered to the ovary, these transgenic animals successfully pass the desired gene to their progeny. Accordingly, the present invention can be used to obtain transgenic animals having the gene of interest incorporated into the germline through transfection of the ovary or the present invention can be used to obtain transgenic animals having the gene of interest  
10 incorporated into the oviduct in a tissue-specific manner. Both types of transgenic animals of the present invention produce large amounts of a desired molecule encoded by the transgene. Transgenic egg-laying animals, particularly avians, produce large amounts of a desired protein that is deposited in the egg for rapid harvest and purification.

15 Any desired gene may be incorporated into the novel transposon-based vectors of the present invention in order to synthesize a desired molecule in the transgenic animals. Proteins, peptides and nucleic acids are preferred desired molecules to be produced by the transgenic animals of the present invention. Particularly preferred proteins are antibody proteins and other immunopharmaceutical proteins.

20 This invention provides a composition useful for the production of transgenic hens capable of producing substantially high amounts of a desired protein or peptide. Entire flocks of transgenic birds may be developed very quickly in order to produce industrial amounts of desired molecules. The present invention solves the problems inherent in the inadequate capacity of fermentation facilities used for bacterial  
25 production of molecules and provides a more efficient and economical way to produce desired molecules. Accordingly, the present invention provides a means to produce large amounts of therapeutic, diagnostic and reagent molecules.

Transgenic chickens are excellent in terms of convenience and efficiency of manufacturing molecules such as proteins and peptides. Starting with a single  
30 transgenic rooster, thousands of transgenic offspring can be produced within a year. (In principle, up to forty million offspring could be produced in just three generations). Each transgenic female is expected to lay at least 250 eggs/year, each potentially containing hundreds of milligrams of the selected protein. Flocks of chickens numbering in the hundreds of thousands are readily handled through

established commercial systems. The technologies for obtaining eggs and fractionating them are also well known and widely accepted. Thus, for each therapeutic, diagnostic, or other protein of interest, large amounts of a substantially pure material can be produced at relatively low incremental cost.

5 A wide range of recombinant peptides and proteins can be produced in transgenic egg-laying animals. Enzymes, hormones, antibodies, growth factors, serum proteins, commodity proteins, biological response modifiers, peptides and designed proteins may all be made through practice of the present invention. For example, rough estimates suggest that it is possible to produce in bulk growth  
10 hormone, insulin, or Factor VIII, and deposit them in egg whites, for an incremental cost in the order of one dollar per gram. At such prices it is feasible to consider administering such medical agents by inhalation or even orally, instead of through injection. Even if bioavailability rates through these avenues were low, the cost of a much higher effective-dose would not be prohibitive.

15 In one embodiment, the egg-laying transgenic animal is an avian. The method of the present invention may be used in avians including Ratites, Psittaciformes, Falconiformes, Piciformes, Strigiformes, Passeriformes, Coraciformes, Ralliformes, Cuculiformes, Columbiformes, Galliformes, Anseriformes, and Herodiones. Preferably, the egg-laying transgenic animal is a poultry bird. More preferably, the  
20 bird is a chicken, turkey, duck, goose or quail. Another preferred bird is a ratite, such as, an emu, an ostrich, a rhea, or a cassowary. Other preferred birds are partridge, pheasant, kiwi, parrot, parakeet, macaw, falcon, eagle, hawk, pigeon, cockatoo, song birds, jay bird, blackbird, finch, warbler, canary, toucan, mynah, or sparrow.

Accordingly, it is an object of the present invention to provide novel  
25 transposon-based vectors.

It is another object of the present invention to provide novel transposon-based vectors that encode for the production of desired proteins or peptides in cells.

It is an object of the present invention to produce transgenic animals through intraoviduct or intraovarian administration of a transposon-based vector.

30 Another object of the present invention is to produce transgenic animals through intraoviduct or intraovarian administration of a transposon-based vector, wherein the transgenic animals produce desired proteins or peptides.

It is further an object of the present invention to provide a method to produce transgenic animals through intraovarian administration of a transposon-based vector that are capable of producing transgenic progeny.

Yet another object of the present invention is to provide a method to produce  
5 transgenic animals through intraoviduct or intraovarian administration of a transposon-based vector that are capable of producing a desired molecule, such as a protein, peptide or nucleic acid.

Another object of the present invention is to provide a method to produce transgenic animals through intraoviduct or intraovarian administration of a  
10 transposon-based vector, wherein such administration results in modulation of endogenous gene expression.

It is yet another object of the present invention to provide a method to produce transgenic avians through intraoviduct or intraovarian administration of a transposon-based vector that are capable of producing proteins, peptides or nucleic acids.

15 It is another object of the present invention to produce transgenic animals through intraoviduct or intraovarian administration of a transposon-based vector encoding an antibody or a fragment thereof.

Still another object of the present invention is to provide a method to produce transgenic avians through intraoviduct or intraovarian administration of a transposon-  
20 based vector that are capable of producing proteins or peptides and depositing these proteins or peptides in the egg.

Another object of the present invention is to provide transgenic avians that contain a stably incorporated transgene.

Still another object of the present invention is to provide eggs containing  
25 desired proteins or peptides encoded by a transgene incorporated into the transgenic avian that produces the egg.

It is further an object of the present invention to provide a method to produce transgenic milk-producing animals through administration of a transposon-based vector that are capable of producing proteins, peptides or nucleic acids.

30 Still another object of the present invention is to provide a method to produce transgenic milk-producing animals through administration of a transposon-based vector that are capable of producing proteins or peptides and depositing these proteins or peptides in their milk.

Another object of the present invention is to provide transgenic milk-producing animals that contain a stably incorporated transgene.

Another object of the present invention is to provide transgenic milk-producing animals that are capable of producing proteins or peptides and depositing  
5 these proteins or peptides in their milk.

Yet another object of the present invention is to provide milk containing desired molecules encoded by a transgene incorporated into the transgenic milk-producing animals that produce the milk.

Still another object of the present invention is to provide milk containing  
10 desired proteins or peptides encoded by a transgene incorporated into the transgenic milk-producing animals that produce the milk.

An advantage of the present invention is that transgenic animals are produced with higher efficiencies than observed in the prior art.

Another advantage of the present invention is that these transgenic animals  
15 possess high copy numbers of the transgene.

Another advantage of the present invention is that the transgenic animals produce large amounts of desired molecules encoded by the transgene.

Still another advantage of the present invention is that desired molecules are produced by the transgenic animals much more efficiently and economically than  
20 prior art methods, thereby providing a means for large scale production of desired molecules, particularly proteins and peptides.

Yet another advantage of the present invention is that the desired proteins and peptides are produced rapidly after making animals transgenic through introduction of the vectors of the present invention.

25 These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and claims.

#### BRIEF DESCRIPTION OF THE FIGURES

30 Figure 1 depicts schematically a transposon-based vector containing a transposase operably linked to a first promoter and a gene of interest operably-linked to a second promoter, wherein the gene of interest and its operably-linked promoter are flanked by insertion sequences (IS) recognized by the transposase. "Pro"

designates a promoter. In this and subsequent figures, the size of the actual nucleotide sequence is not necessarily proportionate to the box representing that sequence.

Figure 2 depicts schematically a transposon-based vector for targeting deposition of a polypeptide in an egg white wherein Ov pro is the ovalbumin promoter, Ov protein is the ovalbumin protein and PolyA is a polyadenylation sequence. The TAG sequence includes a spacer sequence, the gp41 hairpin loop from HIV I and a protease cleavage site.

Figure 3 depicts schematically a transposon-based vector for targeting deposition of a polypeptide in an egg white wherein Ovo pro is the ovomucoid promoter and Ovo SS is the ovomucoid signal sequence. The TAG sequence includes a spacer, the gp41 hairpin loop from HIV I and a protease cleavage site.

Figure 4 depicts schematically a transposon based-vector for expression of an RNAi molecule. "Tet<sub>i</sub> pro" indicates a tetracycline inducible promoter whereas "pro" indicates the pro portion of a prepro sequence as described herein. "Ovgen" indicates approximately 60 base pairs of an ovalbumin gene, "Ovotrans" indicates approximately 60 base pairs of an ovotransferrin gene and "Ovomucin" indicates approximately 60 base pairs of an ovomucin gene.

Figure 5 is a picture of an SDS-PAGE gel wherein a pooled fraction of an isolated proinsulin fusion protein was run in lanes 4 and 6. Lanes 1 and 10 of the gel contain molecular weight standards, lanes 2 and 8 contain non-transgenic chicken egg white, and lanes 3, 5, 7 and 9 are blank.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a new, effective and efficient method of producing transgenic animals, particularly egg-laying animals and milk-producing animals, through administration of a composition comprising a transposon-based vector designed for incorporation of a gene of interest and production of a desired molecule. The transposon-based vectors are administered to a reproductive organ including, but not limited to, an oviduct, an ovary, or into the duct system of the mammary gland. The vectors may be directly administered to a reproductive organ or can be administered to an artery leading to the reproductive organ or to a lymph system proximate to the cells to be genetically altered. The vectors may be administered to a reproductive organ of an animal through the cloaca. One method of direct administration is by injection, and in one embodiment, the lumen of the

magnum of the oviduct is injected with a transposon-based vector. Another method of direct administration is by injection, and in one embodiment, the lumen of the infundibulum of the oviduct is injected with a transposon-based vector. A preferred intrarterial administration is an administration into an artery that supplies the oviduct or the ovary. In some embodiments, administration of the transposon-based vector to an oviduct or an artery that leads to the oviduct results in incorporation of the vector into the epithelial and/or secretory cells of the oviduct. In other embodiments, administration of the transposon-based vector to an ovary or an artery that leads to the ovary or a lymphatic system proximal to the ovary results in incorporation of the vector into an oocyte or a germinal disk inside the ovary.

#### Definitions

It is to be understood that as used in the specification and in the claims, "a" or "an" can mean one or more, depending upon the context in which it is used. Thus, for example, reference to "a cell" can mean that at least one cell can be utilized.

The term "antibody" is used interchangeably with the term "immunoglobulin" and is defined herein as a protein synthesized by an animal or a cell of the immune system in response to the presence of a foreign substance commonly referred to as an "antigen" or an "immunogen". The term antibody includes fragments of antibodies. Antibodies are characterized by specific affinity to a site on the antigen, wherein the site is referred to an "antigenic determinant" or an "epitope". Antigens can be naturally occurring or artificially engineered. Artificially engineered antigens include, but are not limited to, small molecules, such as small peptides, attached to haptens such as macromolecules, for example proteins, nucleic acids, or polysaccharides. Artificially designed or engineered variants of naturally occurring antibodies and artificially designed or engineered antibodies not occurring in nature are all included in the current definition. Such variants include conservatively substituted amino acids and other forms of substitution as described in the section concerning proteins and polypeptides.

As used herein, the term "egg-laying animal" includes all amniotes such as birds, turtles, lizards and monotremes. Monotremes are egg-laying mammals and include the platypus and echidna. The term "bird" or "fowl," as used herein, is defined as a member of the Aves class of animals which are characterized as warm-blooded, egg-laying vertebrates primarily adapted for flying. Avians include, without limitation, Ratites, Psittaciformes, Falconiformes, Piciformes, Strigiformes,

Passeriformes, Coraciformes, Ralliformes, Cuculiformes, Columbiformes, Galliformes, Anseriformes, and Herodiones. The term "Ratite," as used herein, is defined as a group of flightless, mostly large, running birds comprising several orders and including the emus, ostriches, kiwis, and cassowaries. The term "Psittaciformes",  
5 as used herein, includes parrots and refers to a monofamilial order of birds that exhibit zygodactylism and have a strong hooked bill. A "parrot" is defined as any member of the avian family Psittacidae (the single family of the Psittaciformes), distinguished by the short, stout, strongly hooked beak. Avians include all poultry birds, especially chickens, geese, turkeys, ducks and quail. The term "chicken" as used herein denotes  
10 chickens used for table egg production, such as egg-type chickens, chickens reared for public meat consumption, or broilers, and chickens reared for both egg and meat production ("dual-purpose" chickens). The term "chicken" also denotes chickens produced by primary breeder companies, or chickens that are the parents, grandparents, great-grandparents, etc. of those chickens reared for public table egg,  
15 meat, or table egg and meat consumption.

The term "egg" is defined herein as including a large female sex cell enclosed in a porous, calcarous or leathery shell, produced by birds and reptiles. The term "ovum" is defined as a female gamete, and is also known as an egg. Therefore, egg production in all animals other than birds and reptiles, as used herein, is defined as the  
20 production and discharge of an ovum from an ovary, or "ovulation". Accordingly, it is to be understood that the term "egg" as used herein is defined as a large female sex cell enclosed in a porous, calcarous or leathery shell, when a bird or reptile produces it, or it is an ovum when it is produced by all other animals.

The term "milk-producing animal" refers herein to mammals including, but  
25 not limited to, bovine, ovine, porcine, equine, and primate animals. Milk-producing animals include but are not limited to cows, llamas, camels, goats, reindeer, zebu, water buffalo, yak, horses, pigs, rabbits, non-human primates, and humans.

The term "gene" is defined herein to include a coding region for a protein, peptide or polypeptide.

30 The term "transgenic animal" refers to an animal having at least a portion of the transposon-based vector DNA incorporated into its DNA. While a transgenic animal includes an animal wherein the transposon-based vector DNA is incorporated into the germline DNA, a transgenic animal also includes an animal having DNA in one or more cells that contain a portion of the transposon-based vector DNA for any



period of time. In a preferred embodiment, a portion of the transposon-based vector comprises a gene of interest. More preferably, the gene of interest is incorporated into the animal's DNA for a period of at least five days, more preferably the reproductive life of the animal, and most preferably the life of the animal. In a further preferred  
5 embodiment, the animal is an avian.

The term "vector" is used interchangeably with the terms "construct", "DNA construct" and "genetic construct" to denote synthetic nucleotide sequences used for manipulation of genetic material, including but not limited to cloning, subcloning, sequencing, or introduction of exogenous genetic material into cells, tissues or  
10 organisms, such as birds. It is understood by one skilled in the art that vectors may contain synthetic DNA sequences, naturally occurring DNA sequences, or both. The vectors of the present invention are transposon-based vectors as described herein.

When referring to two nucleotide sequences, one being a regulatory sequence, the term "operably-linked" is defined herein to mean that the two sequences are  
15 associated in a manner that allows the regulatory sequence to affect expression of the other nucleotide sequence. It is not required that the operably-linked sequences be directly adjacent to one another with no intervening sequence(s).

The term "regulatory sequence" is defined herein as including promoters, enhancers and other expression control elements such as polyadenylation sequences, matrix attachment sites, insulator regions for expression of multiple genes on a single  
20 construct, ribosome entry/attachment sites, introns that are able to enhance expression, and silencers.

#### Transposon-Based Vectors

While not wanting to be bound by the following statement, it is believed that  
25 the nature of the DNA construct is an important factor in successfully producing transgenic animals. The "standard" types of plasmid and viral vectors that have previously been almost universally used for transgenic work in all species, especially avians, have low efficiencies and may constitute a major reason for the low rates of transformation previously observed. The DNA (or RNA) constructs previously used  
30 often do not integrate into the host DNA, or integrate only at low frequencies. Other factors may have also played a part, such as poor entry of the vector into target cells. The present invention provides transposon-based vectors that can be administered to an animal that overcome the prior art problems relating to low transgene integration frequencies. Two preferred transposon-based vectors of the present invention in

which a transposase, gene of interest and other polynucleotide sequences may be introduced are termed pTnMCS (SEQ ID NO:2) and pTnMod (SEQ ID NO:3).

The transposon-based vectors of the present invention produce integration frequencies an order of magnitude greater than has been achieved with previous  
5 vectors. More specifically, intratesticular injections performed with a prior art transposon-based vector (described in U.S. Patent No. 5,719,055) resulted in 41% sperm positive roosters whereas intratesticular injections performed with the novel transposon-based vectors of the present invention resulted in 77% sperm positive roosters. Actual frequencies of integration were estimated by either or both  
10 comparative strength of the PCR signal from the sperm and histological evaluation of the testes and sperm by quantitative PCR.

The transposon-based vectors of the present invention include a transposase gene operably-linked to a first promoter, and a coding sequence for a desired protein or peptide operably-linked to a second promoter, wherein the coding sequence for the  
15 desired protein or peptide and its operably-linked promoter are flanked by transposase insertion sequences recognized by the transposase. The transposon-based vector also includes one or more of the following characteristics: a) one or more modified Kozak sequences comprising ACCATG (SEQ ID NO:1) at the 3' end of the first promoter to enhance expression of the transposase; b) modifications of the codons for the first  
20 several N-terminal amino acids of the transposase, wherein the third base of each codon was changed to an A or a T without changing the corresponding amino acid; c) addition of one or more stop codons to enhance the termination of transposase synthesis; and/or, d) addition of an effective polyA sequence operably-linked to the transposase to further enhance expression of the transposase gene. The transposon-  
25 based vector may additionally or alternatively include one or more of the following Kozak sequences at the 3' end of any promoter, including the promoter operably-linked to the transposase: ACCATGG (SEQ ID NO:4), AAGATGT (SEQ ID NO:5), ACGATGA (SEQ ID NO:6), AAGATGG (SEQ ID NO:7), GACATGA (SEQ ID NO:8), ACCATGA (SEQ ID NO:9), and ACCATGA (SEQ ID NO:10), ACCATGT  
30 (SEQ ID NO:52).

Figure 1 shows a schematic representation of several components of the transposon-based vector. The present invention further includes vectors containing more than one gene of interest, wherein a second or subsequent gene of interest is operably-linked to the second promoter or to a different promoter. It is also to be

understood that the transposon-based vectors shown in the Figures are representative of the present invention and that the order of the vector elements may be different than that shown in the Figures, that the elements may be present in various orientations, and that the vectors may contain additional elements not shown in the  
5 Figures.

#### Transposases and Insertion Sequences

In a further embodiment of the present invention, the transposase found in the transposase-based vector is an altered target site (ATS) transposase and the insertion sequences are those recognized by the ATS transposase. However, the transposase  
10 located in the transposase-based vectors is not limited to a modified ATS transposase and can be derived from any transposase. Transposases known in the prior art include those found in AC7, Tn5SEQ1, Tn916, Tn951, Tn1721, Tn 2410, Tn1681, Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn9, Tn10, Tn30, Tn101, Tn903, Tn501, Tn1000 ( $\gamma\delta$ ), Tn1681, Tn2901, AC transposons, Mp transposons, Spm transposons, En transposons, Dotted  
15 transposons, Mu transposons, Ds transposons, dSpm transposons and I transposons. According to the present invention, these transposases and their regulatory sequences are modified for improved functioning as follows: a) the addition one or more modified Kozak sequences comprising ACCATG (SEQ ID NO:1) at the 3' end of the promoter operably-linked to the transposase; b) a change of the codons for the first  
20 several amino acids of the transposase, wherein the third base of each codon was changed to an A or a T without changing the corresponding amino acid; c) the addition of one or more stop codons to enhance the termination of transposase synthesis; and/or, d) the addition of an effective polyA sequence operably-linked to the transposase to further enhance expression of the transposase gene.

25 Although not wanting to be bound by the following statement, it is believed that the modifications of the first several N-terminal codons of the transposase gene increase transcription of the transposase gene, in part, by increasing strand dissociation. It is preferable that between approximately 1 and 20, more preferably 3 and 15, and most preferably between 4 and 12 of the first N-terminal codons of the  
30 transposase are modified such that the third base of each codon is changed to an A or a T without changing the encoded amino acid. In one embodiment, the first ten N-terminal codons of the transposase gene are modified in this manner. It is also preferred that the transposase contain mutations that make it less specific for preferred

insertion sites and thus increases the rate of transgene insertion as discussed in U.S. Patent No. 5,719,055.

5 In some embodiments, the transposon-based vectors are optimized for expression in a particular host by changing the methylation patterns of the vector DNA. For example, prokaryotic methylation may be reduced by using a methylation deficient organism for production of the transposon-based vector. The transposon-based vectors may also be methylated to resemble eukaryotic DNA for expression in a eukaryotic host.

10 Transposases and insertion sequences from other analogous eukaryotic transposon-based vectors that can also be modified and used are, for example, the *Drosophila* P element derived vectors disclosed in U.S. Patent No. 6,291,243; the *Drosophila* mariner element described in Sherman et al. (1998); or the sleeping beauty transposon. See also Hackett et al. (1999); D. Lampe et al., 1999. Proc. Natl. Acad. Sci. USA, 96:11428-11433; S. Fischer et al., 2001. Proc. Natl. Acad. Sci. USA, 15 98:6759-6764; L. Zagoraiou et al., 2001. Proc. Natl. Acad. Sci. USA, 98:11474-11478; and D. Berg et al. (Eds.), Mobile DNA, Amer. Soc. Microbiol. (Washington, D.C., 1989). However, it should be noted that bacterial transposon-based elements are preferred, as there is less likelihood that a eukaryotic transposase in the recipient species will recognize prokaryotic insertion sequences bracketing the transgene.

20 Many transposases recognize different insertion sequences, and therefore, it is to be understood that a transposase-based vector will contain insertion sequences recognized by the particular transposase also found in the transposase-based vector. In a preferred embodiment of the invention, the insertion sequences have been shortened to about 70 base pairs in length as compared to those found in wild-type 25 transposons that typically contain insertion sequences of well over 100 base pairs.

While the examples provided below incorporate a "cut and insert" Tn10 based vector that is destroyed following the insertion event, the present invention also encompasses the use of a "rolling replication" type transposon-based vector. Use of a rolling replication type transposon allows multiple copies of the transposon/transgene 30 to be made from a single transgene construct and the copies inserted. This type of transposon-based system thereby provides for insertion of multiple copies of a transgene into a single genome. A rolling replication type transposon-based vector may be preferred when the promoter operably-linked to gene of interest is endogenous to the host cell and present in a high copy number or highly expressed. However, use

of a rolling replication system may require tight control to limit the insertion events to non-lethal levels. Tn1, Tn2, Tn3, Tn4, Tn5, Tn9, Tn21, Tn501, Tn551, Tn951, Tn1721, Tn2410 and Tn2603 are examples of a rolling replication type transposon, although Tn5 could be both a rolling replication and a cut and insert type transposon.

5           Stop Codons and PolyA Sequences

In one embodiment, the transposon-based vector contains two stop codons operably-linked to the transposase and/or to the gene of interest. In an alternate embodiment, one stop codon of UAA or UGA is operably linked to the transposase and/or to the gene of interest.

10           As used herein an "effective polyA sequence" refers to either a synthetic or non-synthetic sequence that contains multiple and sequential nucleotides containing an adenine base (an A polynucleotide string) and that increases expression of the gene to which it is operably-linked. A polyA sequence may be operably-linked to any gene in the transposon-based vector including, but not limited to, a transposase gene and a  
15           gene of interest. A preferred polyA sequence is optimized for use in the host animal or human. In one embodiment, the polyA sequence is optimized for use in an avian species and more specifically, a chicken. An avian optimized polyA sequence generally contains a minimum of 40 base pairs, preferably between approximately 40 and several hundred base pairs, and more preferably approximately 75 base pairs that  
20           precede the A polynucleotide string and thereby separate the stop codon from the A polynucleotide string. In one embodiment of the present invention, the polyA sequence comprises a conalbumin polyA sequence as provided in SEQ ID NO:11 and as taken from GenBank accession # Y00407, base pairs 10651-11058. In another embodiment, the polyA sequence comprises a synthetic polynucleotide sequence  
25           shown in SEQ ID NO:12. In yet another embodiment, the polyA sequence comprises an avian optimized polyA sequence provided in SEQ ID NO:13. A chicken optimized polyA sequence may also have a reduced amount of CT repeats as compared to a synthetic polyA sequence.

It is a surprising discovery of the present invention that such an avian  
30           optimized poly A sequence increases expression of a polynucleotide to which it is operably-linked in an avian as compared to a non-avian optimized polyA sequence. Accordingly, the present invention includes methods of or increasing incorporation of a gene of interest wherein the gene of interest resides in a transposon-based vector containing a transposase gene and wherein the transposase gene is operably linked to

an avian optimized polyA sequence. The present invention also includes methods of increasing expression of a gene of interest in an avian that includes administering a gene of interest to the avian, wherein the gene of interest is operably-linked to an avian optimized polyA sequence. An avian optimized polyA nucleotide string is defined herein as a polynucleotide containing an A polynucleotide string and a minimum of 40 base pairs, preferably between approximately 40 and several hundred base pairs, and more preferably approximately 60 base pairs that precede the A polynucleotide string. The present invention further provides transposon-based vectors containing a gene of interest or transposase gene operably linked to an avian optimized polyA sequence.

#### Promoters and Enhancers

The first promoter operably-linked to the transposase gene and the second promoter operably-linked to the gene of interest can be a constitutive promoter or an inducible promoter. Constitutive promoters include, but are not limited to, immediate early cytomegalovirus (CMV) promoter, herpes simplex virus 1 (HSV1) immediate early promoter, SV40 promoter, lysozyme promoter, early and late CMV promoters, early and late HSV promoters,  $\beta$ -actin promoter, tubulin promoter, Rous-Sarcoma virus (RSV) promoter, and heat-shock protein (HSP) promoter. Inducible promoters include tissue-specific promoters, developmentally-regulated promoters and chemically inducible promoters. Examples of tissue-specific promoters include the glucose 6 phosphate (G6P) promoter, vitellogenin promoter, ovalbumin promoter, ovomucoid promoter, conalbumin promoter, ovotransferrin promoter, prolactin promoter, kidney uromodulin promoter, and placental lactogen promoter. In one embodiment, the vitellogenin promoter includes a polynucleotide sequence of SEQ ID NO:14. The G6P promoter sequence may be deduced from a rat G6P gene untranslated upstream region provided in GenBank accession number U57552.1. Examples of developmentally-regulated promoters include the homeobox promoters and several hormone induced promoters. Examples of chemically inducible promoters include reproductive hormone induced promoters and antibiotic inducible promoters such as the tetracycline inducible promoter and the zinc-inducible metallothionine promoter.

Other inducible promoter systems include the Lac operator repressor system inducible by IPTG (isopropyl beta-D-thiogalactoside) (Cronin, A. et al. 2001. Genes

and Development, v. 15), ecdysone-based inducible systems (Hoppe, U. C. et al. 2000. *Mol. Ther.* 1:159-164); estrogen-based inducible systems (Brasemann, S. et al. 1993. *Proc. Natl. Acad. Sci.* 90:1657-1661); progesterone-based inducible systems using a chimeric regulator, GLVP, which is a hybrid protein consisting of the GAL4  
5 binding domain and the herpes simplex virus transcriptional activation domain, VP16, and a truncated form of the human progesterone receptor that retains the ability to bind ligand and can be turned on by RU486 (Wang, et al. 1994. *Proc. Natl. Acad. Sci.* 91:8180-8184); CID-based inducible systems using chemical inducers of dimerization (CIDs) to regulate gene expression, such as a system wherein rapamycin induces  
10 dimerization of the cellular proteins FKBP12 and FRAP (Belshaw, P. J. et al. 1996. *J. Chem. Biol.* 3:731-738; Fan, L. et al. 1999. *Hum. Gene Ther.* 10:2273-2285; Shariat, S.F. et al. 2001. *Cancer Res.* 61:2562-2571; Spencer, D.M. 1996. *Curr. Biol.* 6:839-847). Chemical substances that activate the chemically inducible promoters can be administered to the animal containing the transgene of interest via any method known  
15 to those of skill in the art.

Other examples of cell or tissue-specific and constitutive promoters include but are not limited to smooth-muscle SM22 promoter, including chimeric SM22alpha/telokin promoters (Hoggatt A.M. et al., 2002. *Circ Res.* 91(12):1151-9); ubiquitin C promoter (*Biochim Biophys Acta*, 2003. Jan. 3;1625(1):52-63); Hsf2  
20 promoter; murine COMP (cartilage oligomeric matrix protein) promoter; early B cell-specific mb-1 promoter (Sigvardsson M., et al., 2002. *Mol. Cell Biol.* 22(24):8539-51); prostate specific antigen (PSA) promoter (Yoshimura I. et al., 2002, *J. Urol.* 168(6):2659-64); exorh promoter and pineal expression-promoting element (Asaoka Y., et al., 2002. *Proc. Natl. Acad. Sci.* 99(24):15456-61); neural and liver ceramidase  
25 gene promoters (Okino N. et al., 2002. *Biochem. Biophys. Res. Commun.* 299(1):160-6); PSP94 gene promoter/enhancer (Gabril M.Y. et al., 2002. *Gene Ther.* 9(23):1589-99); promoter of the human FAT/CD36 gene (Kuriki C., et al., 2002. *Biol. Pharm. Bull.* 25(11):1476-8); VL30 promoter (Staplin W.R. et al., 2002. *Blood* October 24, 2002); and, IL-10 promoter (Brenner S., et al., 2002. *J. Biol. Chem.*  
30 December 18, 2002).

Examples of avian promoters include, but are not limited to, promoters controlling expression of egg white proteins, such as ovalbumin, ovotransferrin (conalbumin), ovomucoid, lysozyme, ovomucin, g2 ovoglobulin, g3 ovoglobulin, ovoflavoprotein, ovostatin (ovomacroglobin), cystatin, avidin, thiamine-binding

protein, glutamyl aminopeptidase minor glycoprotein 1, minor glycoprotein 2; and promoters controlling expression of egg-yolk proteins, such as vitellogenin, very low-density lipoproteins, low density lipoprotein, cobalamin-binding protein, riboflavin-binding protein, biotin-binding protein (Awade, 1996. Z. Lebensm. Unters. Forsch. 5 202:1-14). An advantage of using the vitellogenin promoter is that it is active during the egg-laying stage of an animal's life-cycle, which allows for the production of the protein of interest to be temporally connected to the import of the protein of interest into the egg yolk when the protein of interest is equipped with an appropriate targeting sequence. In some embodiments, the avian promoter is an oviduct-specific 10 promoter. As used herein, the term "oviduct-specific promoter" includes, but is not limited to, ovalbumin; ovotransferrin (conalbumin); ovomucoid; 01, 02, 03, 04 or 05 avidin; ovomucin; g2 ovoglobulin; g3 ovoglobulin; ovo flavoprotein; and ovostatin (ovomacroglobin) promoters.

When germline transformation occurs via intraovarian administration, liver-specific 15 promoters may be operably-linked to the gene of interest to achieve liver-specific expression of the transgene. Liver-specific promoters of the present invention include, but are not limited to, the following promoters, vitellogenin promoter, G6P promoter, cholesterol-7- $\alpha$ -hydroxylase (CYP7A) promoter, phenylalanine hydroxylase (PAH) promoter, protein C gene promoter, insulin-like 20 growth factor I (IGF-I) promoter, bilirubin UDP-glucuronosyltransferase promoter, aldolase B promoter, furin promoter, metallothioneine promoter, albumin promoter, and insulin promoter.

Also included in the present invention are promoters that can be used to target expression of a protein of interest into the milk of a milk-producing animal including, 25 but not limited to,  $\beta$  lactoglobulin promoter, whey acidic protein promoter, lactalbumin promoter and casein promoter.

When germline transformation occurs via intraovarian administration, immune system-specific promoters may be operably-linked to the gene of interest to achieve immune system-specific expression of the transgene. Accordingly, promoters 30 associated with cells of the immune system may also be used. Acute phase promoters such as interleukin (IL)-1 and IL-2 may be employed. Promoters for heavy and light chain Ig may also be employed. The promoters of the T cell receptor components CD4 and CD8, B cell promoters and the promoters of CR2 (complement receptor type



2) may also be employed. Immune system promoters are preferably used when the desired protein is an antibody protein.

Also included in this invention are modified promoters/enhancers wherein elements of a single promoter are duplicated, modified, or otherwise changed. In one embodiment, steroid hormone-binding domains of the ovalbumin promoter are moved from about -6.5 kb to within approximately the first 1000 base pairs of the gene of interest. Modifying an existing promoter with promoter/enhancer elements not found naturally in the promoter, as well as building an entirely synthetic promoter, or drawing promoter/enhancer elements from various genes together on a non-natural backbone, are all encompassed by the current invention.

Accordingly, it is to be understood that the promoters contained within the transposon-based vectors of the present invention may be entire promoter sequences or fragments of promoter sequences. For example, in one embodiment, the promoter operably linked to a gene of interest is an approximately 900 base pair fragment of a chicken ovalbumin promoter (SEQ ID NO:15). The constitutive and inducible promoters contained within the transposon-based vectors may also be modified by the addition of one or more modified Kozak sequences of ACCATG (SEQ ID NO:1).

As indicated above, the present invention includes transposon-based vectors containing one or more enhancers. These enhancers may or may not be operably-linked to their native promoter and may be located at any distance from their operably-linked promoter. A promoter operably-linked to an enhancer and a promoter modified to eliminate repressive regulatory effects are referred to herein as an "enhanced promoter." The enhancers contained within the transposon-based vectors are preferably enhancers found in birds, and more preferably, an ovalbumin enhancer, but are not limited to these types of enhancers. In one embodiment, an approximately 675 base pair enhancer element of an ovalbumin promoter is cloned upstream of an ovalbumin promoter with 300 base pairs of spacer DNA separating the enhancer and promoter. In one embodiment, the enhancer used as a part of the present invention comprises base pairs 1-675 of a chicken ovalbumin enhancer from GenBank accession #S82527.1. The polynucleotide sequence of this enhancer is provided in SEQ ID NO:16.

Also included in some of the transposon-based vectors of the present invention are cap sites and fragments of cap sites. In one embodiment, approximately 50 base pairs of a 5' untranslated region wherein the capsite residues are added on the 3' end of

an enhanced promoter or promoter. An exemplary 5' untranslated region is provided in SEQ ID NO:17. A putative cap-site residing in this 5' untranslated region preferably comprises the polynucleotide sequence provided in SEQ ID NO:18.

In one embodiment of the present invention, the first promoter operably-linked to the transposase gene is a constitutive promoter and the second promoter operably-linked to the gene of interest is a tissue-specific promoter. In the second embodiment, use of the first constitutive promoter allows for constitutive activation of the transposase gene and incorporation of the gene of interest into virtually all cell types, including the germline of the recipient animal. Although the gene of interest is incorporated into the germline generally, the gene of interest may only be expressed in a tissue-specific manner. A transposon-based vector having a constitutive promoter operably-linked to the transposase gene can be administered by any route, and in one embodiment, the vector is administered to an ovary, to an artery leading to the ovary or to a lymphatic system or fluid proximal to the ovary.

It should be noted that cell- or tissue-specific expression as described herein does not require a complete absence of expression in cells or tissues other than the preferred cell or tissue. Instead, "cell-specific" or "tissue-specific" expression refers to a majority of the expression of a particular gene of interest in the preferred cell or tissue, respectively.

When incorporation of the gene of interest into the germline is not preferred, the first promoter operably-linked to the transposase gene can be a tissue-specific promoter. For example, transfection of a transposon-based vector containing a transposase gene operably-linked to an oviduct specific promoter such as the ovalbumin promoter provides for activation of the transposase gene and incorporation of the gene of interest in the cells of the oviduct but not into the germline and other cells generally. In this embodiment, the second promoter operably-linked to the gene of interest can be a constitutive promoter or an inducible promoter. In a preferred embodiment, both the first promoter and the second promoter are an ovalbumin promoter. In embodiments wherein tissue-specific expression or incorporation is desired, it is preferred that the transposon-based vector is administered directly to the tissue of interest, to an artery leading to the tissue of interest or to fluids surrounding the tissue of interest. In a preferred embodiment, the tissue of interest is the oviduct and administration is achieved by direct injection into the oviduct or an artery leading to the oviduct. In a further preferred embodiment, administration is achieved by

direct injection into the lumen of the magnum or the infundibulum of the oviduct. Indirect administration to the oviduct may occur through the cloaca.

Accordingly, cell specific promoters may be used to enhance transcription in selected tissues. In birds, for example, promoters that are found in cells of the fallopian tube, such as ovalbumin, conalbumin, ovomucoid and/or lysozyme, are used in the vectors to ensure transcription of the gene of interest in the epithelial cells and tubular gland cells of the fallopian tube, leading to synthesis of the desired protein encoded by the gene and deposition into the egg white. In mammals, promoters specific for the epithelial cells of the alveoli of the mammary gland, such as prolactin, insulin, beta lactoglobulin, whey acidic protein, lactalbumin, casein, and/or placental lactogen, are used in the design of vectors used for transfection of these cells for the production of desired proteins for deposition into the milk. In liver cells, the G6P promoter may be employed to drive transcription of the gene of interest for protein production. Proteins made in the liver of birds may be delivered to the egg yolk.

In order to achieve higher or more efficient expression of the transposase gene, the promoter and other regulatory sequences operably-linked to the transposase gene may be those derived from the host. These host specific regulatory sequences can be tissue specific as described above or can be of a constitutive nature. For example, an avian actin promoter and its associated polyA sequence can be operably-linked to a transposase in a transposase-based vector for transfection into an avian. Examples of other host specific promoters that could be operably-linked to the transposase include the myosin and DNA or RNA polymerase promoters.

#### Directing Sequences

In some embodiments of the present invention, the gene of interest is operably-linked to a directing sequence or a sequence that provides proper conformation to the desired protein encoded by the gene of interest. As used herein, the term "directing sequence" refers to both signal sequences and targeting sequences. An egg directing sequence includes, but is not limited to, an ovomucoid signal sequence, an ovalbumin signal sequence, a cecropin pre pro signal sequence, and a vitellogenin targeting sequence. The term "signal sequence" refers to an amino acid sequence, or the polynucleotide sequence that encodes the amino acid sequence, that directs the protein to which it is linked to the endoplasmic reticulum in a eukaryote, and more preferably the translocational pores in the endoplasmic reticulum, or the plasma membrane in a prokaryote, or mitochondria, such as for the purpose of gene

therapy for mitochondrial diseases. Signal and targeting sequences can be used to direct a desired protein into, for example, the milk, when the transposon-based vectors are administered to a milk-producing animal.

Signal sequences can also be used to direct a desired protein into, for example, a secretory pathway for incorporation into the egg yolk or the egg white, when the transposon-based vectors are administered to a bird or other egg-laying animal. One example of such a transposon-based vector is provided in Figure 3 wherein the gene of interest is operably linked to the ovomucoid signal sequence. The present invention also includes a gene of interest operably-linked to a second gene containing a signal sequence. An example of such an embodiment is shown in Figure 2 wherein the gene of interest is operably-linked to the ovalbumin gene that contains an ovalbumin signal sequence. Other signal sequences that can be included in the transposon-based vectors include, but are not limited to the ovotransferrin and lysozyme signal sequences. In one embodiment, the signal sequence is an ovalbumin signal sequence including a sequence shown in SEQ ID NO:19. In another embodiment, the signal sequence is a modified ovalbumin signal sequence including a sequence shown in SEQ ID NO:20 or SEQ ID NO:21.

As also used herein, the term "targeting sequence" refers to an amino acid sequence, or the polynucleotide sequence encoding the amino acid sequence, which amino acid sequence is recognized by a receptor located on the exterior of a cell. Binding of the receptor to the targeting sequence results in uptake of the protein or peptide operably-linked to the targeting sequence by the cell. One example of a targeting sequence is a vitellogenin targeting sequence that is recognized by a vitellogenin receptor (or the low density lipoprotein receptor) on the exterior of an oocyte. In one embodiment, the vitellogenin targeting sequence includes the polynucleotide sequence of SEQ ID NO:22. In another embodiment, the vitellogenin targeting sequence includes all or part of the vitellogenin gene. Other targeting sequences include VLDL and Apo E, which are also capable of binding the vitellogenin receptor. Since the ApoE protein is not endogenously expressed in birds, its presence may be used advantageously to identify birds carrying the transposon-based vectors of the present invention.

#### Genes of Interest Encoding Desired Proteins

A gene of interest selected for stable incorporation is designed to encode any desired protein or peptide or to regulate any cellular response. In some embodiments,

the desired proteins or peptides are deposited in an egg or in milk. It is to be understood that the present invention encompasses transposon-based vectors containing multiple genes of interest. The multiple genes of interest may each be operably-linked to a separate promoter and other regulatory sequence(s) or may all be operably-linked to the same promoter and other regulatory sequences(s). In one embodiment, multiple gene of interest are linked to a single promoter and other regulatory sequence(s) and each gene of interest is separated by a cleavage site or a pro portion of a signal sequence. A gene of interest may contain modifications of the codons for the first several N-terminal amino acids of the gene of interest, wherein the third base of each codon is changed to an A or a T without changing the corresponding amino acid.

Protein and peptide hormones are a preferred class of proteins in the present invention. Such protein and peptide hormones are synthesized throughout the endocrine system and include, but are not limited to, hypothalamic hormones and hypophysiotropic hormones, anterior, intermediate and posterior pituitary hormones, pancreatic islet hormones, hormones made in the gastrointestinal system, renal hormones, thymic hormones, parathyroid hormones, adrenal cortical and medullary hormones. Specifically, hormones that can be produced using the present invention include, but are not limited to, chorionic gonadotropin, corticotropin, erythropoietin, glucagons, IGF-1, oxytocin, platelet-derived growth factor, calcitonin, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, insulin, gonadotropin-releasing hormone and its analogs, vasopressin, octreotide, somatostatin, prolactin, adrenocorticotrophic hormone, antidiuretic hormone, thyrotropin-releasing hormone (TRH), growth hormone-releasing hormone (GHRH), dopamine, melatonin, thyroxine ( $T_4$ ), parathyroid hormone (PTH), glucocorticoids such as cortisol, mineralocorticoids such as aldosterone, androgens such as testosterone, adrenaline (epinephrine), noradrenaline (norepinephrine), estrogens such as estradiol, progesterone, glucagons, calcitriol, calciferol, atrial-natriuretic peptide, gastrin, secretin, cholecystokinin (CCK), neuropeptide Y, ghrelin, PYY<sub>3-36</sub>, angiotensinogen, thrombopoietin, and leptin. By using appropriate polynucleotide sequences, species-specific hormones may be made by transgenic animals.

In one embodiment of the present invention, the gene of interest is a proinsulin gene and the desired molecule is insulin. Proinsulin consists of three parts: a C-peptide and two strands of amino acids (the alpha and beta chains) that later become

linked together to form the insulin molecule. Figures 2 and 3 are schematics of transposon-based vector constructs containing a proinsulin gene operably-linked to an ovalbumin promoter and ovalbumin protein or an ovomucoid promoter and ovomucoid signal sequence, respectively. In these embodiments, proinsulin is  
5 expressed in the oviduct tubular gland cells and then deposited in the egg white. One example of a proinsulin polynucleotide sequence is shown in SEQ ID NO:23, wherein the C-peptide cleavage site spans from Arg at position 31 to Arg at position 65.

Serum proteins including lipoproteins such as high density lipoprotein (HDL), HDL-Milano and low density lipoprotein, albumin, clotting cascade factors, factor  
10 VIII, factor IX, fibrinogen, and globulins are also included in the group of desired proteins of the present invention. Immunoglobulins are one class of desired globulin molecules and include but are not limited to IgG, IgM, IgA, IgD, IgE, IgY, lambda chains, kappa chains and fragments thereof; Fc fragments, and Fab fragments. Desired antibodies include, but are not limited to, naturally occurring antibodies,  
15 human antibodies, humanized antibodies, and hybrid antibodies. Genes encoding modified versions of naturally occurring antibodies or fragments thereof and genes encoding artificially designed antibodies or fragments thereof may be incorporated into the transposon-based vectors of the present invention. Desired antibodies also include antibodies with the ability to bind specific ligands, for example, antibodies  
20 against proteins associated with cancer-related molecules, such as anti-her 2, or anti-CA125. Accordingly, the present invention encompasses a transposon-based vector containing one or more genes encoding a heavy immunoglobulin (Ig) chain and a light Ig chain. Further, more than one gene encoding for more than one antibody may be administered in one or more transposon-based vectors of the present invention. In  
25 this manner, an egg may contain more than one type of antibody in the egg white, the egg yolk or both. In one embodiment, a transposon-based vector contains a heavy Ig chain and a light Ig chain, both operably linked to a promoter.

Antibodies used as therapeutic reagents include but are not limited to antibodies for use in cancer immunotherapy against specific antigens, or for providing  
30 passive immunity to an animal or a human against an infectious disease or a toxic agent. Antibodies used as diagnostic reagents include, but are not limited to antibodies that may be labeled and detected with a detector, for example antibodies with a fluorescent label attached that may be detected following exposure to specific wavelengths. Such labeled antibodies may be primary antibodies directed to a

specific antigen, for example, rhodamine-labeled rabbit anti-growth hormone, or may be labeled secondary antibodies, such as fluorescein-labeled goat-anti chicken IgG. Such labeled antibodies are known to one of ordinary skill in the art. Labels useful for attachment to antibodies are also known to one of ordinary skill in the art. Some of these labels are described in the "Handbook of Fluorescent Probes and Research Products", ninth edition, Richard P. Haugland (ed) Molecular Probes, Inc. Eugene, OR), which is incorporated herein in its entirety.

Antibodies produced with using the present invention may be used as laboratory reagents for numerous applications including radioimmunoassay, western blots, dot blots, ELISA, immunoaffinity columns and other procedures requiring antibodies as known to one of ordinary skill in the art. Such antibodies include primary antibodies, secondary antibodies and tertiary antibodies, which may be labeled or unlabeled.

Antibodies that may be made with the practice of the present invention include, but are not limited to primary antibodies, secondary antibodies, designer antibodies, anti-protein antibodies, anti-peptide antibodies, anti-DNA antibodies, anti-RNA antibodies, anti-hormone antibodies, anti-hypophysiotropic peptides, antibodies against non-natural antigens, anti-anterior pituitary hormone antibodies, anti-posterior pituitary hormone antibodies, anti-venom antibodies, anti-tumor marker antibodies, antibodies directed against epitopes associated with infectious disease, including, anti-viral, anti-bacterial, anti-protozoal, anti-fungal, anti-parasitic, anti-receptor, anti-lipid, anti-phospholipid, anti-growth factor, anti-cytokine, anti-monokine, anti-idiotypic, and anti-accessory (presentation) protein antibodies. Antibodies made with the present invention, as well as light chains or heavy chains, may also be used to inhibit enzyme activity.

Antibodies that may be produced using the present invention include, but are not limited to, antibodies made against the following proteins: Bovine  $\gamma$ -Globulin, Serum; Bovine IgG, Plasma; Chicken  $\gamma$ -Globulin, Serum; Human  $\gamma$ -Globulin, Serum; Human IgA, Plasma; Human IgA<sub>1</sub>, Myeloma; Human IgA<sub>2</sub>, Myeloma; Human IgA<sub>2</sub>, Plasma; Human IgD, Plasma; Human IgE, Myeloma; Human IgG, Plasma; Human IgG, Fab Fragment, Plasma; Human IgG, F(ab')<sub>2</sub> Fragment, Plasma; Human IgG, Fc Fragment, Plasma; Human IgG<sub>1</sub>, Myeloma; Human IgG<sub>2</sub>, Myeloma; Human IgG<sub>3</sub>, Myeloma; Human IgG<sub>4</sub>, Myeloma; Human IgM, Myeloma; Human IgM, Plasma; Human Immunoglobulin, Light Chain  $\kappa$ , Urine; Human Immunoglobulin, Light

Chains  $\kappa$  and  $\lambda$ , Plasma; Mouse  $\gamma$ -Globulin, Serum; Mouse IgG, Serum; Mouse IgM, Myeloma; Rabbit  $\gamma$ -Globulin, Serum; Rabbit IgG, Plasma; and Rat  $\gamma$ -Globulin, Serum. In one embodiment, the transposon-based vector comprises the coding sequence of light and heavy chains of a murine monoclonal antibody that shows  
 5 specificity for human seminoprotein (GenBank Accession numbers AY129006 and AY129304 for the light and heavy chains, respectively).

A further non-limiting list of antibodies that recognize other antibodies is as follows: Anti-Chicken IgG, heavy (H) & light (L) Chain Specific (Sheep); Anti-Goat  $\gamma$ -Globulin (Donkey); Anti-Goat IgG, Fc Fragment Specific (Rabbit); Anti-Guinea Pig  
 10  $\gamma$ -Globulin (Goat); Anti-Human Ig, Light Chain, Type  $\kappa$  Specific; Anti-Human Ig, Light Chain, Type  $\lambda$  Specific; Anti-Human IgA,  $\alpha$ -Chain Specific (Goat); Anti-Human IgA, Fab Fragment Specific; Anti-Human IgA, Fc Fragment Specific; Anti-Human IgA, Secretory; Anti-Human IgE,  $\epsilon$ -Chain Specific (Goat); Anti-Human IgE, Fc Fragment Specific; Anti-Human IgG, Fc Fragment Specific (Goat); Anti-Human  
 15 IgG,  $\gamma$ -Chain Specific (Goat); Anti-Human IgG, Fc Fragment Specific; Anti-Human IgG, Fd Fragment Specific; Anti-Human IgG, H & L Chain Specific (Goat); Anti-Human IgG<sub>1</sub>, Fc Fragment Specific; Anti-Human IgG<sub>2</sub>, Fc Fragment Specific; Anti-Human IgG<sub>2</sub>, Fd Fragment Specific; Anti-Human IgG<sub>3</sub>, Hinge Specific; Anti-Human IgG<sub>4</sub>, Fc Fragment Specific; Anti-Human IgM, Fc Fragment Specific; Anti-Human  
 20 IgM,  $\mu$ -Chain Specific; Anti-Mouse IgE,  $\epsilon$ -Chain Specific; Anti-Mouse  $\gamma$ -Globulin (Goat); Anti-Mouse IgG,  $\gamma$ -Chain Specific (Goat); Anti-Mouse IgG,  $\gamma$ -Chain Specific (Goat) F(ab')<sub>2</sub> Fragment; Anti-Mouse IgG, H & L Chain Specific (Goat); Anti-Mouse IgM,  $\mu$ -Chain Specific (Goat); Anti-Mouse IgM, H & L Chain Specific (Goat); Anti-Rabbit  $\gamma$ -Globulin (Goat); Anti-Rabbit IgG, Fc Fragment Specific (Goat); Anti-Rabbit  
 25 IgG, H & L Chain Specific (Goat); Anti-Rat  $\gamma$ -Globulin (Goat); Anti-Rat IgG, H & L Chain Specific; Anti-Rhesus Monkey  $\gamma$ -Globulin (Goat); and, Anti-Sheep IgG, H & L Chain Specific.

Another non-limiting list of the antibodies that may be produced using the present invention is provided in product catalogs of companies such as Phoenix  
 30 Pharmaceuticals, Inc. ([www.phoenixpeptide.com](http://www.phoenixpeptide.com); 530 Harbor Boulevard, Belmont, CA), Peninsula Labs (San Carlos CA), SIGMA (St.Louis, MO [www.sigma-aldrich.com](http://www.sigma-aldrich.com)), Cappel ICN (Irvine, California, [www.icnbiomed.com](http://www.icnbiomed.com)), and Calbiochem (La Jolla, California, [www.calbiochem.com](http://www.calbiochem.com)), which are all incorporated herein by reference in their entirety. The polynucleotide sequences encoding these antibodies



may be obtained from the scientific literature, from patents, and from databases such as GenBank. Alternatively, one of ordinary skill in the art may design the polynucleotide sequence to be incorporated into the genome by choosing the codons that encode for each amino acid in the desired antibody. Antibodies made by the transgenic animals of the present invention include antibodies that may be used as therapeutic reagents, for example in cancer immunotherapy against specific antigens, as diagnostic reagents and as laboratory reagents for numerous applications including immunoneutralization, radioimmunoassay, western blots, dot blots, ELISA, immunoprecipitation and immunoaffinity columns. Some of these antibodies include, but are not limited to, antibodies which bind the following ligands: adrenomedulin, amylin, calcitonin, amyloid, calcitonin gene-related peptide, cholecystokinin, gastrin, gastric inhibitory peptide, gastrin releasing peptide, interleukin, interferon, cortistatin, somatostatin, endothelin, sarafotoxin, glucagon, glucagon-like peptide, insulin, atrial natriuretic peptide, BNP, CNP, neurokinin, substance P, leptin, neuropeptide Y, melanin concentrating hormone, melanocyte stimulating hormone, orphanin, endorphin, dynorphin, enkephalin, leumorphin, peptide F, PACAP, PACAP-related peptide, parathyroid hormone, urocortin, corticotrophin releasing hormone, PHM, PHI, vasoactive intestinal polypeptide, secretin, ACTH, angiotensin, angiotensin, bombesin, endostatin, bradykinin, FMRF amide, galanin, gonadotropin releasing hormone (GnRH) associated peptide, GnRH, growth hormone releasing hormone, inhibin, granulocyte-macrophage colony stimulating factor (GM-CSF), motilin, neurotensin, oxytocin, vasopressin, osteocalcin, pancreastatin, pancreatic polypeptide, peptide YY, proopiomelanocortin, transforming growth factor, vascular endothelial growth factor, vesicular monoamine transporter, vesicular acetylcholine transporter, ghrelin, NPW, NPB, C3d, prokineticin, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone, prolactin, growth hormone, beta-lipotropin, melatonin, kallikriens, kinins, prostaglandins, erythropoietin, p146 (SEQ ID NO:24 amino acid sequence, SEQ ID NO:25, nucleotide sequence), estrogen, testosterone, corticosteroids, mineralocorticoids, thyroid hormone, thymic hormones, connective tissue proteins, nuclear proteins, actin, avidin, activin, agrin, albumin, and prohormones, propeptides, splice variants, fragments and analogs thereof.

The following is yet another non-limiting list of antibodies that can be produced by the methods of present invention: abciximab (ReoPro), abciximab anti-platelet aggregation monoclonal antibody, anti-CD11a (hu1124), anti-CD18 antibody,

anti-CD20 antibody, anti-cytomegalovirus (CMV) antibody, anti-digoxin antibody, anti-hepatitis B antibody, anti-HER-2 antibody, anti-idiotypic antibody to GD3 glycolipid, anti-IgE antibody, anti-IL-2R antibody, antimetastatic cancer antibody (mAb 17-1A), anti-rabies antibody, anti-respiratory syncytial virus (RSV) antibody, 5 anti-Rh antibody, anti-TCR, anti-TNF antibody, anti-VEGF antibody and fab fragment thereof, rattlesnake venom antibody, black widow spider venom antibody, coral snake venom antibody, antibody against very late antigen-4 (VLA-4), C225 humanized antibody to EGF receptor, chimeric (human & mouse) antibody against TNF $\alpha$ , antibody directed against GPIIb/IIIa receptor on human platelets, gamma 10 globulin, anti-hepatitis B immunoglobulin, human anti-D immunoglobulin, human antibodies against *S aureus*, human tetanus immunoglobulin, humanized antibody against the epidermal growth receptor-2, humanized antibody against the  $\alpha$  subunit of the interleukin-2 receptor, humanized antibody CTLA4IG, humanized antibody to the IL-2 R  $\alpha$ -chain, humanized anti-CD40-ligand monoclonal antibody (5c8), humanized 15 mAb against the epidermal growth receptor-2, humanized mAb to rous sarcoma virus, humanized recombinant antibody (IgG1k) against respiratory syncytial virus (RSV), lymphocyte immunoglobulin (anti-thymocyte antibody), lymphocyte immunoglobulin, mAb against factor VII, MDX-210 bi-specific antibody against HER-2, MDX-22, MDX-220 bi-specific antibody against TAG-72 on tumors, MDX- 20 33 antibody to Fc $\gamma$ R1 receptor, MDX-447 bi-specific antibody against EGF receptor, MDX-447 bispecific humanized antibody to EGF receptor, MDX-RA immunotoxin (ricin A linked) antibody, Medi-507 antibody (humanized form of BTI-322) against CD2 receptor on T-cells, monoclonal antibody LDP-02, muromonab-CD3(OKT3) antibody, OKT3 ("muromomab-CD3") antibody, PRO 542 antibody, ReoPro 25 ("abciximab") antibody, and TNF-IgG fusion protein.

The antibodies prepared using the methods of the present invention may also be designed to possess specific labels that may be detected through means known to one of ordinary skill in the art. The antibodies may also be designed to possess specific sequences useful for purification through means known to one of ordinary 30 skill in the art. Specialty antibodies designed for binding specific antigens may also be made in transgenic animals using the transposon-based vectors of the present invention.

Production of a monoclonal antibody using the transposon-based vectors of the present invention can be accomplished in a variety of ways. In one embodiment, two vectors may be constructed: one that encodes the light chain, and a second vector that encodes the heavy chain of the monoclonal antibody. These vectors may then be  
5 incorporated into the genome of the target animal by methods disclosed herein. In an alternative embodiment, the sequences encoding light and heavy chains of a monoclonal antibody may be included on a single DNA construct. For example, the coding sequence of light and heavy chains of a murine monoclonal antibody that show specificity for human seminoprotein can be expressed using transposon-based  
10 constructs of the present invention (GenBank Accession numbers AY129006 and AY129304 for the light and heavy chains, respectively).

Further included in the present invention are proteins and peptides synthesized by the immune system including those synthesized by the thymus, lymph nodes, spleen, and the gastrointestinal associated lymph tissues (GALT) system. The  
15 immune system proteins and peptides proteins that can be made in transgenic animals using the transposon-based vectors of the present invention include, but are not limited to, alpha-interferon, beta-interferon, gamma-interferon, alpha-interferon A, alpha-interferon 1, G-CSF, GM-CSF, interleukin-1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TNF- $\alpha$ , and TNF- $\beta$ . Other cytokines  
20 included in the present invention include cardiotrophin, stromal cell derived factor, macrophage derived chemokine (MDC), melanoma growth stimulatory activity (MGSA), macrophage inflammatory proteins 1 alpha (MIP-1 alpha), 2, 3 alpha, 3 beta, 4 and 5.

Lytic peptides such as p146 are also included in the desired molecules of the  
25 present invention. In one embodiment, the p146 peptide comprises an amino acid sequence of SEQ ID NO:24. The present invention also encompasses a transposon-based vector comprising a p146 nucleic acid comprising a polynucleotide sequence of SEQ ID NO:25.

Enzymes are another class of proteins that may be made through the use of the  
30 transposon-based vectors of the present invention. Such enzymes include but are not limited to adenosine deaminase, alpha-galactosidase, cellulase, collagenase, dnaseI, hyaluronidase, lactase, L-asparaginase, pancreatin, papain, streptokinase B, subtilisin, superoxide dismutase, thrombin, trypsin, urokinase, fibrinolysin, glucocerebrosidase

and plasminogen activator. In some embodiments wherein the enzyme could have deleterious effects, additional amino acids and a protease cleavage site are added to the carboxy end of the enzyme of interest in order to prevent expression of a functional enzyme. Subsequent digestion of the enzyme with a protease results in  
5 activation of the enzyme.

Extracellular matrix proteins are one class of desired proteins that may be made through the use of the present invention. Examples include but are not limited to collagen, fibrin, elastin, laminin, and fibronectin and subtypes thereof. Intracellular proteins and structural proteins are other classes of desired proteins in the present  
10 invention.

Growth factors are another desired class of proteins that may be made through the use of the present invention and include, but are not limited to, transforming growth factor- $\alpha$  ("TGF- $\alpha$ "), transforming growth factor- $\beta$  (TGF- $\beta$ ), platelet-derived growth factors (PDGF), fibroblast growth factors (FGF), including FGF acidic  
15 isoforms 1 and 2, FGF basic form 2 and FGF 4, 8, 9 and 10, nerve growth factors (NGF) including NGF 2.5s, NGF 7.0s and beta NGF and neurotrophins, brain derived neurotrophic factor, cartilage derived factor, growth factors for stimulation of the production of red blood cells, growth factors for stimulation of the production of white blood cells, bone growth factors (BGF), basic fibroblast growth factor, vascular  
20 endothelial growth factor (VEGF), granulocyte colony stimulating factor (G-CSF), insulin like growth factor (IGF) I and II, hepatocyte growth factor, glial neurotrophic growth factor (GDNF), stem cell factor (SCF), keratinocyte growth factor (KGF), transforming growth factors (TGF), including TGFs alpha, beta, beta1, beta2, beta3, skeletal growth factor, bone matrix derived growth factors, bone derived growth  
25 factors, erythropoietin (EPO) and mixtures thereof.

Another desired class of proteins that may be made may be made through the use of the present invention include, but are not limited to, leptin, leukemia inhibitory factor (LIF), tumor necrosis factor alpha and beta, ENBREL, angiostatin, endostatin, thrombospondin, osteogenic protein-1, bone morphogenetic proteins 2 and 7,  
30 osteonectin, somatomedin-like peptide, and osteocalcin.

Yet another desired class of proteins are blood proteins or clotting cascade protein including albumin, Prekallikrein, High molecular weight kininogen (HMWK) (contact activation cofactor; Fitzgerald, Flaoujeac Williams factor), Factor I

(Fibrinogen), Factor II (prothrombin), Factor III (Tissue Factor), Factor IV (calcium), Factor V (proaccelerin, labile factor, accelerator (Ac-) globulin), Factor VI (Va) (accelerin), Factor VII (proconvertin), serum prothrombin conversion accelerator (SPCA), cothromboplastin), Factor VIII (antihemophilic factor A, antihemophilic  
 5 globulin (AHG)), Factor IX (Christmas Factor, antihemophilic factor B, plasma thromboplastin component (PTC)), Factor X (Stuart-Prower Factor), Factor XI (Plasma thromboplastin antecedent (PTA)), Factor XII (Hageman Factor), Factor XIII (rotransglutaminase, fibrin stabilizing factor (FSF), fibrinolygase), von Willebrand factor, Protein C, Protein S, Thrombomodulin, Antithrombin III.

10 A non-limiting list of the peptides and proteins that may be made may be made through the use of the present invention is provided in product catalogs of companies such as Phoenix Pharmaceuticals, Inc. ([www.phoenixpeptide.com](http://www.phoenixpeptide.com); 530 Harbor Boulevard, Belmont, CA), Peninsula Labs (San Carlos CA), SIGMA, (St.Louis, MO [www.sigma-aldrich.com](http://www.sigma-aldrich.com)), Cappel ICN (Irvine, California,  
 15 [www.icnbiomed.com](http://www.icnbiomed.com)), and Calbiochem (La Jolla, California, [www.calbiochem.com](http://www.calbiochem.com)). The polynucleotide sequences encoding these proteins and peptides of interest may be obtained from the scientific literature, from patents, and from databases such as GenBank. Alternatively, one of ordinary skill in the art may design the polynucleotide sequence to be incorporated into the genome by choosing the codons  
 20 that encode for each amino acid in the desired protein or peptide.

Some of these desired proteins or peptides that may be made through the use of the present invention include but are not limited to the following: adrenomedulin, amylin, calcitonin, amyloid, calcitonin gene-related peptide, cholecystokinin, gastrin, gastric inhibitory peptide, gastrin releasing peptide, interleukin, interferon, cortistatin,  
 25 somatostatin, endothelin, sarafotoxin, glucagon, glucagon-like peptide, insulin, atrial natriuretic peptide, BNP, CNP, neurokinin, substance P, leptin, neuropeptide Y, melanin concentrating hormone, melanocyte stimulating hormone, orphanin, endorphin, dynorphin, enkephalin, leumorphin, peptide F, PACAP, PACAP-related peptide, parathyroid hormone, urocortin, corticotrophin releasing hormone, PHM,  
 30 PHI, vasoactive intestinal polypeptide, secretin, ACTH, angiotensin, angiostatin, bombesin, endostatin, bradykinin, FMRF amide, galanin, gonadotropin releasing hormone (GnRH) associated peptide, GnRH, growth hormone releasing hormone, inhibin, granulocyte-macrophage colony stimulating factor (GM-CSF), motilin, neurotensin, oxytocin, vasopressin, osteocalcin, pancreastatin, pancreatic polypeptide,

- peptide YY, proopiomelanocortin, transforming growth factor, vascular endothelial growth factor, vesicular monoamine transporter, vesicular acetylcholine transporter, ghrelin, NPW, NPB, C3d, prokineticin, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone, prolactin, growth hormone, beta-lipotropin, melatonin, kallikriens, kinins, prostaglandins, erythropoietin, p146 (SEQ ID NO:24, amino acid sequence, SEQ ID NO:25, nucleotide sequence), thymic hormones, connective tissue proteins, nuclear proteins, actin, avidin, activin, agrin, albumin, apolipoproteins, apolipoprotein A, apolipoprotein B, and prohormones, propeptides, splice variants, fragments and analogs thereof.
- Other desired proteins that may be made by the transgenic animals of the present invention include bacitracin, polymixin b, vancomycin, cyclosporine, anti-RSV antibody, alpha-1 antitrypsin (AAT), anti-cytomegalovirus antibody, anti-hepatitis antibody, anti-inhibitor coagulant complex, anti-rabies antibody, anti-Rh(D) antibody, adenosine deaminase, anti-digoxin antibody, antivenin crotalidae (rattlesnake venom antibody), antivenin latrodectus (black widow spider venom antibody), antivenin micrurus (coral snake venom antibody), aprotinin, corticotropin (ACTH), diphtheria antitoxin, lymphocyte immune globulin (anti-thymocyte antibody), protamine, thyrotropin, capreomycin,  $\alpha$ -galactosidase, gramicidin, streptokinase, tetanus toxoid, thyrothricin, IGF-1, proteins of varicella vaccine, anti-TNF antibody, anti-IL-2r antibody, anti-HER-2 antibody, OKT3 ("muromonab-CD3") antibody, TNF-IgG fusion protein, ReoPro ("abciximab") antibody, ACTH fragment 1-24, desmopressin, gonadotropin-releasing hormone, histrelin, leuprolide, lypressin, nafarelin, peptide that binds GPIIb/GPIIIa on platelets (integrilin), goserelin, capreomycin, colistin, anti-respiratory syncytial virus, lymphocyte immune globulin (Thymoglovin, Atgam), panorex, alpha-antitrypsin, botulinin, lung surfactant protein, tumor necrosis receptor-IgG fusion protein (enbrel), gonadorelin, proteins of influenza vaccine, proteins of rotavirus vaccine, proteins of haemophilus b conjugate vaccine, proteins of poliovirus vaccine, proteins of pneumococcal conjugate vaccine, proteins of meningococcal C vaccine, proteins of influenza vaccine, megakaryocyte growth and development factor (MGDF), neuroimmunophilin ligand-A (NIL-A), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), leptin (native), leptin B, leptin C, IL-1RA (interleukin-1RA), R-568, novel erythropoiesis-stimulating protein (NESP), humanized mAb to rous sarcoma virus

(MEDI-493), glutamyl-tryptophan dipeptide IM862, LFA-3TIP immunosuppressive, humanized anti-CD40-ligand monoclonal antibody (5c8), gelsolin enzyme, tissue factor pathway inhibitor (TFPI), proteins of meningitis B vaccine, antimetastatic cancer antibody (mAb 17-1A), chimeric (human & mouse) mAb against TNF $\alpha$ , mAb  
5 against factor VII, relaxin, capreomycin, glycopeptide (LY333328), recombinant human activated protein C (rhAPC), humanized mAb against the epidermal growth receptor-2, altepase, anti-CD20 antigen, C2B8 antibody, insulin-like growth factor-1, atrial natriuretic peptide (anaritide), tenectaplastase, anti-CD11a antibody (hu 1124), anti-CD18 antibody, mAb LDP-02, anti-VEGF antibody, fab fragment of anti-VEGF  
10 Ab, APO2 ligand (tumor necrosis factor-related apoptosis-inducing ligand), rTGF- $\beta$  (transforming growth factor- $\beta$ ), alpha-antitrypsin, ananain (a pineapple enzyme), humanized mAb CTLA4IG, PRO 542 (mAb), D2E7 (mAb), calf intestine alkaline phosphatase,  $\alpha$ -L-iduronidase,  $\alpha$ -L-galactosidase (humanglutamic acid decarboxylase, acid sphingomyelinase, bone morphogenetic protein-2 (rhBMP-2), proteins of HIV  
15 vaccine, T cell receptor (TCR) peptide vaccine, TCR peptides, V beta 3 and V beta 13.1. (IR502), (IR501), BI 1050/1272 mAb against very late antigen-4 (VLA-4), C225 humanized mAb to EGF receptor, anti-idiotypic antibody to GD3 glycolipid, antibacterial peptide against *H. pylori*, MDX-447 bispecific humanized mAb to EGF receptor, anti-cytomegalovirus (CMV), Medi-491 B19 parvovirus vaccine, humanized  
20 recombinant mAb (IgG1k) against respiratory syncytial virus (RSV), urinary tract infection vaccine (against "pili" on *Escherichia coli* strains), proteins of lyme disease vaccine against *B. burgdorferi* protein (DbpA), proteins of Medi-501 human papilloma virus-11 vaccine (HPV), *Streptococcus pneumoniae* vaccine, Medi-507 mAb (humanized form of BTI-322) against CD2 receptor on T-cells, MDX-33 mAb  
25 to Fc $\gamma$ R1 receptor, MDX-RA immunotoxin (ricin A linked) mAb, MDX-210 bi-specific mAb against HER-2, MDX-447 bi-specific mAb against EGF receptor, MDX-22, MDX-220 bi-specific mAb against TAG-72 on tumors, colony-stimulating factor (CSF) (molgramostim), humanized mAb to the IL-2 R  $\alpha$ -chain (basiliximab), mAb to IgE (IGE 025A), myelin basic protein-altered peptide (MSP771A),  
30 humanized mAb against the epidermal growth receptor-2, humanized mAb against the  $\alpha$  subunit of the interleukin-2 receptor, low molecular weight heparin, anti-hemophilic factor, and bactericidal/permeability-increasing protein (r-BPI).

The peptides and proteins made using the present invention may be labeled using labels and techniques known to one of ordinary skill in the art. Some of these

labels are described in the "Handbook of Fluorescent Probes and Research Products", ninth edition, Richard P. Haugland (ed) Molecular Probes, Inc. Eugene, OR), which is incorporated herein in its entirety. Some of these labels may be genetically engineered into the polynucleotide sequence for the expression of the selected protein or peptide. The peptides and proteins may also have label-incorporation "handles" incorporated to allow labeling of an otherwise difficult or impossible to label protein.

It is to be understood that the various classes of desired peptides and proteins, as well as specific peptides and proteins described in this section may be modified as described below by inserting selected codons for desired amino acid substitutions into the gene incorporated into the transgenic animal.

The present invention may also be used to produce desired molecules other than proteins and peptides including, but not limited to, lipoproteins such as high density lipoprotein (HDL), HDL-Milano, and low density lipoprotein, lipids, carbohydrates, siRNA and ribozymes. In these embodiments, a gene of interest encodes a nucleic acid molecule or a protein that directs production of the desired molecule.

The present invention further encompasses the use of inhibitory molecules to inhibit endogenous (i.e., non-vector) protein production. These inhibitory molecules include antisense nucleic acids, siRNA and inhibitory proteins. In a preferred embodiment, the endogenous protein whose expression is inhibited is an egg white protein including, but not limited to ovalbumin, ovotransferrin, and ovomucin. In one embodiment, a transposon-based vector containing an ovalbumin DNA sequence, that upon transcription forms a double stranded RNA molecule, is transfected into an animal such as a bird and the bird's production of endogenous ovalbumin protein is reduced by the interference RNA mechanism (RNAi). In other embodiments, a transposon-based vector encodes an inhibitory RNA molecule that inhibits the expression of more than one egg white protein. One exemplary construct is provided in Figure 4 wherein "Ovgen" indicates approximately 60 base pairs of an ovalbumin gene, "Ovotrans" indicates approximately 60 base pairs of an ovotransferrin gene and "Ovomucin" indicates approximately 60 base pairs of an ovomucin gene. These ovalbumin, ovotransferrin and ovomucin can be from any avian species, and in some embodiments, are from a chicken or quail. The term "pro" indicates the pro portion of a prepro sequence. One exemplary prepro sequence is that of cecropin and comprising base pairs 563-733 of the Cecropin cap site and Prepro provided in



Genbank accession number X07404. Additional cecropin prepro and pro sequences are provided in SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51. Additionally, inducible knockouts or knockdowns of the endogenous protein may be created to achieve a reduction or inhibition of endogenous protein production.

5 Endogenous egg white production can be inhibited in an avian at any time, but is preferably inhibited preceding, or immediately preceding, the harvest of eggs.

#### Modified Desired Proteins and Peptides

"Proteins", "peptides," "polypeptides" and "oligopeptides" are chains of amino acids (typically L-amino acids) whose alpha carbons are linked through peptide bonds

10 formed by a condensation reaction between the carboxyl group of the alpha carbon of one amino acid and the amino group of the alpha carbon of another amino acid. The terminal amino acid at one end of the chain (i.e., the amino terminal) has a free amino group, while the terminal amino acid at the other end of the chain (i.e., the carboxy terminal) has a free carboxyl group. As such, the term "amino terminus" (abbreviated

15 N-terminus) refers to the free alpha-amino group on the amino acid at the amino terminal of the protein, or to the alpha-amino group (imino group when participating in a peptide bond) of an amino acid at any other location within the protein. Similarly, the term "carboxy terminus" (abbreviated C-terminus) refers to the free carboxyl group on the amino acid at the carboxy terminus of a protein, or to the

20 carboxyl group of an amino acid at any other location within the protein.

Typically, the amino acids making up a protein are numbered in order, starting at the amino terminal and increasing in the direction toward the carboxy terminal of the protein. Thus, when one amino acid is said to "follow" another, that amino acid is positioned closer to the carboxy terminal of the protein than the preceding amino acid.

25 The term "residue" is used herein to refer to an amino acid (D or L) or an amino acid mimetic that is incorporated into a protein by an amide bond. As such, the amino acid may be a naturally occurring amino acid or, unless otherwise limited, may encompass known analogs of natural amino acids that function in a manner similar to the naturally occurring amino acids (i.e., amino acid mimetics). Moreover, an amide

30 bond mimetic includes peptide backbone modifications well known to those skilled in the art.

Furthermore, one of skill will recognize that, as mentioned above, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (typically less than about 5%, more typically less

than about 1%) in an encoded sequence are conservatively modified variations where the alterations result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids

5 that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 10 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

A conservative substitution is a substitution in which the substituting amino acid (naturally occurring or modified) is structurally related to the amino acid being substituted, i.e., has about the same size and electronic properties as the amino acid

15 being substituted. Thus, the substituting amino acid would have the same or a similar functional group in the side chain as the original amino acid. A "conservative substitution" also refers to utilizing a substituting amino acid which is identical to the amino acid being substituted except that a functional group in the side chain is protected with a suitable protecting group.

20 Suitable protecting groups are described in Green and Wuts, "Protecting Groups in Organic Synthesis", John Wiley and Sons, Chapters 5 and 7, 1991, the teachings of which are incorporated herein by reference. Preferred protecting groups are those which facilitate transport of the peptide through membranes, for example, by reducing the hydrophilicity and increasing the lipophilicity of the peptide, and which

25 can be cleaved, either by hydrolysis or enzymatically (Ditter et al., 1968. J. Pharm. Sci. 57:783; Ditter et al., 1968. J. Pharm. Sci. 57:828; Ditter et al., 1969. J. Pharm. Sci. 58:557; King et al., 1987. Biochemistry 26:2294; Lindberg et al., 1989. Drug Metabolism and Disposition 17:311; Tunek et al., 1988. Biochem. Pharm. 37:3867; Anderson et al., 1985 Arch. Biochem. Biophys. 239:538; and Singhal et al., 1987.

30 FASEB J. 1:220). Suitable hydroxyl protecting groups include ester, carbonate and carbamate protecting groups. Suitable amine protecting groups include acyl groups and alkoxy or aryloxy carbonyl groups, as described above for N-terminal protecting groups. Suitable carboxylic acid protecting groups include aliphatic, benzyl and aryl esters, as described below for C-terminal protecting groups. In one embodiment, the

carboxylic acid group in the side chain of one or more glutamic acid or aspartic acid residues in a peptide of the present invention is protected, preferably as a methyl, ethyl, benzyl or substituted benzyl ester, more preferably as a benzyl ester.

5 Provided below are groups of naturally occurring and modified amino acids in which each amino acid in a group has similar electronic and steric properties. Thus, a conservative substitution can be made by substituting an amino acid with another amino acid from the same group. It is to be understood that these groups are non-limiting, i.e. that there are additional modified amino acids which could be included in each group.

10 Group I includes leucine, isoleucine, valine, methionine and modified amino acids having the following side chains: ethyl, n-propyl n-butyl. Preferably, Group I includes leucine, isoleucine, valine and methionine.

Group II includes glycine, alanine, valine and a modified amino acid having an ethyl side chain. Preferably, Group II includes glycine and alanine.

15 Group III includes phenylalanine, phenylglycine, tyrosine, tryptophan, cyclohexylmethyl glycine, and modified amino residues having substituted benzyl or phenyl side chains. Preferred substituents include one or more of the following: halogen, methyl, ethyl, nitro,  $\text{—NH}_2$ , methoxy, ethoxy and  $\text{—CN}$ . Preferably, Group III includes phenylalanine, tyrosine and tryptophan.

20 Group IV includes glutamic acid, aspartic acid, a substituted or unsubstituted aliphatic, aromatic or benzylic ester of glutamic or aspartic acid (e.g., methyl, ethyl, n-propyl iso-propyl, cyclohexyl, benzyl or substituted benzyl), glutamine, asparagine,  $\text{—CO—NH—}$  alkylated glutamine or asparagines (e.g., methyl, ethyl, n-propyl and iso-propyl) and modified amino acids having the side chain  $\text{—(CH}_2)_3\text{—COOH}$ , an ester thereof (substituted or unsubstituted aliphatic, aromatic or benzylic ester), an amide thereof and a substituted or  
25 unsubstituted N-alkylated amide thereof. Preferably, Group IV includes glutamic acid, aspartic acid, methyl aspartate, ethyl aspartate, benzyl aspartate and methyl glutamate, ethyl glutamate and benzyl glutamate, glutamine and asparagine.

30 Group V includes histidine, lysine, ornithine, arginine, N-nitroarginine,  $\beta$ -cycloarginine,  $\gamma$ -hydroxyarginine, N-amidinocitruline and 2-amino-4-guanidinobutanoic acid, homologs of lysine, homologs of arginine and homologs of ornithine. Preferably, Group V includes histidine, lysine,

arginine and ornithine. A homolog of an amino acid includes from 1 to about 3 additional or subtracted methylene units in the side chain.

Group VI includes serine, threonine, cysteine and modified amino acids having C1-C5 straight or branched alkyl side chains substituted with —OH or —SH, for example, —CH<sub>2</sub>CH<sub>2</sub>OH, —CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH or —CH<sub>2</sub>CH<sub>2</sub>OHCH<sub>3</sub>. Preferably, Group VI includes serine, cysteine or threonine.

In another aspect, suitable substitutions for amino acid residues include “severe” substitutions. A “severe substitution” is a substitution in which the substituting amino acid (naturally occurring or modified) has significantly different size and/or electronic properties compared with the amino acid being substituted. Thus, the side chain of the substituting amino acid can be significantly larger (or smaller) than the side chain of the amino acid being substituted and/or can have functional groups with significantly different electronic properties than the amino acid being substituted. Examples of severe substitutions of this type include the substitution of phenylalanine or cyclohexylmethyl glycine for alanine, isoleucine for glycine, a D amino acid for the corresponding L amino acid, or —NH—CH[(—CH<sub>2</sub>)<sub>5</sub>—COOH]—CO— for aspartic acid. Alternatively, a functional group may be added to the side chain, deleted from the side chain or exchanged with another functional group. Examples of severe substitutions of this type include adding of valine, leucine or isoleucine, exchanging the carboxylic acid in the side chain of aspartic acid or glutamic acid with an amine, or deleting the amine group in the side chain of lysine or ornithine. In yet another alternative, the side chain of the substituting amino acid can have significantly different steric and electronic properties than the functional group of the amino acid being substituted. Examples of such modifications include tryptophan for glycine, lysine for aspartic acid and —(CH<sub>2</sub>)<sub>4</sub>COOH for the side chain of serine. These examples are not meant to be limiting.

In another embodiment, for example in the synthesis of a peptide 26 amino acids in length, the individual amino acids may be substituted according in the following manner:

AA<sub>1</sub> is serine, glycine, alanine, cysteine or threonine;

AA<sub>2</sub> is alanine, threonine, glycine, cysteine or serine;

- AA<sub>3</sub> is valine, arginine, leucine, isoleucine, methionine, ornithine, lysine, N-nitroarginine,  $\beta$ -cycloarginine,  $\gamma$ -hydroxyarginine, N-amidinocitruline or 2-amino-4-guanidinobutanoic acid;
- AA<sub>4</sub> is proline, leucine, valine, isoleucine or methionine;
- 5 AA<sub>5</sub> is tryptophan, alanine, phenylalanine, tyrosine or glycine;
- AA<sub>6</sub> is serine, glycine, alanine, cysteine or threonine;
- AA<sub>7</sub> is proline, leucine, valine, isoleucine or methionine;
- AA<sub>8</sub> is alanine, threonine, glycine, cysteine or serine;
- AA<sub>9</sub> is alanine, threonine, glycine, cysteine or serine;
- 10 AA<sub>10</sub> is leucine, isoleucine, methionine or valine;
- AA<sub>11</sub> is serine, glycine, alanine, cysteine or threonine;
- AA<sub>12</sub> is leucine, isoleucine, methionine or valine;
- AA<sub>13</sub> is leucine, isoleucine, methionine or valine;
- AA<sub>14</sub> is glutamine, glutamic acid, aspartic acid, asparagine, or a substituted or
- 15 unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;
- AA<sub>15</sub> is arginine, N-nitroarginine,  $\beta$ -cycloarginine,  $\gamma$ -hydroxy-arginine, N-amidinocitruline or 2-amino-4-guanidino-butanoic acid
- AA<sub>16</sub> is proline, leucine, valine, isoleucine or methionine;
- AA<sub>17</sub> is serine, glycine, alanine, cysteine or threonine;
- 20 AA<sub>18</sub> is glutamic acid, aspartic acid, asparagine, glutamine or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;
- AA<sub>19</sub> is aspartic acid, asparagine, glutamic acid, glutamine, leucine, valine, isoleucine, methionine or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;
- 25 AA<sub>20</sub> is valine, arginine, leucine, isoleucine, methionine, ornithine, lysine, N-nitroarginine,  $\beta$ -cycloarginine,  $\gamma$ -hydroxyarginine, N-amidinocitruline or 2-amino-4-guanidinobutanoic acid;
- AA<sub>21</sub> is alanine, threonine, glycine, cysteine or serine;
- AA<sub>22</sub> is alanine, threonine, glycine, cysteine or serine;
- 30 AA<sub>23</sub> is histidine, serine, threonine, cysteine, lysine or ornithine;
- AA<sub>24</sub> is threonine, aspartic acid, serine, glutamic acid or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;

AA<sub>25</sub> is asparagine, aspartic acid,, glutamic acid, glutamine, leucine, valine, isoleucine, methionine or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid; and

AA<sub>26</sub> is cysteine, histidine, serine, threonine, lysine or ornithine.

5 It is to be understood that these amino acid substitutions may be made for longer or shorter peptides than the 26 mer in the preceding example above, and for proteins.

In one embodiment of the present invention, codons for the first several N-terminal amino acids of the transposase are modified such that the third base of each  
10 codon is changed to an A or a T without changing the corresponding amino acid. It is preferable that between approximately 1 and 20, more preferably 3 and 15, and most preferably between 4 and 12 of the first N-terminal codons of the gene of interest are modified such that the third base of each codon is changed to an A or a T without changing the corresponding amino acid. In one embodiment, the first ten N-terminal  
15 codons of the gene of interest are modified in this manner.

When several desired proteins, protein fragments or peptides are encoded in the gene of interest to be incorporated into the genome, one of skill in the art will appreciate that the proteins, protein fragments or peptides may be separated by a  
20 spacer molecule such as, for example, a peptide, consisting of one or more amino acids. Generally, the spacer will have no specific biological activity other than to join the desired proteins, protein fragments or peptides together, or to preserve some minimum distance or other spatial relationship between them. However, the constituent amino acids of the spacer may be selected to influence some property of the molecule such as the folding, net charge, or hydrophobicity. The spacer may also  
25 be contained within a nucleotide sequence with a purification handle or be flanked by cleavage sites, such as proteolytic cleavage sites.

Such polypeptide spacers may have from about 5 to about 40 amino acid residues. The spacers in a polypeptide are independently chosen, but are preferably all the same. The spacers should allow for flexibility of movement in space and are  
30 therefore typically rich in small amino acids, for example, glycine, serine, proline or alanine. Preferably, peptide spacers contain at least 60%, more preferably at least 80% glycine or alanine. In addition, peptide spacers generally have little or no biological and antigenic activity. Preferred spacers are (Gly-Pro-Gly-Gly)<sub>x</sub> (SEQ ID

NO:26) and (Gly<sub>4</sub>-Ser)<sub>y</sub>, wherein x is an integer from about 3 to about 9 and y is an integer from about 1 to about 8. Specific examples of suitable spacers include (Gly-Pro-Gly-Gly)<sub>3</sub>

SEQ ID NO:27 Gly Pro Gly Gly Gly Pro Gly Gly Gly Pro Gly Gly

5 (Gly<sub>4</sub>-Ser)<sub>3</sub>

SEQ ID NO:28 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
or (Gly<sub>4</sub>-Ser)<sub>4</sub>

SEQ ID NO:29 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
Gly Gly Gly Gly Ser.

10 Nucleotide sequences encoding for the production of residues which may be useful in purification of the expressed recombinant protein may also be built into the vector. Such sequences are known in the art and include the glutathione binding domain from glutathione S-transferase, polylysine, hexa-histidine or other cationic amino acids, thioredoxin, hemagglutinin antigen and maltose binding protein.

15 Additionally, nucleotide sequences may be inserted into the gene of interest to be incorporated so that the protein or peptide can also include from one to about six amino acids that create signals for proteolytic cleavage. In this manner, if a gene is designed to make one or more peptides or proteins of interest in the transgenic animal, specific nucleotide sequences encoding for amino acids recognized by enzymes may  
20 be incorporated into the gene to facilitate cleavage of the large protein or peptide sequence into desired peptides or proteins or both. For example, nucleotides encoding a proteolytic cleavage site can be introduced into the gene of interest so that a signal sequence can be cleaved from a protein or peptide encoded by the gene of interest. Nucleotide sequences encoding other amino acid sequences which display pH  
25 sensitivity or chemical sensitivity may also be added to the vector to facilitate separation of the signal sequence from the peptide or protein of interest.

Proteolytic cleavage sites include cleavage sites recognized by exopeptidases such as carboxypeptidase A, carboxypeptidase B, aminopeptidase I, and dipeptidylaminopeptidase; endopeptidases such as trypsin, V8-protease, enterokinase,  
30 factor Xa, collagenase, endoproteinase, subtilisin, and thrombin; and proteases such as Protease 3C IgA protease (Igase) Rhinovirus 3C(preScission)protease. Chemical cleavage sites are also included in the definition of cleavage site as used herein. Chemical cleavage sites include, but are not limited to, site cleaved by cyanogen bromide, hydroxylamine, formic acid, and acetic acid.

In one embodiment of the present invention, a TAG sequence is linked to the gene of interest. The TAG sequence serves three purposes: 1) it allows free rotation of the peptide or protein to be isolated so there is no interference from the native protein or signal sequence, i.e. vitellogenin, 2) it provides a "purification handle" to isolate the protein using column purification, and 3) it includes a cleavage site to remove the desired protein from the signal and purification sequences. Accordingly, as used herein, a TAG sequence includes a spacer sequence, a purification handle and a cleavage site. The spacer sequences in the TAG proteins contain one or more repeats shown in SEQ ID NO:30. A preferred spacer sequence comprises the sequence provided in SEQ ID NO:31. One example of a purification handle is the gp41 hairpin loop from HIV I. Exemplary gp41 polynucleotide and polypeptide sequences are provided in SEQ ID NO:32 and SEQ ID NO:33, respectively. However, it should be understood that any antigenic region may be used as a purification handle, including any antigenic region of gp41. Preferred purification handles are those that elicit highly specific antibodies. Additionally, the cleavage site can be any protein cleavage site known to one of ordinary skill in the art and includes an enterokinase cleavage site comprising the Asp Asp Asp Asp Lys sequence (SEQ ID NO:34) and a furin cleavage site. Constructs containing a TAG sequence are shown in Figures 2 and 3. In one embodiment of the present invention, the TAG sequence comprises a polynucleotide sequence of SEQ ID NO:35.

#### Methods of Administering Transposon-Based Vectors

In addition to the transposon-based vectors described above, the present invention also includes methods of administering the transposon-based vectors to an animal, methods of producing a transgenic animal wherein a gene of interest is incorporated into the germline of the animal and methods of producing a transgenic animal wherein a gene of interest is incorporated into cells other than the germline cells (somatic cells) of the animal. The transposon-based vectors of the present invention are administered to a reproductive organ of an animal via any method known to those of skill in the art. Preferred reproductive organs include an ovary, an oviduct, a mammary gland, and a fallopian tube.

In some embodiments, a transposon-based vector is directly administered to the reproductive organ. Direct administration encompasses injection into the organ, and in a preferred embodiment, a transposon-based vector is injected into the lumen of the oviduct, and more preferably, the lumen of the magnum or the infundibulum of



the oviduct. The transposon-based vectors may additionally or alternatively be placed in an artery supplying the reproductive organ. Administering the vectors to the artery supplying the ovary results in transfection of follicles and oocytes in the ovary to create a germline transgenic animal. Alternatively, supplying the vectors through an artery leading to the oviduct would preferably transfect the tubular gland and epithelial cells. Such transfected cells could manufacture a desired protein or peptide for deposition in the egg white. In one embodiment, a transposon-based vector is administered into the lumen of the magnum or the infundibulum of the oviduct and to an artery supplying the oviduct. Indirect administration to the oviduct epithelium may occur through the cloaca. Direct administration into the mammary gland comprises introduction into the duct system of the mammary gland.

Administration of transposon-based vectors may occur in arteries supplying the ovary and or through direct intrathecal administration into the ovary through injection.

The transposon-based vectors may be administered in a single administration, multiple administrations, continuously, or intermittently. The transposon-based vectors may be administered by injection, via a catheter, an osmotic mini-pump or any other method. In some embodiments, the transposon-based vector is administered to an animal in multiple administrations, each administration containing the vector and a different transfecting reagent.

The transposon-based vectors may be administered to the animal at any point during the lifetime of the animal, however, it is preferable that the vectors are administered prior to the animal reaching sexual maturity. The transposon-based vectors are preferably administered to a chicken between approximately 14 and 16 weeks of age and to a quail between approximately 5 and 10 weeks of age, more preferably 5 and 8 weeks of age, and most preferably between 5 and 6 weeks of age, when standard poultry rearing practices are used. The vectors may be administered at earlier ages when exogenous hormones are used to induce early sexual maturation in the bird. In some embodiments, the transposon-based vector is administered to an animal following an increase in proliferation of the oviduct epithelial cells and/or the tubular gland cells. Such an increase in proliferation normally follows an influx of reproductive hormones in the area of the oviduct. When the animal is an avian, the transposon-based vector is administered following an increase in proliferation of the oviduct epithelial cells and before the avian begins to produce egg white constituents.

In a preferred embodiment, the animal is an egg-laying animal, and more preferably, an avian. In one embodiment, between approximately 1 and 150  $\mu\text{g}$ , 1 and 100  $\mu\text{g}$ , 1 and 50  $\mu\text{g}$ , preferably between 1 and 20  $\mu\text{g}$ , and more preferably between 5 and 10  $\mu\text{g}$  of transposon-based vector DNA is administered to the oviduct of a bird.

5 Optimal ranges depend upon the type of bird and the bird's stage of sexual maturity. In a chicken, it is preferred that between approximately 1 and 100  $\mu\text{g}$ , or 5 and 50  $\mu\text{g}$  are administered. In a quail, it is preferred that between approximately 5 and 10  $\mu\text{g}$  are administered. Intraoviduct administration of the transposon-based vectors of the present invention result in incorporation of the gene of interest into the cells of the

10 oviduct as evidenced by a PCR positive signal in the oviduct tissue. In other embodiments, the transposon-based vector is administered to an artery that supplies the oviduct. These methods of administration may also be combined with any methods for facilitating transfection, including without limitation, electroporation, gene guns, injection of naked DNA, and use of dimethyl sulfoxide (DMSO).

15 According to the present invention, the transposon-based vector is administered in conjunction with an acceptable carrier and/or transfection reagent. Acceptable carriers include, but are not limited to, water, saline, Hanks Balanced Salt Solution (HBSS), Tris-EDTA (TE) and lyotropic liquid crystals. Transfection reagents commonly known to one of ordinary skill in the art that may be employed

20 include, but are not limited to, the following: cationic lipid transfection reagents, cationic lipid mixtures, polyamine reagents, liposomes and combinations thereof; SUPERFECT®, Cytofectene, BioPORTER®, GenePORTER®, NeuroPORTER®, and perfectin from Gene Therapy Systems; lipofectamine, cellfectin, DMRIE-C oligofectamine, TROJENE® and PLUS reagent from InVitrogen; Xtreme gene,

25 fugene, DOSPER and DOTAP from Roche; Lipotaxi and Genejammer from Strategene; and Escort from SIGMA. In one embodiment, the transfection reagent is SUPERFECT®. The ratio of DNA to transfection reagent may vary based upon the method of administration. In one embodiment, the transposon-based vector is administered to the oviduct and the ratio of DNA to transfection reagent can be from

30 1:1.5 to 1:15, preferably 1:2 to 1:5, all expressed as wt/vol. Transfection may also be accomplished using other means known to one of ordinary skill in the art, including without limitation electroporation, gene guns, injection of naked DNA, and use of dimethyl sulfoxide (DMSO).

Depending upon the cell or tissue type targeted for transfection, the form of the transposon-based vector may be important. Plasmids harvested from bacteria are generally closed circular supercoiled molecules, and this is the preferred state of a vector for gene delivery because of the ease of preparation. In some instances, transposase expression and insertion may be more efficient in a relaxed, closed circular configuration or in a linear configuration. In still other instances, a purified transposase protein may be co-injected with a transposon-based vector containing the gene of interest for more immediate insertion. This could be accomplished by using a transfection reagent complexed with both the purified transposase protein and the transposon-based vector.

#### Testing for and Breeding Animals Carrying the Transgene

Following administration of a transposon-based vector to an animal, DNA is extracted from the animal to confirm integration of the gene of interest. Advantages provided by the present invention include the high rates of integration, or incorporation, and transcription of the gene of interest when administered to a bird via an intraoviduct or intraovarian route (including intraarterial administrations to arteries leading to the oviduct or ovary). Example 6 below describes isolation of a proinsulin/ENT TAG protein from a transgenic hen following ammonium sulfate precipitation and ion exchange chromatography. Figure 5 demonstrates successful administration of a transposon-based vector to a hen, successful integration of the gene of interest, successful production of a protein encoded by the gene of interest, and successful deposition of the protein in egg white produced by the transgenic hen.

Actual frequencies of integration may be estimated both by comparative strength of the PCR signal, and by histological evaluation of the tissues by quantitative PCR. Another method for estimating the rate of transgene insertion is the so-called primed in situ hybridization technique (PRINS). This method determines not only which cells carry a transgene of interest, but also into which chromosome the gene has inserted, and even what portion of the chromosome. Briefly, labeled primers are annealed to chromosome spreads (affixed to glass slides) through one round of PCR, and the slides are then developed through normal in situ hybridization procedures. This technique combines the best features of in situ PCR and fluorescence in situ hybridization (FISH) to provide distinct chromosome location and copy number of the gene in question.

Breeding experiments are also conducted to determine if germline transmission of the transgene has occurred. In a general bird breeding experiment performed according to the present invention, each male bird was exposed to 2-3 different adult female birds for 3-4 days each. This procedure was continued with  
5 different females for a total period of 6-12 weeks. Eggs are collected daily for up to 14 days after the last exposure to the transgenic male, and each egg is incubated in a standard incubator. The resulting embryos are examined for transgene presence at day 3 or 4 using PCR. It is to be understood that the above procedure can be modified to suit animals other than birds and that selective breeding techniques may be  
10 performed to amplify gene copy numbers and protein output.

#### Production of Desired Proteins or Peptides in Egg White

In one embodiment, the transposon-based vectors of the present invention may be administered to a bird for production of desired proteins or peptides in the egg white. These transposon-based vectors preferably contain one or more of an  
15 ovalbumin promoter, an ovomucoid promoter, an ovalbumin signal sequence and an ovomucoid signal sequence. Oviduct-specific ovalbumin promoters are described in B. O'Malley et al., 1987. EMBO J., vol. 6, pp. 2305-12; A. Qiu et al., 1994. Proc. Nat. Acad. Sci. (USA), vol. 91, pp. 4451-4455; D. Monroe et al., 2000. Biochim. Biophys. Acta, 1517 (1):27-32; H. Park et al., 2000. Biochem., 39:8537-8545; and T.  
20 Muramatsu et al., 1996. Poult. Avian Biol. Rev., 6:107-123. Examples of transposon-based vectors designed for production of a desired protein in an egg white are shown in Figures 2 and 3.

#### Production of Desired Proteins or Peptides in Egg Yolk

The present invention is particularly advantageous for production of  
25 recombinant peptides and proteins of low solubility in the egg yolk. Such proteins include, but are not limited to, membrane-associated or membrane-bound proteins, lipophilic compounds; attachment factors, receptors, and components of second messenger transduction machinery. Low solubility peptides and proteins are particularly challenging to produce using conventional recombinant protein  
30 production techniques (cell and tissue cultures) because they aggregate in water-based, hydrophilic environments. Such aggregation necessitates denaturation and re-folding of the recombinantly-produced proteins, which may deleteriously affect their structure and function. Moreover, even highly soluble recombinant peptides and proteins may precipitate and require denaturation and renaturation when produced in

sufficiently high amounts in recombinant protein production systems. The present invention provides an advantageous resolution of the problem of protein and peptide solubility during production of large amounts of recombinant proteins.

In one embodiment of the present invention wherein germline transfection is obtained via intraovarian administration of the transposon-based vector, deposition of a desired protein into the egg yolk is accomplished in offspring by attaching a sequence encoding a protein capable of binding to the yolk vitellogenin receptor to a gene of interest that encodes a desired protein. This transposon-based vector can be used for the receptor-mediated uptake of the desired protein by the oocytes. In a preferred embodiment, the sequence ensuring the binding to the vitellogenin receptor is a targeting sequence of a vitellogenin protein. The invention encompasses various vitellogenin proteins and their targeting sequences. In a preferred embodiment, a chicken vitellogenin protein targeting sequence is used, however, due to the high degree of conservation among vitellogenin protein sequences and known cross-species reactivity of vitellogenin targeting sequences with their egg-yolk receptors, other vitellogenin targeting sequences can be substituted. One example of a construct for use in the transposon-based vectors of the present invention and for deposition of an insulin protein in an egg yolk is a transposon-based vector containing a vitellogenin promoter, a vitellogenin targeting sequence, a TAG sequence, a pro-insulin sequence and a synthetic polyA sequence. The present invention includes, but is not limited to, vitellogenin targeting sequences residing in the N-terminal domain of vitellogenin, particularly in lipovitellin I. In one embodiment, the vitellogenin targeting sequence contains the polynucleotide sequence of SEQ ID NO:22. In a preferred embodiment, the transposon-based vector contains a transposase gene operably-linked to a constitutive promoter and a gene of interest operably-linked to a liver-specific promoter and a vitellogenin targeting sequence.

#### Isolation and Purification of Desired Protein or Peptide

For large-scale production of protein, an animal breeding stock that is homozygous for the transgene is preferred. Such homozygous individuals are obtained and identified through, for example, standard animal breeding procedures or PCR protocols.

Once expressed, peptides, polypeptides and proteins can be purified according to standard procedures known to one of ordinary skill in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis,

high performance liquid chromatography, immunoprecipitation and the like. Substantially pure compositions of about 50 to 99% homogeneity are preferred, and 80 to 95% or greater homogeneity are most preferred for use as therapeutic agents.

In one embodiment of the present invention, the animal in which the desired protein is produced is an egg-laying animal. In a preferred embodiment of the present invention, the animal is an avian and a desired peptide, polypeptide or protein is isolated from an egg white. Egg white containing the exogenous protein or peptide is separated from the yolk and other egg constituents on an industrial scale by any of a variety of methods known in the egg industry. See, e.g., W. Stadelman et al. (Eds.), Egg Science & Technology, Haworth Press, Binghamton, NY (1995). Isolation of the exogenous peptide or protein from the other egg white constituents is accomplished by any of a number of polypeptide isolation and purification methods well known to one of ordinary skill in the art. These techniques include, for example, chromatographic methods such as gel permeation, ion exchange, affinity separation, metal chelation, HPLC, and the like, either alone or in combination. Another means that may be used for isolation or purification, either in lieu of or in addition to chromatographic separation methods, includes electrophoresis. Successful isolation and purification is confirmed by standard analytic techniques, including HPLC, mass spectroscopy, and spectrophotometry. These separation methods are often facilitated if the first step in the separation is the removal of the endogenous ovalbumin fraction of egg white, as doing so will reduce the total protein content to be further purified by about 50%.

To facilitate or enable purification of a desired protein or peptide, transposon-based vectors may include one or more additional epitopes or domains. Such epitopes or domains include DNA sequences encoding enzymatic or chemical cleavage sites including, but not limited to, an enterokinase cleavage site; the glutathione binding domain from glutathione S-transferase; polylysine; hexa-histidine or other cationic amino acids; thioredoxin; hemagglutinin antigen; maltose binding protein; a fragment of gp41 from HIV; and other purification epitopes or domains commonly known to one of skill in the art.

In one representative embodiment, purification of desired proteins from egg white utilizes the antigenicity of the ovalbumin carrier protein and particular attributes of a TAG linker sequence that spans ovalbumin and the desired protein. The TAG sequence is particularly useful in this process because it contains 1) a highly antigenic

epitope, a fragment of gp41 from HIV, allowing for stringent affinity purification, and, 2) a recognition site for the protease enterokinase immediately juxtaposed to the desired protein. In a preferred embodiment, the TAG sequence comprises approximately 50 amino acids. A representative TAG sequence is provided below.

5

Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp  
Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Thr Thr Cys Ile Leu Lys Gly Ser Cys  
Gly Trp Ile Gly Leu Leu Asp Asp Asp Asp Lys (SEQ ID NO:35)

10 The underlined sequences were taken from the hairpin loop domain of HIV gp-41 (SEQ ID NO:33). Sequences in italics represent the cleavage site for enterokinase (SEQ ID NO:34). The spacer sequence upstream of the loop domain was made from repeats of (Pro Ala Asp Asp Ala) (SEQ ID NO:31) to provide free rotation and promote surface availability of the hairpin loop from the ovalbumin carrier protein.

15 Isolation and purification of a desired protein is performed as follows:

1. Enrichment of the egg white protein fraction containing ovalbumin and the transgenic ovalbumin-TAG-desired protein.
2. Size exclusion chromatography to isolate only those proteins within a narrow range of molecular weights (a further enrichment of step 1).
- 20 3. Ovalbumin affinity chromatography. Highly specific antibodies to ovalbumin will eliminate virtually all extraneous egg white proteins except ovalbumin and the transgenic ovalbumin-TAG-desired protein.
4. gp41 affinity chromatography using anti-gp41 antibodies. Stringent application of this step will result in virtually pure transgenic ovalbumin-
- 25 TAG-desired protein.
5. Cleavage of the transgene product can be accomplished in at least one of two ways:
  - a. The transgenic ovalbumin-TAG-desired protein is left attached to the gp41 affinity resin (beads) from step 4 and the protease enterokinase is
  - 30 added. This liberates the transgene target protein from the gp41 affinity resin while the ovalbumin-TAG sequence is retained. Separation by centrifugation (in a batch process) or flow through (in a column purification), leaves the desired protein together with enterokinase in solution. Enterokinase is recovered and reused.

- b. Alternatively, enterokinase is immobilized on resin (beads) by the addition of poly-lysine moieties to a non-catalytic area of the protease. The transgenic ovalbumin-TAG-desired protein eluted from the affinity column of step 4 is then applied to the protease resin. Protease action cleaves the ovalbumin-TAG sequence from the desired protein and leaves both entities in solution. The immobilized enterokinase resin is recharged and reused.
- c. The choice of these alternatives is made depending upon the size and chemical composition of the transgene target protein.
6. A final separation of either of these two (5a or 5b) protein mixtures is made using size exclusion, or enterokinase affinity chromatography. This step allows for desalting, buffer exchange and/or polishing, as needed.
- Cleavage of the transgene product (ovalbumin-TAG-desired protein) by enterokinase, then, results in two products: ovalbumin-TAG and the desired protein.
- More specific methods for isolation using the TAG label is provided in the Examples. Some desired proteins may require additions or modifications of the above-described approach as known to one of ordinary skill in the art. The method is scaleable from the laboratory bench to pilot and production facility largely because the techniques applied are well documented in each of these settings.
- In another representative embodiment, egg whites containing a protein of interest were pooled and separated, in any order, from the yolks and other egg constituents by methods known to one skilled in the art. A variety of such methods is described in manuals known in the art, such as *Egg Science & Technology*, W. Stadelman, *et al.* (Eds.), Haworth Press, Binghamton, NY (1995).
- One non-limiting example of a method for isolating a desired peptide, polypeptide or protein from an egg white is as follows. It is to be understood that this method may be employed to isolate any desired peptide, polypeptide or protein from the eggs of transgenic animals of the present invention. This present example involved transgenes that used a portion of or the entire ovalbumin protein, or specific ovalbumin epitopes, as a carrier, linked to the protein of interest via the specified TAG sequence, or another affinity/cleavage sequence. The TAG sequence contains the hairpin loop epitope from HIV I followed by an enterokinase cleavage site.
- First, the viscosity of the egg white was lowered by subjecting the egg white to low shear forces of 3140 cps (Tung et al., 1969). The resulting pourable solution



was then filtered to remove chalazae. An ammonium sulfate precipitation was then used to enrich the fraction of transgenic protein (see, for example, *Practical Protein Chemistry A Handbook* A. Darbre (Ed.), John Wiley & Sons Ltd., 1986). Other methods of crude fractionation known in the art are also used as needed. The supernatant of this separation was then fractionated using size-exclusion chromatography, further enriching the transgenic fusion protein fraction and eliminating the ammonium sulfate from the material. The fusion protein was isolated by anti-ovalbumin affinity chromatography (batch or column) using methods known to one skilled in the art. This step may capture native ovalbumin in addition to an ovalbumin-transgene fusion protein. After elution from the anti-ovalbumin affinity resin, the transgenic protein was specifically isolated using anti-gp41 affinity chromatography (batch or column) using methods known to one skilled in the art.

Cleavage of the transgene product from the carrier and the TAG sequences was accomplished in one of at least two ways:

1) The transgenic ovalbumin-TAG-transgene target protein was left attached to the gp41 affinity resin and the protease enterokinase was added. Cleavage of the transgene by enterokinase liberated the transgene target protein from the gp41 affinity resin while the ovalbumin-TAG sequence was retained. Separation by centrifugation (in a batch process) or flow through (in a column purification), kept the transgene target protein together with enterokinase in solution. Enterokinase was recovered and reused.

2) Alternatively, enterokinase was immobilized on resin (beads) by the addition of poly-lysine moieties to a non-catalytic area of the protease. The transgenic ovalbumin-TAG-transgene target protein was eluted from the gp41 affinity chromatography resin and then applied to the protease resin. Protease action cleaved the ovalbumin-TAG sequence from the transgene target protein and left both entities in solution. The immobilized enterokinase resin was recharged and reused. The choice between these alternatives is made on a case-by case basis, depending upon the size and chemical composition of the transgene target protein.

A final separation of either of these two (process 1 or 2) protein mixtures was made using size exclusion chromatography, or enterokinase affinity chromatography. This step also allows for desalting, concentrating, buffer exchange and/or polishing, as needed.

It is believed that a typical chicken egg produced by a transgenic animal of the present invention will contain at least 0.001 mg, from about 0.001 to 1.0 mg, or from about 0.001 to 100.0 mg of exogenous protein, peptide or polypeptide, in addition to the normal constituents of egg white (or possibly replacing a small fraction of the latter). In some embodiments, a chicken egg will contain between 50 and 75 mg of exogenous protein.

One of skill in the art will recognize that after biological expression or purification, the desired proteins, fragments thereof and peptides may possess a conformation substantially different than the native conformations of the proteins, fragments thereof and peptides. In this case, it is often necessary to denature and reduce protein and then to cause the protein to re-fold into the preferred conformation. Methods of reducing and denaturing proteins and inducing re-folding are well known to those of skill in the art.

#### Production of Protein or Peptide in Milk

In addition to methods of producing eggs containing transgenic proteins or peptides, the present invention encompasses methods for the production of milk containing transgenic proteins or peptides. These methods include the administration of a transposon-based vector described above to a mammal through the duct system. In one embodiment, the transposon-based vector contains a transposase operably-linked to a constitutive promoter and a gene of interest operably-linked to mammary specific promoter. Genes of interest can include, but are not limited to antiviral and antibacterial proteins and immunoglobulins. In other embodiments, a transposon-based vector is administered to the ovary of an animal and germline transformation is obtained. In these embodiments, offspring of the transfected animal express a gene of interest in the mammary gland under the control of a mammary gland-specific promoter.

The following examples will serve to further illustrate the present invention without, at the same time, however, constituting any limitation thereof. On the contrary, it is to be clearly understood that resort may be had to various embodiments, modifications and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the invention.

## EXAMPLE 1

*IntraOviduct Administration of Transposon-Based Vectors*

Quail or chicken were selected for administration of the transposon-based vectors of the present invention. Feathers were removed from the area where surgery was performed and the area was cleansed and sterilized by rinsing it with ethanol (alcohol) and 0.5% chlorhexidine. Using the scalpel, a dorsolateral incision was made through the skin over the ovary approximately 2 cm in length. Using blunt scissors, a second incision was made through the muscle between the last two ribs to expose the oviduct beneath. A small animal retractor was used to spread the last two ribs, exposing the oviduct beneath. The oviduct was further exposed using retractors to pull the intestines to one side.

A delivery solution containing a transposon-based vector and SUPERFECT® was prepared fresh immediately before surgery. Specific ratios of vector and SUPERFECT® that were used in each experiment are provided in the Examples below. The delivery solution was warmed to room temperature prior to injection into the bird. Approximately 250-500 µl of the delivery solution was injected into the lumen of the magnum of the oviduct using a 1 cc syringe with a 27 gauge needle attached. The wound was closed and antibiotic cream liberally applied to the area surrounding the wound.

20

## EXAMPLE 2

*Preparation of Transposon-Based Vector pTnMod*

A vector was designed for inserting a desired coding sequence into the genome of eukaryotic cells, given below as SEQ ID NO:3. The vector of SEQ ID NO:3, termed pTnMod, was constructed and its sequence verified.

This vector employed a cytomegalovirus (CMV) promoter. A modified Kozak sequence (ACCATG) (SEQ ID NO:1) was added to the promoter. The nucleotide in the wobble position in nucleotide triplet codons encoding the first 10 amino acids of transposase was changed to an adenine (A) or thymine (T), which did not alter the amino acid encoded by this codon. Two stop codons were added and a synthetic polyA was used to provide a strong termination sequence. This vector uses a promoter designed to be active soon after entering the cell (without any induction) to increase the likelihood of stable integration. The additional stop codons and synthetic

30

polyA insures proper termination without read through to potential genes downstream.

The first step in constructing this vector was to modify the transposase to have the desired changes. Modifications to the transposase were accomplished with the

5 primers High Efficiency forward primer (Hef) Altered transposase (ATS)-Hef 5' ATCTCGAGACCATGTGTGAACTTGATATTTTACATGATTCTCTTTACC 3' (SEQ ID NO:36) and Altered transposase- High efficiency reverse primer (Her) 5' GATTGATCATTATCATAATTTCCCAAAGCGTAACC 3' (SEQ ID NO:37, a reverse complement primer). In the 5' forward primer ATS-Hef, the sequence

10 CTCGAG (SEQ ID NO:38) is the recognition site for the restriction enzyme Xho I, which permits directional cloning of the amplified gene. The sequence ACCATG (SEQ ID NO:1) contains the Kozak sequence and start codon for the transposase and the underlined bases represent changes in the wobble position to an A or T of codons for the first 10 amino acids (without changing the amino acid coded by the codon).

15 Primer ATS-Her (SEQ ID NO:37) contains an additional stop codon TAA in addition to native stop codon TGA and adds a Bcl I restriction site, TGATCA (SEQ ID NO:39), to allow directional cloning. These primers were used in a PCR reaction with pTnLac (p defines plasmid, tn defines transposon, and lac defines the beta fragment of the lactose gene, which contains a multiple cloning site) as the template

20 for the transposase and a FailSafe™ PCR System (which includes enzyme, buffers, dNTP's, MgCl<sub>2</sub> and PCR Enhancer; Epicentre Technologies, Madison, WI). Amplified PCR product was electrophoresed on a 1% agarose gel, stained with ethidium bromide, and visualized on an ultraviolet transilluminator. A band corresponding to the expected size was excised from the gel and purified from the

25 agarose using a Zymo Clean Gel Recovery Kit (Zymo Research, Orange, CA). Purified DNA was digested with restriction enzymes Xho I (5') and Bcl I (3') (New England Biolabs, Beverly, MA) according to the manufacturer's protocol. Digested DNA was purified from restriction enzymes using a Zymo DNA Clean and Concentrator kit (Zymo Research).

30 Plasmid gWhiz (Gene Therapy Systems, San Diego, CA) was digested with restriction enzymes Sal I and BamH I (New England Biolabs), which are compatible with Xho I and Bcl I, but destroy the restriction sites. Digested gWhiz was separated on an agarose gel, the desired band excised and purified as described above. Cutting

the vector in this manner facilitated directional cloning of the modified transposase (mATS) between the CMV promoter and synthetic polyA.

To insert the mATS between the CMV promoter and synthetic polyA in gWhiz, a Stratagene T4 Ligase Kit (Stratagene, Inc. La Jolla, CA) was used and the  
5 ligation set up according to the manufacturer's protocol. Ligated product was transformed into *E. coli* Top10 competent cells (Invitrogen Life Technologies, Carlsbad, CA) using chemical transformation according to Invitrogen's protocol. Transformed bacteria were incubated in 1 ml of SOC (GIBCO BRL, CAT# 15544-042) medium for 1 hour at 37° C before being spread to LB (Luria-Bertani media  
10 (broth or agar)) plates supplemented with 100 µg/ml ampicillin (LB/amp plates). These plates were incubated overnight at 37° C and resulting colonies picked to LB/amp broth for overnight growth at 37° C. Plasmid DNA was isolated using a modified alkaline lysis protocol (Sambrook et al., 1989), electrophoresed on a 1% agarose gel, and visualized on a U.V. transilluminator after ethidium bromide  
15 staining. Colonies producing a plasmid of the expected size (approximately 6.4 kbp) were cultured in at least 250 ml of LB/amp broth and plasmid DNA harvested using a Qiagen Maxi-Prep Kit (column purification) according to the manufacturer's protocol (Qiagen, Inc., Chatsworth, CA). Column purified DNA was used as template for sequencing to verify the changes made in the transposase were the desired changes  
20 and no further changes or mutations occurred due to PCR amplification. For sequencing, Perkin-Elmer's Big Dye Sequencing Kit was used. All samples were sent to the Gene Probes and Expression Laboratory (LSU School of Veterinary Medicine) for sequencing on a Perkin-Elmer Model 377 Automated Sequencer.

Once a clone was identified that contained the desired mATS in the correct  
25 orientation, primers CMVf-NgoM IV (5' TTGCCGGCATCAGATTGGCTAT (SEQ ID NO:40); underlined bases denote a NgoM IV recognition site) and Syn-polyA-BstE II (5' AGAGGTCACCGGGTCAATTCTTCAGCACCTGGTA (SEQ ID NO:41); underlined bases denote a BstE II recognition site) were used to PCR amplify the entire CMV promoter, mATS, and synthetic polyA for cloning upstream of the  
30 transposon in pTnLac. The PCR was conducted with FailSafe<sup>TM</sup> as described above, purified using the Zymo Clean and Concentrator kit, the ends digested with NgoM IV and BstE II (New England Biolabs), purified with the Zymo kit again and cloned upstream of the transposon in pTnLac as described below.

Plasmid pTnLac was digested with NgoM IV and BstE II to remove the ptac promoter and transposase and the fragments separated on an agarose gel. The band corresponding to the vector and transposon was excised, purified from the agarose, and dephosphorylated with calf intestinal alkaline phosphatase (New England Biolabs) to prevent self-annealing. The enzyme was removed from the vector using a Zymo DNA Clean and Concentrator-5. The purified vector and CMVp/mATS/polyA were ligated together using a Stratagene T4 Ligase Kit and transformed into *E. coli* as described above.

Colonies resulting from this transformation were screened (mini-preps) as describe above and clones that were the correct size were verified by DNA sequence analysis as described above. The vector was given the name pTnMod (SEQ ID NO:3) and includes the following components:

Base pairs 1-130 are a remainder of F1(-) on from pBluescriptII sk(-) (Stratagene), corresponding to base pairs 1-130 of pBluescriptII sk(-).

Base pairs 131 - 132 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 133 -1777 are the CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems), corresponding to bp 229-1873 of pGWiz. The CMV promoter was modified by the addition of an ACC sequence upstream of ATG.

Base pairs 1778-1779 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 1780 - 2987 are the coding sequence for the transposase, modified from Tn10 (GenBank accession J01829) by optimizing codons for stability of the transposase mRNA and for the expression of protein. More specifically, in each of the codons for the first ten amino acids of the transposase, G or C was changed to A or T when such a substitution would not alter the amino acid that was encoded.

Base pairs 2988-2993 are two engineered stop codons.

Base pair 2994 is a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 2995 - 3410 are a synthetic polyA sequence taken from the pGWiz vector (Gene Therapy Systems), corresponding to bp 1922-2337 of 10 pGWiz.

Base pairs 3415 - 3718 are non-coding DNA that is residual from vector pNK2859.

Base pairs 3719 - 3761 are non-coding  $\lambda$  DNA that is residual from pNK2859.

Base pairs 3762 - 3831 are the 70 bp of the left insertion sequence recognized by the transposon Tn10.

Base pairs 3832-3837 are a residue from ligation of restriction enzyme sites used in constructing the vector.

5        Base pairs 3838 - 4527 are the multiple cloning site from pBluescriptII sk(20), corresponding to bp 924-235 of pBluescriptII sk(-). This multiple cloning site may be used to insert any coding sequence of interest into the vector.

Base pairs 4528-4532 are a residue from ligation of restriction enzyme sites used in constructing the vector.

10        Base pairs 4533 - 4602 are the 70 bp of the right insertion sequence recognized by the transposon Tn10.

Base pairs 4603 - 4644 are non-coding  $\lambda$  DNA that is residual from pNK2859.

Base pairs 4645 - 5488 are non-coding DNA that is residual from pNK2859.

15        Base pairs 5489 - 7689 are from the pBluescriptII sk(-) base vector - (Stratagene, Inc.), corresponding to bp 761-2961 of pBluescriptII sk(-).

Completing pTnMod is a pBlueScript backbone that contains a *colE1* origin of replication and an antibiotic resistance marker (ampicillin).

20        It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

25        All plasmid DNA was isolated by standard procedures. Briefly, *Escherichia coli* containing the plasmid was grown in 500 mL aliquots of LB broth (supplemented with an appropriate antibiotic) at 37°C overnight with shaking. Plasmid DNA was recovered from the bacteria using a Qiagen Maxi-Prep kit (Qiagen, Inc., Chatsworth, CA) according to the manufacturer's protocol. Plasmid DNA was resuspended in 500  $\mu$ L of PCR-grade water and stored at -20°C until used.

### EXAMPLE 3

#### *Transposon-Based Vector pTnMCS*

30        Another transposon-based vector was designed for inserting a desired coding sequence into the genome of eukaryotic cells. This vector was termed pTnMCS and its constituents are provided below. The sequence of the pTnMCS vector is provided in SEQ ID NO:2. The pTnMCS vector contains an avian optimized polyA sequence

- operably-linked to the transposase gene. The avian optimized polyA sequence contains approximately 40 nucleotides that precede the A nucleotide string.
- Bp 1 – 130 Remainder of F1 (-) ori of pBluescriptII sk(-) (Stratagene) bp1-130
- Bp 133 – 1777 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems) bp 229-1873
- 5 Bp 1783 – 2991 Transposase, from Tn10 (GenBank accession #J01829) bp 108-1316
- Bp 2992 – 3344 Non coding DNA from vector pNK2859
- Bp 3345 – 3387 Lambda DNA from pNK2859
- Bp 3388 – 3457 70 bp of IS10 left from Tn10
- 10 Bp 3464 – 3670 Multiple cloning site from pBluescriptII sk(-), thru the XmaI site bp 924-718
- Bp 3671 - 3715 Multiple cloning site from pBluescriptII sk(-), from the XmaI site thru the XhoI site. These base pairs are usually lost when cloning into pTnMCS bp 717-673
- 15 Bp 3716 – 4153 Multiple cloning site from pBluescriptII sk(-), from the XhoI site bp 672-235
- Bp 4159 - 4228 70 bp of IS10 right from Tn10
- Bp 4229 - 4270 Lambda DNA from pNK2859
- Bp 4271 – 5114 Non-coding DNA from pNK2859
- 20 Bp 5115 - 7315 pBluescript sk (-) base vector (Stratagene, Inc.) bp 761-2961.

#### EXAMPLE 4

##### *Preparation of Transposon-Based Vector pTnMod(Oval/ENT TAG/ProIns/PA) – Chicken*

- 25 A vector was designed to insert a human proinsulin coding sequence under the control of a chicken ovalbumin promoter, and a ovalbumin gene including an ovalbumin signal sequence, into the genome of a bird given below as SEQ ID NO:42.

- Base pairs 1 - 130 are a remainder of F1(-) ori of pBluescriptII sk(-) (Stratagene) corresponding to base pairs 1-130 of pBluescriptII sk(-).
- 30

Base pairs 133 – 1777 are a CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems) corresponding to base pairs 229-1873 of pGWiz.

Base pairs 1780 – 2987 are a transposase, modified from Tn10 (GenBank accession number J01829).



Base pairs 2988-2993 are two engineered stop codons.

Base pairs 2995 – 3410 are a synthetic polyA from pGWiz (Gene Therapy Systems) corresponding to base pairs 1922- 2337 of pGWiz.

Base pairs 3415 – 3718 are non coding DNA that is residual from vector  
5 pNK2859.

Base pairs 3719 – 3761 are  $\lambda$  DNA that is residual from pNK2859.

Base pairs 3762 – 3831 are the 70 base pairs of the left insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 3838 – 4044 are a multiple cloning site from pBlueScriptII sk(-)  
10 corresponding to base pairs 924-718 of pBluescriptII sk(-).

Base pairs 4050 - 4951 are a chicken ovalbumin promoter (including SDRE) that corresponds to base pairs 431-1332 of the chicken ovalbumin promoter in GenBank Accession Number J00895 M24999.

Base pairs 4958 - 6115 are a chicken ovalbumin signal sequence and  
15 ovalbumin gene that correspond to base pairs 66-1223 of GenBank Accession Number V00383.1. (The STOP codon being omitted).

Base pairs 6122 - 6271 are a TAG sequence containing a gp41 hairpin loop from HIV I, an enterokinase cleavage site and a spacer (synthetic).

Base pairs 6272 – 6531 are a proinsulin gene.

Base pairs 6539 – 6891 are a synthetic polyadenylation sequence from pGWiz  
20 (Gene Therapy Systems) corresponding to base pairs 1920 - 2272 of pGWiz.

Base pairs 6897 - 7329 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 667-235 of pBluescriptII sk(-).

Base pairs 7335- 7404 are the 70 base pairs of the right insertion sequence  
25 (IS10) recognized by the transposon Tn10.

Base pairs 7405 - 7446 are  $\lambda$  DNA that is residual from pNK2859.

Base pairs 7447 – 8311 are non coding DNA that is residual from pNK2859.

Base pairs 8312 - 10512 are pBlueScript sk(-) base vector (Stratagene, Inc.)  
30 corresponding to base pairs 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

## EXAMPLE 5

*Transposon-Based Vector pTnMOD (CMV-CHOVg-ent-ProInsulin-synPA)*

A vector was designed to insert a proinsulin coding sequence under the control of a quail ovalbumin promoter, and a ovalbumin gene including an ovalbumin signal sequence, into the genome of a bird given below as SEQ ID NO:43.

- Bp 1 – 4045 from vector pTnMod, bp 1 - 4045
- Bp 4051 – 5695 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy systems), bp 230-1864
- 10 Bp 5702 –6855 Chicken ovalbumin gene taken from GenBank accession # V00383, bp 66-1219
- Bp 6862 - 7011 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 7012 – 7272 Human Proinsulin taken from GenBank accession # NM000207, bp 15 117-377
- Bp 7273 – 7317 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and pGWIZ (Gene Therapy Systems)
- Bp 7318 - 7670 Synthetic polyA from the cloning vector pGWIZ (Gene Therapy Systems), bp 1920-2271
- 20 Bp 7672 –11271 from cloning vector pTnMCS, bp 3716-7315

## EXAMPLE 6

*Transfection of Japanese Quail using a Transposon-based Vector containing a Proinsulin Gene via Oviduct Injections*

- 25 Two experiments were conducted in Japanese quail using transposon-based vectors containing either Oval promoter/Oval gene/GP41 Enterokinase TAG/Proinsulin/Poly A (SEQ ID NO:42) or CMV promoter/Oval gene/GP41 Enterokinase TAG/Proinsulin/Poly A (SEQ ID NO:43).

- 30 In the first experiment, the Oval promoter/Oval gene/GP41 Enterokinase TAG/Proinsulin/Poly A containing construct was injected into the lumen of the oviduct of sexually mature quail; three hens received 5  $\mu$ g at a 1:3 SUPERFECT® ratio and three received 10  $\mu$ g at a 1:3 SUPERFECT® ratio. As of the writing of the present application, at least one bird that received above-mentioned construct was producing human proinsulin in egg white (other birds remain to be tested). This

experiment indicates that 1) the DNA has been stable for at least 3 months; 2) protein levels are comparable to those observed with a constitutive promoter such as the CMV promoter; and 3) sexually mature birds can be injected and results obtained without the need for cell culture. It is estimated that each quail egg contains  
5 approximately 1.4 µg/ml of the proinsulin protein. It is also estimated that each transgenic chicken egg contains 50-75 mg of protein encoded by the gene of interest.

In the second experiment, the transposon-based vector containing CMV promoter/Oval gene/GP41 Enterokinase TAG/Proinsulin/Poly A was injected into the lumen of the oviduct of sexually immature Japanese quail. A total of 9 birds were  
10 injected. Of the 8 survivors, 3 produced human proinsulin in the white of their eggs for over 6 weeks. An ELISA assay described in detail below was developed to detect GP41 in the fusion peptide (Oval gene/GP41 Enterokinase TAG/Proinsulin) since the GP41 peptide sequence is unique and not found as part of normal egg white protein. In all ELISA assays, the same birds produced positive results and all controls worked  
15 as expected.

ELISA Procedure: Individual egg white samples were diluted in sodium carbonate buffer, pH 9.6, and added to individual wells of 96 well microtiter ELISA plates at a total volume of 0.1 ml. These plates were then allowed to coat overnight at 4°C. Prior to ELISA development, the plates were allowed warm to room  
20 temperature. Upon decanting the coating solutions and blotting away any excess, non-specific binding of antibodies was blocked by adding a solution of phosphate buffered saline (PBS), 1% (w/v) BSA, and 0.05% (v/v) Tween 20 and allowing it to incubate with shaking for a minimum of 45 minutes. This blocking solution was subsequently decanted and replaced with a solution of the primary antibody (Goat  
25 Anti-GP41 TAG) diluted in fresh PBS/BSA/Tween 20. After a two hour period of incubation with the primary antibody, each plate was washed with a solution of PBS and 0.05% Tween 20 in an automated plate washer to remove unbound antibody. Next, the secondary antibody, Rabbit anti-Goat Alkaline Phosphatase-conjugated, was diluted in PBS/BSA/Tween 20 and allowed to incubate 1 hour. The plates were then  
30 subjected to a second wash with PBS/Tween 20. Antigen was detected using a solution of *p*-Nitrophenyl Phosphate in Diethanolamine Substrate Buffer for Alkaline Phosphatase and measuring the absorbance at 30 minutes and 1 hour.

Additionally, a proinsulin fusion protein produced using a construct described above was isolated from egg white using ammonium sulfate precipitation and ion exchange chromatography. A pooled fraction of the isolated fusion protein was run on an SDS-PAGE gel shown in Figure 5, lanes 4 and 6. Lanes 1 and 10 of the gel contain molecular weight standards, lanes 2 and 8 contain non-transgenic chicken egg white, whereas lanes 3, 5, 7 and 9 are blank.

#### EXAMPLE 7

##### *Isolation of Human Proinsulin Using Anti-TAG Column Chromatography*

10 A HiTrap NHS-activated 1 mL column (Amersham) was charged with a 30 amino acid peptide that contained the gp-41 epitope containing gp-41's native disulfide bond that stabilizes the formation of the gp-41 hairpin loop. The 30 amino acid gp41 peptide is provided as SEQ ID NO:32. Approximately 10 mg of the peptide was dissolved in coupling buffer (0.2 M NaHCO<sub>3</sub>, 0.5 M NaCl, pH 8.3 and  
15 the ligand was circulated on the column for 2 hours at room temperature at 0.5 mL/minute. Excess active groups were then deactivated using 6 column volumes of 0.5 M ethanolamine, 0.5 M NaCl, pH 8.3 and the column was washed alternately with 6 column volumes of acetate buffer (0.1 M acetate, 0.5 M NaCl, pH 4.0) and ethanolamine (above). The column was neutralized using 1 X PBS. The column was  
20 then washed with buffers to be used in affinity purification: 75 mM Tris, pH 8.0 and elution buffer, 100 mM glycine-HCl, 0.5 M NaCl, pH 2.7. Finally, the column was equilibrated in 75 mM Tris buffer, pH 8.0.

Antibodies to gp-41 were raised in goats by inoculation with the gp-41 peptide described above. More specifically, goats were inoculated, given a booster injection  
25 of the gp-41 peptide and blood samples were obtained by veinupuncture. Serum was harvested by centrifugation. Approximately 30 mL of goat serum was filtered to 0.45 uM and passed over a TAG column at a rate of 0.5 mL/min. The column was washed with 75 mM Tris, pH 8.0 until absorbance at 280 nm reached a baseline. Three column volumes (3 mL) of elution buffer (100 mM glycine, 0.5 M NaCl, pH 2.7) was  
30 applied, followed by 75 mM Tris buffer, pH 8.0, all at a rate of 0.5 mL/min. One milliliter fractions were collected. Fractions were collected into 200 uL 1 M Tris, pH 9.0 to neutralize acidic fractions as rapidly as possible. A large peak eluted from the column, coincident with the application the elution buffer. Fractions were pooled. Analysis by SDS-PAGE showed a high molecular weight species that separated into

two fragments under reducing condition, in keeping with the heavy and light chain structure of IgG.

Pooled antibody fractions were used to charge two 1 mL HiTrap NHS-activated columns, attached in series. Coupling was carried out in the same manner as that used for charging the TAG column.

#### Isolation of Ovalbumin-TAG-Proinsulin from Egg White

Egg white from quail and chickens treated by intra-oviduct injection of the CMV-ovalbumin-TAG-proinsulin construct were pooled. Viscosity was lowered by subjecting the allantoic fluid to successively finer pore sizes using negative pressure filtration, finishing with a 0.22  $\mu$ M pore size. Through the process, egg white was diluted approximately 1:16. The clarified sample was loaded on the Anti-TAG column and eluted in the same manner as described for the purification of the anti-TAG antibodies. A peak of absorbance at 280 nm, coincident with the application of the elution buffer, indicated that protein had been specifically eluted from the TAG column. Fractions containing the eluted peak were pooled for analysis.

The pooled fractions from the Anti-TAG affinity column were characterized by SDS-PAGE and western blot analysis. SDS-PAGE of the pooled fractions revealed a 60 kDa molecular weight band not present in control egg white fluid, consistent with the predicted molecular weight of the transgenic protein. Although some contaminating bands were observed, the 60 kDa species was greatly enriched compared to the other proteins. An aliquot of the pooled fractions was cleaved overnight at room temperature with the protease, enterokinase. SDS-PAGE analysis of the cleavage product, revealed a band not present in the uncut material that co-migrated with a commercial human proinsulin positive control. Western blot analysis showed specific binding to the 60 kDa species under non-reducing condition (which preserved the hairpin epitope of gp-41 by retaining the disulfide bond). Western analysis of the low molecular weight species that appeared upon cleavage with an anti-human proinsulin antibody, conclusively identified the cleaved fragment as human proinsulin.

### EXAMPLE 8

#### *Purification Procedures for Insulin*

##### I. ELISA data for egg characterization/identification

An ELISA was employed for the initial screening of eggs and, thereby, identification of hens producing positive eggs. With further modifications this procedure was used for the initial quantification of recombinant protein amounts. These procedures were aided by the successful purification of an initial stock of the recombinant proinsulin (RPI). This stock of protein is used in the development of a double antibody assay that increases the sensitivity and reduces the background in the assay. Subsequent identification of hens producing positive eggs obviate the need to screen each egg collected. Only periodic checks are needed to determine if production levels are consistent.

## 10 II. Egg White (EW) or Albumin Preparation

### A. Clarification – Ovomucin precipitation

Eggs from hens positively identified as producing RPI are pooled for RPI purification. The initial purification step involved diluting the pool 1:1 with 100 mM Tris-HCl, pH 8 for a final concentration of 50 mM Tris-HCl. The pH of this solution was then adjusted to 6 and ovomucin was allowed to precipitate at 4°C for a minimum of 3hrs (preferably overnight) with constant stirring. The precipitated ovomucin was then pelleted and removed by centrifugation at 2400 x g. After collection of the RPI containing supernatant, the pH of this solution was readjusted to 8.

### B. Filtration

20 To prepare the egg white for loading onto the column and, thereby, minimize the potential for clogging the columns during loading, the egg white solution was filtered to at least 0.45 um.

Initially, the ovomucin precipitated egg white solution was subjected to successive filtration steps with the pore size of the filtration membrane decreasing at each step. This procedure involved time and dilution of the egg white solution to reach 0.45 um filtration.

Amersham's hollow-fiber ultrafiltration apparatus was used to produced a column-ready solution filtered down to < 0.2 um with an undiluted starting solution. This approach minimized the time and the solution dilution needed to prepare the egg white solution for column loading.

## 30 III. Purification

### A. Affinity Chromatography –

Using antibody with specificity to a synthetic peptide modeled after the enterokinase recognition site, initial purification schemes involved developing a one-step column purification procedure for the RPI.

Goats immunized with the synthetic Ent peptide were employed to produce anti-Ent Tag antiserum which was used in the egg screening ELISAs followed by antibody purification. The purified goat Anti-Ent Tag antibodies were covalently

bound to the matrix of HiTrap NHS-activated HP columns (Amersham) and subsequently used to specifically bind and purify the RPI.

5 An initial attempt was made to direct the first purification step against the ovalbumin portion of the recombinant protein using an antibody specific for the ovalbumin portion. The present purification scheme employed a combination of classical techniques such as ammonium sulfate precipitation, ion exchange, and gel filtration chromatography.

10 After the initial ovomucin precipitation, the egg white solution was subjected to protein precipitation using a 40% ammonium sulfate fractionation. The precipitated protein was subsequently collected via centrifugation and resuspended in 50 mM Tris-HCl, pH 8. The resuspended protein solution was dialyzed to remove residual  $(\text{NH}_4)_2\text{SO}_4$  or subjected to gel filtration to remove the  $(\text{NH}_4)_2\text{SO}_4$  and partially isolate the RPI from the remaining egg white protein. The RPI was further isolated via anion exchange chromatography using a 0 to 0.5M NaCl gradient in 50 mM Tris-HCl, pH 8. Two possible elution profiles were observed. One at approximately 25% of the 0.5 M NaCl gradient without  $(\text{NH}_4)_2\text{SO}_4$  precipitation. The second was observed at less than 16% gradient (approximately 7%) following 40%  $(\text{NH}_4)_2\text{SO}_4$  precipitation and a longer gradient. Fractions containing RPI were identified by SDS-PAGE analysis and pooled.

20 Three gel filtration columns, differing by column size and fractionation range, were employed in RPI purification and/or desalting: Superdex 75 10/300 GL, Hiload 26/60 Superdex 75, and Hiload 26/60 Superdex 200. Using these individual columns at different steps in the purification scheme increased the efficiency of the process. Fractions containing RPI were identified by SDS-PAGE analysis and pooled.

25 Cleavage of the RPI Enterokinase recognition site was accomplished using purified enterokinase from Sigma. Enterokinase, 0.004 Unit/ $\mu\text{l}$  per reaction, was applied to the pooled and, if necessary, concentrated protein solution. The digestion reaction was incubated at room temperature (up to 30°C in a rolling hybridization oven) for a minimum of 16 h and in some cases up to 48 hrs of incubation. The digestion efficiency was followed using 16.5% Tris-Tricine SDS-PAGE peptide gels. All gel staining utilized Simply Blue Coomassie Staining Solutions. Free Proinsulin was observed on gels after digestion.

30 A subsequent gel filtration separation was employed to obtain purified Proinsulin, and to remove the remaining Ovalbumin portion of the RPI and residual native EW proteins. Select steps in the purification process were analyzed using the 2-dimensional Beckman Coulter ProteomeLab PF2D Protein Fractionation System.

## EXAMPLE 9

*Optimization of Intra-oviduct and Intra-ovarian Arterial Injections*

Overall transfection rates of oviduct cells in a flock of chicken or quail hens are enhanced by synchronizing the development of the oviduct and ovary within the flock. When the development of the oviducts and ovaries are uniform across a group of hens and when the stage of oviduct and ovarian development can be determined or predicted, timing of injections is optimized to transfect the greatest number of cells. Accordingly, oviduct development is synchronized as described below to ensure that a large and uniform proportion of oviduct secretory cells are transfected with the gene of interest.

Hens are treated with estradiol to stimulate oviduct maturation as described in Oka and Schimke (T. Oka and RT Schimke, J. Cell Biol., 41, 816 (1969)), Palmiter, Christensen and Schimke (J Biol. Chem. 245(4):833-845, 1970). Specifically, repeated daily injections of 1 mg estradiol benzoate are performed sometime before the onset of sexual maturation, a period ranging from 1 – 14 weeks of age. After a stimulation period sufficient to maximize development of the oviduct, hormone treatment is withdrawn thereby causing regression in oviduct secretory cell size but not cell number. At an optimum time after hormone withdrawal, the lumens of the oviducts of treated hens are injected with the transposon-based vector. Hens are subjected to additional estrogen stimulation after an optimized time during which the transposon-based vector is taken up into oviduct secretory cells. Re-stimulation by estrogen activates transposon expression, causing the integration of the gene of interest into the host genome. Estrogen stimulation is then withdrawn and hens continue normal sexual development. If a developmentally regulated promoter such as the ovalbumin promoter is used, expression of the transposon-based vector initiates in the oviduct at the time of sexual maturation. Intra-ovarian artery injection during this window allows for high and uniform transfection efficiencies of ovarian follicles to produce germ-line transfections and possibly oviduct expression.

Other means are also used to synchronize the development, or regression, of the oviduct and ovary to allow high and uniform transfection efficiencies. Alterations of lighting and/or feed regimens, for example, cause hens to 'molt' during which time the oviduct and ovary regress. Molting is used to synchronize hens for transfection, and may be used in conjunction with other hormonal methods to control regression and/or development of the oviduct and ovary.



## EXAMPLE 10

*Preparation of Transposon-Based Vector pTnMod(Oval/ENT TAG/ProIns/PA) – Quail*

- 5 A vector is designed for inserting a proinsulin gene under the control of a quail ovalbumin promoter, and a ovalbumin gene including an ovalbumin signal sequence, into the genome of a bird given below as SEQ ID NO:44.

Base pairs 1 -130 are a remainder of F1(-) ori of pBluescriptII sk(-)  
 10 (Stratagene) corresponding to base pairs 1-130 of pBluescriptII sk(-).

Base pairs 133 – 1777 are a CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems) corresponding to base pairs 229-1873 of pGWiz.

Base pairs 1780 – 2987 are a transposase, modified from Tn10 (GenBank accession number J01829).

15 Base pairs 2988-2993 are an engineered stop codon.

Base pairs 2995 – 3410 are a synthetic polyA from pGWiz (Gene Therapy Systems) corresponding to base pairs 1922- 2337 of pGWiz.

Base pairs 3415 – 3718 are non coding DNA that is residual from vector pNK2859.

20 Base pairs 3719 – 3761 are  $\lambda$  DNA that is residual from pNK2859.

Base pairs 3762 – 3831 are the 70 base pairs of the left insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 3838 – 4044 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 924-718 of pBluescriptII sk(-).

25 Base pairs 4050 - 4938 are the Japanese quail ovalbumin promoter (including SDRE, steroid-dependent response element). The Japanese quail ovalbumin promoter was isolated by its high degree of homology to the chicken ovalbumin promoter (GenBank accession number J00895 M24999, base pairs 431-1332). Some deletions were noted in the quail sequence, as compared to the chicken sequence.

30 Base pairs 4945 - 6092 are a quail ovalbumin signal sequence and ovalbumin gene that corresponds to base pairs 54 – 1201 of GenBank accession number X53964.1. (The STOP codon being omitted).

Base pairs 6093 - 6246 are a TAG sequence containing a gp41 hairpin loop from HIV I an enterokinase cleavage site and a spacer (synthetic).

Base pairs 6247 – 6507 are a proinsulin gene.

Base pairs 6514 – 6866 are a synthetic polyadenylation sequence from pGWiz (Gene Therapy Systems) corresponding to base pairs 1920 - 2272 of pGWiz.

Base pairs 6867 - 7303 are a multiple cloning site from pBlueScriptII sk(-)  
5 corresponding to base pairs 667-235 of pBluescriptII sk(-).

Base pairs 7304- 7379 are the 70 base pairs of the right insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 7380 - 7421 are  $\lambda$  DNA that is residual from pNK2859.

Base pairs 7422 – 8286 are non coding DNA that is residual from pNK2859.

10 Base pairs 8287 - 10487 are pBlueScript sk(-) base vector (Stratagene, Inc.) corresponding to base pairs 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences  
15 in the above construct represent restriction site remnants.

#### EXAMPLE 11

*Preparation of Transposon-Based Vector pTnMod(Oval/ENT TAG/p146/PA) – Chicken*

20 A vector was designed for inserting a p146 gene under the control of a chicken ovalbumin promoter, and a ovalbumin gene including an ovalbumin signal sequence, into the genome of a bird. The vector sequence is provided below as SEQ ID NO:45.

Base pairs 1 - 130 are a remainder of F1(-) ori of pBluescriptII sk(-) (Stratagene) corresponding to base pairs 1-130 of pBluescriptII sk(-).

25 Base pairs 133 – 1777 are a CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems) corresponding to base pairs 229-1873 of pGWiz.

Base pairs 1780 – 2987 are a transposase, modified from Tn10 (GenBank accession number J01829).

Base pairs 2988-2993 are an engineered stop codon.

30 Base pairs 2995 – 3410 are a synthetic polyA from pGWiz (Gene Therapy Systems) corresponding to base pairs 1922- 2337 of pGWiz.

Base pairs 3415 – 3718 are non coding DNA that is residual from vector pNK2859.

Base pairs 3719 – 3761 are  $\lambda$  DNA that is residual from pNK2859.

Base pairs 3762 – 3831 are the 70 base pairs of the left insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 3838 – 4044 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 924-718 of pBluescriptII sk(-).

5       Base pairs 4050 - 4951 are a chicken ovalbumin promoter (including SDRE, steroid-dependent response element) that corresponds to base pairs 431-1332 of the chicken ovalbumin promoter in GenBank Accession Number J00895 M24999.

Base pairs 4958 - 6115 are a chicken ovalbumin signal sequence and Ovalbumin gene that correspond to base pairs 66-1223 of GenBank Accession  
10   Number V00383.1 (The STOP codon being omitted).

Base pairs 6122 - 6271 are a TAG sequence containing a gp41 hairpin loop from HIV I, an enterokinase cleavage site and a spacer (synthetic).

Base pairs 6272 – 6316 are a p146 sequence (synthetic) with 2 added stop codons.

15       Base pairs 6324 – 6676 are a synthetic polyadenylation sequence from pGWiz (Gene Therapy Systems) corresponding to base pairs 1920 - 2272 of pGWiz.

Base pairs 6682 - 7114 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 667-235 of pBluescriptII sk(-).

Base pairs 7120- 7189 are the 70 base pairs of the right insertion sequence  
20   (IS10) recognized by the transposon Tn10.

Base pairs 7190 - 7231 are  $\lambda$  DNA that is residual from pNK2859.

Base pairs 7232 – 8096 are non coding DNA that is residual from pNK2859.

Base pairs 8097 - 10297 are pBlueScript sk(-) base vector (Stratagene, Inc.) corresponding to base pairs 761-2961 of pBluescriptII sk(-).

25

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

30

## EXAMPLE 12

### *Preparation of Transposon-Based Vector pTnMod(Oval/ENT TAG/p146/PA) – Quail*

A vector was designed for inserting a p146 gene under the control of a quail ovalbumin promoter, and a ovalbumin gene including an ovalbumin signal sequence, into the genome of a bird. The vector sequence is given below as SEQ ID NO:46.

Base pairs 1 - 130 are a remainder of F1(-) ori of pBluescriptII sk(-) (Stratagene) corresponding to base pairs 1-130 of pBluescriptII sk(-).

Base pairs 133 - 1777 are a CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems) corresponding to base pairs 229-1873 of pGWiz.

5       Base pairs 1780 - 2987 are a transposase, modified from Tn10 (GenBank accession number J01829).

Base pairs 2988-2993 are an engineered stop codon.

Base pairs 2995 - 3410 are a synthetic polyA from pGWiz (Gene Therapy Systems) corresponding to base pairs 1922-2337 of pGWiz.

10       Base pairs 3415 - 3718 are non coding DNA that is residual from vector pNK2859.

Base pairs 3719 - 3761 are  $\lambda$  DNA that is residual from pNK2859.

Base pairs 3762 - 3831 are the 70 base pairs of the left insertion sequence (IS10) recognized by the transposon Tn10.

15       Base pairs 3838 - 4044 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 924-718 of pBluescriptII sk(-).

Base pairs 4050 - 4938 are the Japanese quail ovalbumin promoter (including SDRE, steroid-dependent response element). The Japanese quail ovalbumin promoter was isolated by its high degree of homology to the chicken ovalbumin promoter  
20 (GenBank accession number J00895 M24999, base pairs 431-1332).

Bp 4945 - 6092 are a quail ovalbumin signal sequence and ovalbumin gene that corresponds to base pairs 54 - 1201 of GenBank accession number X53964.1. (The STOP codon being omitted).

Base pairs 6097 - 6246 are a TAG sequence containing a gp41 hairpin loop  
25 from HIV I, an enterokinase cleavage site and a spacer (synthetic).

Base pairs 6247 - 6291 are a p146 sequence (synthetic) with 2 added stop codons.

Base pairs 6299 - 6651 are a synthetic polyadenylation sequence from pGWiz (Gene Therapy Systems) corresponding to base pairs 1920 - 2272 of pGWiz.

30       Base pairs 6657 - 7089 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 667-235 of pBluescriptII sk(-).

Base pairs 7095- 7164 are the 70 base pairs of the right insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 7165 - 7206 are  $\lambda$  DNA that is residual from pNK2859.

Base pairs 7207 – 8071 are non coding DNA that is residual from pNK2859.

Base pairs 8072 - 10272 are pBlueScript sk(-) base vector (Stratagene, Inc.) corresponding to base pairs 761-2961 of pBluescriptII sk(-).

- 5           It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

### EXAMPLE 13

#### 10    *Additional Transposon-Based Vectors for Administration to an Animal*

- The following example provides a description of various transposon-based vectors of the present invention and several constructs that have been made for insertion into the transposon-based vectors of the present invention. These examples are not meant to be limiting in any way. The constructs for insertion into a transposon-based vector are provided in a cloning vector pTnMCS or pTnMod, both described above.

#### pTnMCS (CMV-CHOVg-ent-ProInsulin-synPA) (SEQ ID NO:47)

- Bp 1 – 3670 from vector PTnMCS, bp 1 - 3670
- 20   Bp 3676 – 5320 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems), bp 230-1864
- Bp 5327 – 6480 Chicken ovalbumin gene taken from GenBank accession # V00383, bp 66-1219
- Bp 6487 - 6636 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- 25   Bp 6637 – 6897 Human Proinsulin taken from GenBank accession # NM000207, bp 117-377
- Bp 6898 – 6942 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and pGWIZ (Gene Therapy Systems)
- 30   Bp 6943 - 7295 Synthetic polyA from the cloning vector pGWIZ (Gene Therapy Systems), bp 1920-2271
- Bp 7296 – 10895 from cloning vector pTnMCS, bp 3716-7315

pTnMCS (CMV-prepro-ent-ProInsulin-synPA)

Bp 1 – 3670 from vector pTnMCS, bp 1 - 3670

Bp 3676 – 5320 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems), bp 230-1864

- 5 Bp 5326 - 5496 Capsite/prepro taken from GenBank accession # X07404, bp 563–733  
 Bp 5504 - 5652 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 5653 – 5913 Human Proinsulin taken from GenBank accession # NM000207, bp 117-377

- 10 Bp 5914 – 5958 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and pGWIZ (Gene Therapy Systems)

Bp 5959-6310 Synthetic polyA from the cloning vector pGWIZ (Gene Therapy Systems), bp 1920-2271

Bp 6313–9912 from cloning vector pTnMCS, bp 3716-7315

15

pTnMCS(Chicken OVep+OVg'+ENT+proins+syn polyA)

Bp 1–3670 from vector pTnMCS, bp 1 - 3670

Bp 3676–4350 Chicken Ovalbumin enhancer taken from GenBank accession #S82527.1 bp 1-675

- 20 Bp 4357–5692 Chicken Ovalbumin promoter taken from GenBank accession # J00895M24999 bp 1-1336

Bp 5699–6917 Chicken Ovalbumin gene from GenBank Accession # V00383.1 bp 2-1220. (This sequence includes the 5'UTR, containing putative cap site, bp 5699-5762.)

- 25 Bp 6924-7073 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 7074-7334 Human proinsulin GenBank Accession # NM000207 bp 117-377

Bp 7335-7379 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)

- 30 Bp 7380-7731 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271

Bp 7733–11332 from vector pTnMCS, bp 3716 - 7315

pTnMCS(Chicken OVep+prepro+ENT+proins+syn polyA)

- Bp 1 – 3670 from cloning vector pTnMCS, bp 1 - 3670
- Bp 3676 – 4350 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1 bp 1-675
- 5 Bp 4357 – 5692 Chicken Ovalbumin promoter taken from GenBank accession # J00895-M24999 bp 1-1336
- Bp 5699–5869 Cecropin cap site and prepro, Genbank accession # X07404 bp 563-733
- Bp 5876 - 6025 Synthetic spacer sequence and hairpin loop of HIV gp41 with an
- 10 added enterokinase cleavage site
- Bp 6026 - 6286 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 6287 - 6331 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- Bp 6332 - 6683 Synthetic polyA from the cloning vector gWIZ (Gene Therapy
- 15 Systems) bp 1920 - 2271
- Bp 6685 – 10284 from cloning vector pTnMCS, bp 3716 - 7315

pTnMCS(Quail OVep+OVg'+ENT+proins+syn polyA)

- Bp 1 – 3670 from cloning vector pTnMCS, bp 1 - 3670
- 20 Bp 3676 – 4333 Quail Ovalbumin enhancer: 658 bp sequence, amplified in-house from quail genomic DNA, roughly equivalent to the far-upstream chicken ovalbumin enhancer, GenBank accession # S82527.1, bp 1-675. (There are multiple base pair substitutions and deletions in the quail sequence, relative to chicken, so the number of bases does not correspond exactly.)
- 25 Bp 4340 – 5705 Quail Ovalbumin promoter: 1366 bp sequence, amplified in-house from quail genomic DNA, roughly corresponding to chicken ovalbumin promoter, GenBank accession # J00895-M24999 bp 1-1336. (There are multiple base pair substitutions and deletions between the quail and chicken sequences, so the number of bases does not correspond exactly.)
- 30 Bp 5712 – 6910 Quail Ovalbumin gene, EMBL accession # X53964, bp 1-1199. (This sequence includes the 5'UTR, containing putative cap site bp 5712-5764.)
- Bp 6917 - 7066 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 7067 - 7327 Human proinsulin GenBank Accession # NM000207 bp 117-377

- Bp 7328 - 7372 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- Bp 7373 - 7724 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- 5 Bp 7726 – 11325 from cloning vector pTnMCS, bp 3716 - 7315
- pTnMCS(Quail OVep+prepro+ENT+proins+syn polyA)
- Bp 1 – 3670 from cloning vector pTnMCS, bp 1 - 3670
- Bp 3676 – 4333 Quail Ovalbumin enhancer: 658 bp sequence, amplified from quail
- 10 genomic DNA, roughly equivalent to the far- upstream chicken ovalbumin enhancer, GenBank accession #S82527.1, bp 1-675. (There are multiple base pair substitutions and deletions in the quail sequence, relative to chicken, so the number of bases does not correspond exactly.)
- Bp 4340 – 5705 Quail Ovalbumin promoter: 1366 bp sequence, amplified from quail
- 15 genomic DNA, roughly corresponding to chicken ovalbumin promoter, GenBank accession # J00895-M24999 bp 1-1336. (There are multiple base pair substitutions and deletions between the quail and chicken sequences, so the number of bases does not correspond exactly.)
- Bp 5712–5882 Cecropin cap site and prepro, Genbank accession # X07404 bp 563-
- 20 733
- Bp 5889 - 6038 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 6039 - 6299 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 6300 - 6344 Spacer DNA, derived as an artifact from the cloning vectors pTOPO
- 25 Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- Bp 6345 - 6696 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- Bp 6698 – 10297 from cloning vector pTnMCS, bp 3716 - 7315.
- 30 pTnMOD (CMV-prepro-ent-proins-synPA)
- Bp 1 – 4045 from vector PTnMCS, bp 1 - 4045
- Bp 4051 – 5695 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy systems), bp 230-1864
- Bp 5701-5871 Capsite/prepro taken from GenBank accession # X07404, bp 563–733



- Bp 5879 - 6027 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 6028-6288 Human Proinsulin taken from GenBank accession # NM000207, bp 117-377
- 5 Bp 6289 – 6333 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and pGWIZ (Gene Therapy Systems)
- Bp 6334 - 6685 Synthetic polyA from the cloning vector pGWIZ (Gene Therapy Systems), bp 1920-2271
- Bp 6687 –10286 from cloning vector pTnMCS, bp 3716-7315
- 10 pTnMOD(Chicken OVep+OVg'+ENT+proins+syn polyA)
- Bp 1 – 4045 from cloning vector pTnMod, bp 1 - 4045
- Bp 4051 – 4725 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1 bp 1-675
- 15 Bp 4732 – 6067 Chicken Ovalbumin promoter taken from GenBank accession # J00895-M24999 bp 1-1336
- Bp 6074 – 7292 Chicken Ovalbumin gene from GenBank Accession # V00383.1 bp 2-1220. (This sequence includes the 5'UTR, containing putative cap site bp 6074-6137.)
- 20 Bp 7299 - 7448 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 7449 - 7709 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 7710 - 7754 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- 25 Bp 7755 - 8106 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- Bp 8108 – 11707 from cloning vector pTnMod, bp 3716 - 7315
- pTnMOD(Chicken OVep+prepro+ENT+proins+syn polyA)
- 30 Bp 1 – 4045 from cloning vector pTnMCS, bp 1 - 4045
- Bp 4051 – 4725 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1 bp 1-675
- Bp 4732 – 6067 Chicken Ovalbumin promoter taken from GenBank accession # J00895-M24999 bp 1-1336

- Bp 6074–6244 Cecropin cap site and prepro, Genbank accession # X07404 bp 563-733
- Bp 6251 - 6400 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- 5 Bp 6401 - 6661 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 6662 - 6706 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- Bp 6707 - 7058 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- 10 Bp 7060 – 10659 from cloning vector pTnMCS, bp 3716 - 7315
- pTnMOD(Quail OVep+OVg'+ENT+proins+syn polyA)
- Bp 1 – 4045 from cloning vector pTnMCS, bp 1 - 4045
- Bp 4051 – 4708 Quail Ovalbumin enhancer: 658 bp sequence, amplified in-house
- 15 from quail genomic DNA, roughly equivalent to the far-upstream chicken ovalbumin enhancer, GenBank accession # S82527.1, bp 1-675. (There are multiple base pair substitutions and deletions in the quail sequence, relative to chicken, so the number of bases does not correspond exactly.)
- Bp 4715 – 6080 Quail Ovalbumin promoter: 1366 bp sequence, amplified in-house
- 20 from quail genomic DNA, roughly corresponding to chicken ovalbumin promoter, GenBank accession # J00895-M24999 bp 1-1336. (There are multiple base pair substitutions and deletions between the quail and chicken sequences, so the number of bases does not correspond exactly.)
- Bp 6087 – 7285 Quail Ovalbumin gene, EMBL accession # X53964, bp 1-1199. (This
- 25 sequence includes the 5'UTR, containing putative cap site bp 6087-6139.)
- Bp 7292 - 7441 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 7442 - 7702 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 7703 - 7747 Spacer DNA, derived as an artifact from the cloning vectors pTOPO
- 30 Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- Bp 7748 - 8099 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- Bp 8101 – 11700 from cloning vector pTnMCS, bp 3716 - 7315

pTnMOD(Quail OVep+prepro+ENT+proins+syn polyA)

- Bp 1 – 4045 from cloning vector pTnMCS, bp 1 - 4045
- Bp 4051 – 4708 Quail Ovalbumin enhancer: 658 bp sequence, amplified in-house from quail genomic DNA, roughly equivalent to the far-upstream chicken ovalbumin enhancer, GenBank accession #S82527.1, bp 1-675. (There are multiple base pair substitutions and deletions in the quail sequence, relative to chicken, so the number of bases does not correspond exactly.)
- 5 Bp 4715 – 6080 Quail Ovalbumin promoter: 1366 bp sequence, amplified in-house from quail genomic DNA, roughly corresponding to chicken ovalbumin promoter, GenBank accession # J00895-M24999 bp 1-1336. (There are multiple base pair substitutions and deletions between the quail and chicken sequences, so the number of bases does not correspond exactly.)
- 10 Bp 6087–6257 Cecropin cap site and Prepro, Genbank accession # X07404 bp 563-733
- 15 Bp 6264 - 6413 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 6414 - 6674 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 6675 - 6719 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- 20 Bp 6720 - 7071 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- Bp 7073 – 10672 from cloning vector pTnMCS, bp 3716 - 7315

pTnMOD (CMV-prepro-ent-hGH-CPA)

- 25 Bp 1–4045 from vector PTnMOD, bp 1 - 4045
- Bp 4051–5694 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy systems), bp 230-1873
- Bp 5701-5871 Capsite/Prepro taken from GenBank accession # X07404, bp 563–733
- Bp 5878-6012 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- 30 Bp 6013–6666 Human growth hormone taken from GenBank accession # V00519, bp 1-654
- Bp 6673–7080 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058

Bp 7082–10681 from cloning vector pTnMOD, bp 4091-7690

pTnMCS (CHOVep-prepro-ent-hGH-CPA)

Bp 1–3670 from vector PTnMCS, bp 1-3670

- 5 Bp 3676–4350 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1, bp 1–675

Bp 4357–5692 Chicken Ovalbumin promoter taken from GenBank accession # J00899-M24999, bp 1-1336

Bp 5699–5869 Capsite/Prepro taken from GenBank accession # X07404, bp 563–733

- 10 Bp 5876–6010 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 6011–6664 Human growth hormone taken from GenBank accession # V00519, bp 1-654

- Bp 6671–7078 Conalbumin polyA taken from GenBank accession # Y00407, bp 15 10651-11058

Bp 7080–10679 from cloning vector pTnMCS, bp 3716-7315

pTnMCS (CMV-prepro-ent-hGH-CPA)

Bp 1 – 3670 from vector PTnMCS, bp 1 - 3670

- 20 Bp 3676–5319 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy systems), bp 230-1873

Bp 5326–5496 Capsite/Prepro taken from GenBank accession # X07404, bp 563 – 733

Bp 5503–5637 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

- 25 Bp 5638–6291 Human growth hormone taken from GenBank accession # V00519, bp 1-654

Bp 6298–6705 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058

Bp 6707–10306 from cloning vector pTnMCS, bp 3716-7315

30

pTnMOD (CHOVep-prepro-ent-hGH-CPA)

Bp 1–4045 from vector PTnMOD, bp 1-4045

Bp 4051–4725 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1, bp 1–675

- Bp 4732-6067 Chicken Ovalbumin promoter taken from GenBank accession # J00899-M24999, bp 1-1336
- Bp 6074-6244 Capsite/Prepro taken from GenBank accession # X07404, bp 563-733
- Bp 6251-6385 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- 5 Bp 6386-7039 Human growth hormone taken from GenBank accession # V00519, bp 1-654
- Bp 7046-7453 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058
- 10 Bp 7455-11054 from cloning vector pTnMOD, bp 4091-7690
- PTnMod(CMV/Transposase/ChickOvep/prepro/ProteinA/ConpolyA)
- BP 1-130 remainder of F1 (-) ori of pBluescriptII sk(-) (Stratagene) bp 1-130.
- BP 133-1777 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems) bp 229-1873.
- 15 BP 1780-2987 Transposase, modified from Tn10 (GenBank #J01829).
- BP 2988-2993 Engineered DOUBLE stop codon.
- BP 2994-3343 non coding DNA from vector pNK2859.
- BP 3344-3386 Lambda DNA from pNK2859.
- 20 BP 3387-3456 70bp of IS10 left from Tn10.
- BP 3457-3674 multiple cloning site from pBluescriptII sk(-) bp 924-707.
- BP 3675-5691 Chicken Ovalbumin enhancer plus promoter from a Topo Clone 10 maxi 040303 (5' XmaI, 3' BamHI)
- BP 5698-5865 prepro with Cap site amplified from cecropin of pMON200 GenBank # X07404 (5'BamHI, 3'KpnI)
- 25 BP 5872-7338 Protein A gene from GenBank# J01786, mature peptide bp 292-1755 (5'KpnI, 3'SacII)
- BP 7345-7752 ConPolyA from Chicken conalbumin polyA from GenBank # Y00407 bp 10651-11058. (5'SacII, 3'XhoI)
- 30 BP 7753-8195 multiple cloning site from pBluescriptII sk(-) bp 677-235.
- BP 8196-8265 70 bp of IS10 left from Tn10.
- BP 8266-8307 Lambda DNA from pNK2859
- BP 8308-9151 noncoding DNA from pNK2859
- BP 9152-11352 pBluescriptII sk(-) base vector (Stratagene, INC.) bp 761-2961

All patents, publications and abstracts cited above are incorporated herein by reference in their entirety. It should be understood that the foregoing relates only to preferred embodiments of the present invention and that numerous modifications or  
5 alterations may be made therein without departing from the spirit and the scope of the present invention as defined in the following claims.

## CLAIMS

We Claim:

1. A method of producing a transgenic animal comprising, administering  
5 to an oviduct or an ovary of an animal a composition comprising a transposon-based vector.
2. The method of claim 1, wherein the composition is injected into an  
artery leading to the oviduct or the ovary.
- 10 3. The method of claim 1, wherein the composition is injected into a lumen of the oviduct.
4. The method of claim 1, wherein the composition further comprises a  
15 transfection reagent.
5. The method of claim 1, wherein the transposon-based vector comprises:
  - a) a transposase gene operably linked to a first promoter, the  
20 transposase gene encoding for a transposase; and
  - b) one or more genes of interest operably-linked to one or more additional promoters; wherein the one or more genes of interest and their operably-linked promoters are flanked by transposase insertion sequences recognized by the transposase, and wherein the first promoter comprises a  
25 modified Kozak sequence comprising ACCATG (SEQ ID NO:1).
6. The method of claim 5, wherein one to twenty codons at a beginning of the transposase gene are modified by changing a nucleotide at a third base position of the codon to an adenine or thymine without modifying the amino  
30 acid encoded by the codon.
7. The method of claim 1, wherein the transposon-based vector comprises:
  - a) a transposase gene operably linked to a first promoter and an  
35 avian optimized polyA sequence, the transposase gene encoding for a transposase; and
  - b) one or more genes of interest operably-linked to one or more additional promoters;

c) wherein the one or more genes of interest and their operably-linked promoters are flanked by transposase insertion sequences recognized by the transposase.

5           8.     The method of claim 7, wherein the first promoter is a constitutive promoter.

          9.     The method of claim 7, wherein the first promoter is an oviduct-specific promoter selected from the group consisting of ovalbumin,  
10     ovotransferrin, ovomucoid, ovomucin, g2 ovoglobulin, g3 ovoglobulin, ovoflavoprotein, and ovostatin.

          10.    The method of claim 7, wherein the one or more gene of interest is operably-linked to a second promoter.

15           11.    The method of claim 10, wherein the second promoter is an oviduct-specific promoter selected from the group consisting of ovalbumin, ovotransferrin, ovomucoid, ovomucin, g2 ovoglobulin, g3 ovoglobulin, ovoflavoprotein, and ovostatin.

20           12.    The method of claim 7, wherein the transposon-based vector further comprises an egg directing sequence or an enhancer operably-linked to the one or more genes of interest.

25           13.    A method of increasing expression of a polynucleotide sequence in an avian comprising, administering to the avian a composition comprising the polynucleotide sequence operably-linked to an avian optimized polyA sequence.

30           14.    A transgenic animal made with the method of Claim 1.

          15.    The transgenic animal of Claim 14, wherein the animal is a bird.

          16.    An egg produced by the transgenic bird of Claim 15.

35           17.    The egg of Claim 16, wherein the egg contains a protein, a polypeptide or a peptide encoded by the transposon-based vector.



18. A method of producing proteins, polypeptides or peptides comprising:  
a) administering to an oviduct of an egg-laying animal a composition comprising a transposon-based vector, wherein transposon-based vector comprises a transposase gene operably linked to a first promoter, the transposase gene encoding for a transposase, and one or more genes of interest operably-linked to one or more additional promoters; and,  
b) permitting the one or more genes of interest to be expressed into a protein, a polypeptide or a peptide.
19. The method of Claim 18, further comprising  
a) collecting an egg from the egg-laying animal;  
b) harvesting egg white containing the protein, the polypeptide or the peptide; and,  
c) purifying the protein, the polypeptide or the peptide.
20. The method of any of the preceding claims, wherein the animal is a bird.
21. The method of any of the preceding claims, wherein the animal is a poultry bird.
22. The method of any of the preceding claims, wherein the transposase is a Tn10 transposase.
23. A method of producing a transgenic mammal comprising, administering to an intramammary duct system of a mammal a composition comprising a transposon-based vector.
24. A transgenic mammal made with the method of Claim 23.
25. Milk produced by the transgenic mammal of Claim 24.
26. The milk of Claim 25, wherein the milk contains a protein, a polypeptide or a peptide encoded by the transposon-based vector.
27. A method of producing proteins, polypeptides or peptides comprising:  
a) administering to an intramammary duct system of a mammal a composition comprising a transposon-based vector, wherein transposon-based

vector comprises a transposase gene operably linked to a first promoter, the transposase gene encoding for a transposase, and one or more genes of interest operably-linked to one or more additional promoters; and,

- 5           b)     permitting the one or more genes of interest to be expressed into a protein, a polypeptide or a peptide.

28.     The method of Claim 27, further comprising

- a)     collecting milk from the mammal; and,  
          b)     purifying the protein, the polypeptide or the peptide.
- 10

1/5

FIGURE 1






FIGURE 3




4/5

FIGURE 4

IS	Tet; Pro	Ovgen	Pro	Ovotrans	Pro	Ovomucin	IS
----	----------	-------	-----	----------	-----	----------	----

5/5

FIGURE 5



## Appendix A

SEQ ID NO:1 (modified Kozak sequence)  
ACCATG

5

SEQ ID NO:2 (pTnMCS)

1 ctgacgcgcc ctgtacggcg gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga  
61 ccgctacact tgcacgcgcc ctacgcgccg ctcccttcgc tttcttccct tcctttctcg  
10 121 ccacgttcgc cggcatcaga ttggctattg gccattgcat acgttgatc catatcataa  
181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac  
241 tagttattaa tagtaataa ttacggggtc attagtcat agcccatata tggagttccg  
301 cgttacataa cttacggtaa atggcccgcc tggctgacg cccaacgacc cccgccatt  
361 gacgtcaata atgacgtatg ttcccatagt aacgccataa gggactttcc attgacgtca  
15 421 atgggtggag tatttacggg aaactgcccc cttggcagta catcaagtgt atcatatgcc  
481 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgccagta  
541 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac  
601 catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcaccggg  
661 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg  
20 721 ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg gtaggcgtgt  
781 acggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg  
841 ccacccacgc tgttttgacc tccatagaag acaccgggac cgatccagcc tccgcccgcg  
901 ggaacgggtg attggaacgc ggattccccg tgccaagagt gacgtaagta ccgctatag  
961 actctatagg cacacccctt tggctcttat gcatgctata ctgtttttgg cttggggcct  
25 1021 atacaccccc gcttccttat gctatagggt atggtatagc ttagcctata ggtgtgggtt  
1081 attgaccatt attgaccact cccctattgg tgacgatact ttccattact aatccataac  
1141 atggctcttt gccacaacta tctctattgg ctatatgcca atactctgtc cttcagagac  
1201 tgacacggac tctgtatttt tacaggatgg ggtcccattt attatttaca aatccacata  
1261 tacaacaacg ccgtcccccg tgcccgcagt ttttattaaa catagcgtgg gatctccacg  
30 1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctcgc gtacgcccgg agcttccaca  
1381 tccgagccct ggtcccatgc ctccagcgcc tcatggtcgc tccgagctc cttgtctcta  
1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag  
1501 gccgtggcgg tagggtatgt gtctgaaaat gagcgtggag attgggctcg caccggtgac  
1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgtgtattc  
35 1621 tgataaagat cagaggtaac tcccgttgcg gtgctgttaa cgggtggagg cagtgtagt  
1681 tgagcagtag tgggtgtgct cgcgcgcgcc accagacata atagctgaca gactaacaga  
1741 ctgttccctt ccatgggtct tttctgcagt caccgtcggg ccatgtgca actcgatatt  
1801 ttacacgact ctctttacca attctgcccc gaattacact taaaacgact caacagctta  
1861 atgcttggctt gccacgcatt acttgactgt aaaactctca ctcttaccga acttggcctg  
40 1921 aacgtgccaa ccaaaagcgg aacaaaacat aacatcaaac gaatcgaccg attgttaggt  
1981 aatcgtcacc tccacaaaga gcgactcgct gtataccgtt ggcagctag ctttatctgt  
2041 tccggcaata cgtagcccat tgtacttgtt gactggtctg atattcgtga gcaaaaacga  
2101 cttatgggat tgcgagcttc agtcgcacta caccgtctgt ctgttactct tttatgagaa  
2161 gcgttcccg tttcagagca atgttcaaa aaagctcatg accaatttct agccgacctt  
45 2221 gcgagcattc taccgagtaa caccacaccg ctcatgtca gtgatgctgg ctttaaagt  
2281 ccatggataa aatccgttga gaagctgggt tgggtactgt taagtcgagt aagaggaaaa  
2341 gtacaatatg cagacctagg agcggaaaac tggaaaacta tcagcaactt acatgatatt  
2401 tcatctagtc actcaaagac tttaggctat aagaggctga ctaaaagcaa tccaatctca  
2461 tggcaaaattc tattgtataa atctcgtct aaaggccgaa aaaatcagcg ctgcacacgg  
50 2521 actcattgtc accacccgct acctaaaatc tactcagcgt cggcaaaagg gccatgggtt  
2581 ctacgaacta acttaoctgt tgaaattoga acacccaaac aacttgtaa tatctattcg  
2641 aagcgaatgc agattgaaga aacctccga gacttgaaa gtccctgcta cggactaggc  
2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg  
2761 atgcttcaac taacatgttg gcttgcgggc gttcatgctc agaaacaagg ttgggacaag  
55 2821 cacttccagg ctaacacagt cagaaatoga aacgtactct caacagttcg cttaggcatg  
2881 gaagttttgc ggcattctgg ctacacaata acaagggaag acttactcgt ggctgcaacc  
2941 ctactagctc aaaatttatt cacacatggg tacgctttgg ggaattatg aggggatcgc  
3001 tctagagcga tccgggatct cgggaaaagc gttggtgacc aaagggtgcct tttatcatca  
3061 ctttaaaaat aaaaaacaat tactcagtcg ctgttataag cagcaattaa tttatgttga  
60 3121 tgcctacatc acaacaaaaa ctgatttaac aaatgggttg tctgccttag aaagtatatt  
3181 tgaacattat cttgattata ttattgataa taataaaac cttatcccta tccaagaagt  
3241 gatgcctatc attggttga atgaacttga aaaaaattag ccttgaatac attactggta  
3301 aggtaaacgc cattgtcagc aaattgatcc aagagaacca acttaagct ttctgacgg  
3361 aatgttaatt ctggttgacc ctgagcactg atgaatcccc taatgatttt gtaaaaaatc  
65 3421 attaaagtaa ggtggatata catcttgtca tatgatcccg gtaatgtgag ttagctcact  
3481 cattaggcac cccaggcttt acactttatg cttccgctc gtatgttgtg tggaaattgtg



3541 agcggataac aatttcacac aggaacacgc tatgaccatg attacgcaa gcgcgcaatt  
 3601 aaccctcact aaaggggaaca aaagctggag ctccaccgcg gtggcgccgc ctctagaact  
 3661 agtggatccc ccgggctgca ggaattcgat atcaagctta tggataccgc tgacctcgag  
 3721 ggggggcccc gtacccaatt cgccttatag tgagtcgtat tacgcgcgct cactggccgt  
 5 3781 cgtttttacaa cgtcgtgact gggaaaaccc tggcgttacc caacttaac gccttgacgc  
 3841 acatccccct ttcgccaagt ggcgtaatag cgaagagggc cgcaccgatc gcccttccca  
 3901 acagttgcgc agcctgaatg gcgaatggaa attgtaagcg ttaatatatt gttaaaattc  
 3961 gcgttaaatt tttgttaaat cagctcattt tttaaaccaat agggccgaat cggcaaaatc  
 4021 ccttataaat caaaaagaata gaccgagata ggggttgagt ttgttccagt ttggaacaag  
 10 4081 agtcaccactat taaagaacgt ggactccaac gtcaaaagggc gaaaaaccgt ctatcagggc  
 4141 gatggcccac tactccggga tcatatgaca agatgtgtat ccaccttaac ttaatgattt  
 4201 ttaccaaaat cattagggga tcatcagtg ctcagggtca acgagaatta acattccgtc  
 4261 aggaaagcct atgatgatga tgtgcttaaa aacttactca atggctggtt atgcatatcg  
 4321 caatacatgc gaaaaaccta aaagagcttg ccgataaaaa aggccaattt attgctattt  
 15 4381 accggcgctt tttattgagc ttgaaagata aataaaatag atagggttta ttggaagcta  
 4441 aatcttcttt atcgtaaaaa atgcctcttt ggggttatcaa gagggctcatt atatttcgcg  
 4501 gaataacatc atttgggtgac gaaataacta agcacttgct tctgtttac tccctcgagc  
 4561 ttgagggggtt aacatgaagg tcatcgatag caggataata atacagtaaa acgctaaacc  
 4621 aataatccaa atccagccat cccaaattgg tagtgaatga ttataaataa cagcaaacag  
 20 4681 taatgggcca ataacaccgc ttgcatgtgt aaggctcacc aataatccct gtaaagcacc  
 4741 ttgctgatga ctctttgttt ggatagacat cactccctgt aatgcaggta aagcgatccc  
 4801 accaccagcc aataaaaatta aaacagggaa aactaaccac ccttcagata taaacgctaa  
 4861 aaaggcaaat gcactactat ctgcaataaa tccgagcagt actgcgcttt tttcgcctat  
 4921 ttagtggtcta ttcttctgc cacaagggtt tggaaacttg agtgtaaaag accaagaccc  
 25 4981 gtaatgaaaa gccaacatc atgctatcca tcatcacgat ttctgtaata gcaccacacc  
 5041 gtgctggatt ggctatcaat gcgctgaaat aataatcaac aaatggcatc gttataaag  
 5101 tgatgtatac cgtcagctt ttgttccctt tagtgagggt taattgcgcg cttggcgtaa  
 5161 tcatgggtcat agctgtttcc tgtgtgaaat tgttatccgc tcacaattcc acacaacata  
 5221 cgagccggaa gcataaagt taaagcctgg ggtgcctaat gactgagcta actcacatta  
 30 5281 attgcgttgc gctcactgcc cgttttccag tcgggaaacc tgcgtgcca gctgcattaa  
 5341 tgaatcggcc aacgcgcggg gagaggcggg ttgctgattg ggcgctcttc cgttccctcg  
 5401 ctactcgact cgtcgcgtc ggtcgttcgg ctgcggcgag cggtatcagc tcaactcaag  
 5461 gcggtaatac ggttatccac agaatcaggg gataacgcag gaaagaacat gtgagcaaaa  
 5521 ggccagcaaa agggccaggaa ccgtaaaaag gccgcgttgc tggcggtttt ccataggctc  
 35 5581 cgcccccttg acgagcatca caaaaatcga cgtcaagtc agagggtggc aaaccggaca  
 5641 ggactataaa gataccagcg gtttccccct tctgctgcgc tctgttcccg  
 5701 accctgccgc ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct  
 5761 catagctcac gctgtaggta tctcagttcg gtgtaggctg ttcgctccaa gctgggctgt  
 5821 gtgcacgaac ccccggttca gcccgaccgc tgcgccttat ccggtaacta tctgtttgag  
 40 5881 tccaaccggg taagacagca cttatcgcca ctggcgagc cactgggtaa caggatagc  
 5941 agagcgaggt atgtaggcg gctacagag ttcttgaagt ggtggcctaa ctacggctac  
 6001 actagaagga cagtatttgg tatctgcgct ctgctgaagc cagttacctt cggaaaaaga  
 6061 gttggttagct cttgatccgg caaacaacc accgctggtg gcggtgggtt ttttgtttgc  
 6121 aagcagcaga ttacgcgcag aaaaaaagga tctcaagaag atcctttgat cttttctacg  
 45 6181 gggctctgacg ctcaagtggaa cgaaaactca cgttaaggga ttttgggtcat gagattatca  
 6241 aaaaggatct tcacctagat ctttttaaat taaaaatgaa gttttaaatc aatctaaggt  
 6301 atatatgagt aaacttggtc tgacagttac caatgcttaa tcagtggagg acctatctca  
 6361 gcgatctgtc tatttcgttc atoccatagtt gcctgactcc cgtcgtgta gataactacg  
 50 6421 atacgggagg gcttaccatc tggccccagt gctgcaatga taccgggaga cccacgctca  
 6481 ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg cagaagtggg  
 6541 cctgcaactt tatccgcctc catccagctt attaattgtt gccgggaagc tagagtaagt  
 6601 agttcgccag ttaatagttt gcgcaacggt gttgccattg ctacaggcat cgtgggtgca  
 6661 cgctcgtcgt ttggtatggc ttcattcagc tccgggttccc aacgatcaag gcgagttaca  
 55 6721 tgatccccc tgttgtgcaa aaaagcgggt agctccttcg gtctcctgat cgttgtcaga  
 6781 agtaagttgg ccgcagtggt atcactcatg gttatggcag cactgcataa ttctcttact  
 6841 gtcatgccat ccgtaagatg cttttctgtg actgggtgagt actcaaccaa gtcattctga  
 6901 gaatagtgtg tgcggcgacc gagttgctct tgccggcggt caatacggga taataccgcg  
 6961 ccacatagca gaactttaaa agtgctcatc attggaaaac gttcttcggg gcgaaaactc  
 60 7021 tcaaggatct taccgctggt gagatccagt tcgatgtaac ccactcgtgc acccaactga  
 7081 tcttccagcat cttttacttt caccagcggt tctgggtgag caaaaacagg aaggcaaaat  
 7141 gccgcaaaaa agggaataag ggcgacacgg aaatggtgaa tactcatact cttccttttt  
 7201 caatattatt gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt  
 7261 atttagaaaa ataaacaaat aggggttcgc cgcacatttc cccgaaaagt gccac

65

SEQ ID NO:3 (pTnMod)

	CTGACGCGCC	CTGTAGCGGC	GCATTAAGCG	CGGCGGGTGT	GGTGGTTACG	50
	CCGAGCGTGA	CCGCTACACT	TGCCAGCGCC	CTAGCGCCCC	CTCCTTTCGC	100
	TTTCTTCCCT	TCCTTCTCG	CCACGTTCCG	CGGCATCAGA	TTGGCTATTG	150
5	GCCATTGCAT	ACGTTGTATC	CATATCATAA	TATGTACATT	TATATTGGCT	200
	CATGTCCAAC	ATTACCGCCA	TGTTGACATT	GATTATTGAC	TAGTTATTAA	250
	TAGTAATCAA	TTACGGGGTC	ATTAGTTCAT	AGCCCATATA	TGGAGTTCCG	300
	CGTTACATAA	CTTACGGTAA	ATGGCCCGCC	TGGCTGACCG	CCCAACGACC	350
	CCGCCCCATT	GACGTCAATA	ATGACGTATG	TTCCCATAGT	AACGCCAATA	400
10	GGGACTTTCC	ATTGACGTCA	ATGGGTGGAG	TATTTACGGT	AAACTGCCCC	450
	CTTGGCAGTA	ATCAAGTGT	ATCATATGCC	AAGTACGCCC	CCTATTGACG	500
	TCAATGACGG	TAAATGGCCC	GCCTGGCATT	ATGCCCAGTA	CATGACCTTA	550
	TGGGACTTTC	CTACTTGGCA	GTACATCTAC	GTATTAGTCA	TCGCTATTAC	600
	CATGGTGATG	CGGTTTTGGC	AGTACATCAA	TGGGCGTGGA	TAGCGGTTTG	650
	ACTCACGGGG	ATTTCCAAGT	CTCCACCCCA	TTGACGTCAA	TGGGAGTTTG	700
15	TTTTGGCACC	AAAATCAACG	GGACTTTCCA	AAATGTCGTA	ACAACCTCCG	750
	CCCATTTGACG	CAAATGGGCG	GTAGGCGTGT	ACGGTGGGAG	GTCTATATAA	800
	GCAGAGCTCG	TTTAGTGAAC	CGTCAGATCG	CCTGGAGACG	CCATCCACGC	850
	TGTTTTGACC	TCCATAGAAG	ACACCGGGAC	CGATCCAGCC	TCCGCGGCCG	900
	GGAACGGTGC	ATTGGAACGC	GGATTCCCCG	TGCCAAGAGT	GACGTAAGTA	950
20	CCGCTTATAG	ACTCTATAGG	CACACCCCTT	TGGCTCTTAT	GCATGCTATA	1000
	CTGTTTTTGG	CTTGGGGCCT	ATACACCCCC	GCTTCCTTAT	GCTATAGGTG	1050
	ATGGTATAGC	TTAGCCTATA	GGTGTGGGTT	ATTGACCATT	ATTGACCACT	1100
	CCCCTATTGG	TGACGATACT	TTCCATTACT	AATCCATAAC	ATGGCTCTTT	1150
	GCCACAACCTA	TCTCTATTGG	CTATATGCCA	ATACTCTGTC	CTTCAGAGAC	1200
25	TGACACGGAC	TCTGTATTTT	TACAGGATGG	GGTCCCATT	ATTATTTACA	1250
	AATTCACATA	TACAACAACG	CCGTCCCCCG	TGCCCGCAGT	TTTATTAAA	1300
	CATAGCGTGG	GATCTCCACG	CGAATCTCGG	GTACGTGTTT	CGGACATGGG	1350
	CTCTTCTCCG	GTAGCGGCGG	AGCTTCCACA	TCCGAGCCCT	GGTCCCATGC	1400
	CTCCAGCGGC	TCATGGTCGC	TCGGCAGCTC	CTTGCTCCTA	ACAGTGGAGG	1450
30	CCAGACTTAG	GCACAGCACA	ATGCCACCA	CCACCAGTGT	GCCGCACAAG	1500
	GCCGTGGCGG	TAGGGTATGT	GTCTGAAAAT	GAGCGTGGAG	ATTGGGCTCG	1550
	CACGGCTGAC	GCAGATGGAA	GACTTAAGGC	AGCGGCAGAA	GAAGATGCAG	1600
	GCAGCTGAGT	TGTTGTATTC	TGATAAGAGT	CAGAGGTAAC	TCCCCTTGCG	1650
	GTGCTGTAA	CGGTGGAGGG	CAGTGTAGTC	TGAGCAGTAC	TCGTTGCTGC	1700
35	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GACTAACAGA	CTGTTCTTTT	1750
	CCATGGGTCT	TTTCTGCAGT	CACCGTCGGA	CCATGTGTGA	ACTTGATATT	1800
	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAACGACT	1850
	CAACAGCTTA	ACGTTGGCTT	GCCACGCATT	ACTTGACTGT	AAAACCTCTA	1900
	CTCTTACCGA	ACTTGGCCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
40	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCAAC	TCCACAAAGA	2000
	GCGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
	GATGCCCAT	GTACTTGTG	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAC	2100
	TTATGGTATT	GCGAGCTTCA	GTCGCACTAC	ACGGTCGTTT	TGTTACTCTT	2150
	TATGAGAAAG	GTTTCCCGCT	TTGAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
45	CCAATTTCTA	GCCGACCTTG	CGAGCATCTT	ACCGAGTAAC	ACCACACCGC	2250
	TCATTGTCAG	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAATATGC	2350
	AGACCTAGGA	GCGGAAAAC	GGAAACCTAT	CAGCAACTTA	CATGATATGT	2400
	CATCTAGTCA	CTCAAAGACT	TTAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
50	CCAATCTCAT	GCCAAATCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
	AAATCAGCGC	TCGACACGGA	CTCATTGTCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTT	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTTCGAA	CACCCAAACA	ACTTGTTAAT	ATCTATTCTGA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
55	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTGATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTCCG	TTAGGCATGG	AAGTTTTGCG	GCATTCTGGC	2900
	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
60	AAATTTATTC	ACACATGGTT	ACGCTTTGGG	GAAATTATGA	TAATGATCCA	3000
	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050

	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
	CCCTCCCCCG	TGCCTTCCTT	GACCCTGGAA	GGTGCCACTC	CCACTGTCCT	3150
	TTCTTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3200
	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
5	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
10	CATCACAACA	AAAACCTGAT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
	CCTATCCAAG	AAGTGATGCC	TATCATTTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
15	GACCCTGAGC	ACTGATGAAT	CCCTAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCAATATGAT	CCCGGTAATG	TGAGTTAGCT	3850
	CACTCATTAG	GCACCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
	CATGATTACG	CCAAGCGCGC	AATTAACCTT	CACATAAGGG	AACAAAAGCT	4000
20	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGG	TCCCCCGGGC	4050
	TGCAGGAATT	CGATATCAAG	CTTATCGATA	CCGCTGACCT	CGAGGGGGGG	4100
	CCCGGTACCC	AATTCGCCCT	ATAGTGAGTC	GTATTACGCG	CGCTCACTGG	4150
	CCGTCGTTTT	ACAACGTCTG	GACTGGGAAA	ACCCTGGCGT	TACCCAACCT	4200
	AATCGCCTTG	CAGCACATCC	CCCTTTTCGCC	AGCTGGCGTA	ATAGCGAAGA	4250
25	GGCCCCGACC	GATCGCCCTT	CCCAACAGTT	GCGCAGCCTG	AATGGCGAAT	4300
	GGAAATTGTA	AGCGTTAATA	TTTTGTTAAA	ATTGCGGTTA	AATTTTTGTT	4350
	AAATCAGCTC	ATTTTTTAAC	CAATAGGCCG	AAATCGGCAA	AATCCCTTAT	4400
	AAATCAAAAG	AATAGACCGA	GATAGGGTTG	AGTGTGTTC	CAGTTTGGAA	4450
	CAAGAGTCCA	CTATTAAAGA	ACGTGGACTC	CAACGTCAAA	GGGCGAAAAA	4500
30	CCGTCTATCA	GGGCGATGGC	CCACTACTCC	GGGATCATAT	GACAAGATGT	4550
	GTATCCACCT	TAACCTAATG	ATTTTTACCA	AAATCATTAG	GGGATTCATC	4600
	AGTGCTCAGG	GTCAACGAGA	ATTAACATTC	CGTCAGGAAA	GCTTATGATG	4650
	ATGATGTGCT	TAAAACTTA	CTCAATGGCT	GGTTATGCAT	ATCGCAATAC	4700
	ATGCGAAAAA	CCTAAAAGAG	CTTGCCGATA	AAAAAGGCCA	ATTTATTGCT	4750
35	ATTTACCGCG	GCTTTTTATT	GAGCTTGAAA	GATAAATAAA	ATAGATAGGT	4800
	TTTATTTGAA	GCTAAATCTT	CTTTATCGTA	AAAAATGCCC	TCTTGGGTTA	4850
	TCAAGAGGGT	CATTATATTT	CGCGGAATAA	CATCATTTGG	TGACGAAATA	4900
	ACTAAGCACT	TGTCTCCTGT	TTACTCCCCT	GAGCTTGAGG	GGTTAACATG	4950
	AAGTTCATCG	ATAGCAGGAT	AATAATACAG	TAAAACGCTA	AACCAATAAT	5000
40	CCAAATCCAG	CCATCCCAAA	TTGGTAGTGA	ATGATTATAA	ATAACAGCAA	5050
	ACAGTAATGG	GCCAATAACA	CCGTTGTCAT	TGGTAAGGCT	CACCAATAAT	5100
	CCCTGTAAAG	CACCTTGCTG	ATGACTCTTT	GTTTGGATAG	ACATCACTCC	5150
	CTGTAATGCA	GGTAAAGCGA	TCCCACCACC	AGCCAATAAA	ATTAAAAACAG	5200
	GGAAAACTAA	CCAACCTTCA	GATATAAACG	CTAAAAAGGC	AAATGCACTA	5250
45	CTATCTGCAA	TAAATCCGAG	CAGTACTGCC	GTTTTTTTCGC	CCATTTAGTG	5300
	GCTATTCTTC	CTGCCACAAA	GGCTTGGAAT	ACTGAGTGTA	AAAGACCAAG	5350
	ACCCGTAATG	AAAAGCCAAC	CATCATGCTA	TTCATCATCA	CGATTTCTGT	5400
	AATAGCACCA	CACCGTGCTG	GATTGGCTAT	CAATGCGCTG	AAATAATAAT	5450
	CAACAAATGG	CATCGTTAAA	TAAGTGATGT	ATACCGATCA	GCTTTTGTTC	5500
50	CCTTTAGTGA	GGGTAAATTG	CGCGCTTGCC	GTAATCATGG	TCATAGCTGT	5550
	TTCTGTGTG	AAATTGTTAT	CCGCTCACAA	TTCCACACAA	CATACGAGCC	5600
	GGAAGCATAA	AGTGTAAGC	TGCGGGTGCC	TAATGAGTGA	GCTAACTCAC	5650
	ATTAAATTGCG	TTGCGCTCAC	TGCCCCGTTT	CCAGTCGGGA	AACCTGTCGT	5700
	GCCAGCTGCA	TTAATGAATC	GGCCAACGCG	CGGGGAGAGG	CGGTTTGCGT	5750
55	ATTGGGCGCT	CTTCCGCTTC	CTCGCTCACT	GACTCGCTGC	GCTCGGTCGT	5800
	TCGGCTGCGG	CGAGCGGTAT	CAGCTCACTC	AAAGGCGGTA	ATACGGTTAT	5850
	CCACAGAAATC	AGGGGATAAC	GCAGGAAAGA	ACATGTGAGC	AAAAGGCCAG	5900
	CAAAAGGCCA	GGAACCGTAA	AAAGGCCGCG	TTGCTGGCGT	TTTTCCATAG	5950
	GCTCCGCCCC	CCTGACGAGC	ATCACAAAAA	TCGACGCTCA	AGTCAGAGGT	6000
60	GGCGAAACCC	GACAGGACTA	TAAAGATACC	AGGCGTTTCC	CCCTGGAAGC	6050
	TCCCTCGTGC	GCTCTCCTGT	TCCGACCCTG	CCGCTTACCG	GATACCTGTC	6100

CGCCTTTCTC CCTTCGGGAA GCGTGGCGCT TTCTCATAGC TCACGCTGTA 6150  
 GGTATCTCAG TTCGGTGTAG GTCGTTCGCT CCAAGCTGGG CTGTGTGCAC 6200  
 GAACCCCCCG TTCAGCCCGA CCGCTGCGCC TTATCCGGTA ACTATCGTCT 6250  
 TGAGTCCAAC CCGGTAAGAC ACGACTTATC GCCACTGGCA GCAGCCACTG 6300  
 5 GTAACAGGAT TAGCAGAGCG AGGTATGTAG GCGGTGCTAC AGAGTTCTTG 6350  
 AAGTGGTGGC CTAACACGG CTACACTAGA AGGACAGTAT TTGGTATCTG 6400  
 CGCTCTGCTG AAGCCAGTTA CCTTCGGAAA AAGAGTTGGT AGCTCTTGAT 6450  
 CCGGCAAAAC AACCACCGCT GGTAGCGGTG GTTTTTTTGT TTGCAAGCAG 6500  
 CAGATTACGC GCAGAAAAAA AGGATCTCAA GAAGATCCTT TGATCTTTTC 6550  
 10 TACGGGGTCT GACGCTCAGT GGAACGAAAA CTCACGTTAA GGGATTTTGG 6600  
 TCATGAGATT ATCAAAAAGG ATCTTCACCT AGATCCTTTT AAATTAATAA 6650  
 TGAAGTTTAA AATCAATCTA AAGTATATAT GAGTAAACTT GGTCTGACAG 6700  
 TTACCAATGC TTAATCAGTG AGGCACCTAT CTCAGCGATC TGTCTATTTT 6750  
 GTTCATCCAT AGTTGCCTGA CTCCCCGTCG TGTAGATAAC TACGATACGG 6800  
 15 GAGGGCTTAC CATCTGGCCC CAGTGCTGCA ATGATACCGC GAGACCCACG 6850  
 CTCACCGGCT CCAGATTAT CAGCAATAAA CCAGCCAGCC GGAAGGGCCG 6900  
 AGCGCAGAAG TGGTCCTGCA ACTTTATCCG CCTCCATCCA GTCTATTAAT 6950  
 TGTTCGCGGG AAGCTAGAGT AAGTAGTTCG CCAGTTAATA GTTTGCGCAA 7000  
 CGTTGTTGCC ATTGCTACAG GCATCGTGGT GTCACGCTCG TCGTTTGTA 7050  
 20 TGGCTTCATT CAGCTCCGT TCCCAACGAT CAAGGCGAGT TACATGATCC 7100  
 CCCATGTTGT GCAAAAAGC GGTTAGCTCC TTCGGTCTC CGATCGTTGT 7150  
 CAGAAGTAAG TTGGCCGCGAG TGTTATCACT CATGGTTATG GCAGCACTGC 7200  
 ATAATTCTCT TACTGTCTAT CCATCCGTAA GATGCTTTTC TGTGACTGGT 7250  
 GAGTACTCAA CCAAGTCATT CTGAGAATAG TGTATGCGGC GACCGAGTTG 7300  
 25 CTCTTGCCCG GCGTCAATAC GGGATAATAC CGCGCCACAT AGCAGAACTT 7350  
 TAAAAGTGCT CATCATTGGA AAACGTTCTT CGGGGCGAAA ACTCTCAAGG 7400  
 ATCTTACCGC TGTTGAGATC CAGTTCGATG TAACCCACTC GTGCACCCAA 7450  
 CTGATCTTCA GCATCTTTTA CTTTCACCAG CGTTTCTGGG TGAGCAAAAA 7500  
 CAGGAAGGCA AAATGCCGCA AAAAAGGGAA TAAGGGCGAC ACGGAAATGT 7550  
 30 TGAATACTCA TACTCTTCCT TTTTCAATAT TATTGAAGCA TTTATCAGGG 7600  
 TTATTGTCTC ATGAGCGGAT ACATATTTGA ATGTATTTAG AAAAATAAAC 7650  
 AAATAGGGGT TCCGCGCACA TTTCCCCGAA AAGTGCCAC 7689

35 SEQ ID NO:4 (a Kozak sequence)  
 ACCATGG

SEQ ID NO:5 (a Kozak sequence)  
 40 ACCATGT

SEQ ID NO:6 (a Kozak sequence)  
 AAGATGT

SEQ ID NO:7 (a Kozak sequence)  
 45 ACGATGA

SEQ ID NO:8 (a Kozak sequence)  
 AAGATGG

50 SEQ ID NO:9 (a Kozak sequence)  
 GACATGA

SEQ ID NO:10 (a Kozak sequence)  
 55 ACCATGA

SEQ ID NO:11 (conalbumin polyA)  
 tctgccattg ctgcttcctc tgcccttcct cgctcactctg aatgtggctt cttcgctact  
 gccacagcaa gaaataaaat ctcaacatct aaatgggttt cctgaggttt ttcaagagtc

gttaagcaca ttccttcccc agcaccctt gctgcaggcc agtgccaggc accaacttgg  
 ctactgctgc ccatgagaga aatccagttc aatattttcc aaagcaaat ggattacata  
 tggcctagat cctgattaac aggcgtttgt attatctagt gctttcgctt caccagatt  
 atcccattgc ctccc

5

SEQ ID NO:12 (synthetic polyA)

GGCGCCTGGATCCAGATCACTTCTGGCTAATAAAAGATCAGAGCTCTAGAGATCTGTGTGTTGGTTTTT  
 TGTGGATCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCTCCCCCGTGCCTTCCTTGACC  
 CTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGG  
 TGTCACTTCTATTCTGGGGGGTGGGGTGGGGCAGCACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGG  
 CATGCTGGGGATGCGGTGGGCTCTATGGGTACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTC  
 TCTCGGTACCTCTCTC

10

SEQ ID NO:13 (avian optimized polyA)

15

ggggatcgc tctagagcga  
 tccgggatct cgggaaaagc  
 gttggtgacc aaaggtgcct  
 tttatcatca ctttaaaaat  
 aaaaaacaat tactcagtg  
 ctgttataag cagcaattaa  
 ttatgattga tgcctacatc  
 acaacaaaaa ctgatttaac  
 aaatggttgg tctgccttag  
 aaagtatat tgaacattat  
 cttgattata ttattgataa  
 taataaaaaa cttatcccta  
 tccaagaagt gatgcctatc  
 attggttggga atgaacttga  
 aaaaaattag ccttgaatac  
 attactggta aggtaaacgc  
 cattgtcagc aaattgatcc  
 aagagaacca a

20

25

30

35

SEQ ID NO:14  
 (vitellogenin promoter)

TGAATGTGTT CTTGTGTTAT  
 CAATATAAAT CACAGTTAGT  
 GATGAAGTTG GCTGCAAGCC  
 TGCATCAGTT CAGCTACTTG  
 GCTGCATTTT GTATTTGGTT  
 CTGTAGGAAA TGCAAAAGGT  
 TCTAGGCTGA CCTGCACTTC  
 TATCCCTCTT GCCTTACTGC  
 TGAGAATCTC TGCAGGTTTT  
 AATTGTTTAC ATTTTGCTCC  
 CATTACTTTT GGAAGATAAA  
 ATATTTACAG AATGCTTATG  
 AAACCTTTGT TCATTTAAAA  
 ATATTCCTGG TCAGCGTGAC  
 CGGAGCTGAA AGAACACATT  
 GATCCCGTGA TTTCAATAAA  
 TACATATGTT CCATATATTG  
 TTTCTCAGTA GCCTCTTAAA  
 TCATGTGCGT TGGTGACAT  
 ATGAATACAT GAATAGCAAA  
 GGTTTATCTG GATTACGCTC  
 TGGCCTGCAG GAATGGCCAT  
 AAACCAAAGC TGAGGGAAGA

40

45

50

55

60

GGGAGAGTAT AGTCAATGTA  
 GATTATACTG ATTGCTGATT  
 GGGTTATTAT CAGCTAGATA  
 ACAAATTGGG TCAGGTGCCA  
 5 GGTCAACATA ACCTGGGCAA  
 AACCAGTCTC ATCTGTGGCA  
 GGACCATGTA CCAGCAGCCA  
 GCCGTGACCC AATCTAGGAA  
 AGCAAGTAGC ACATCAATTT  
 10 TAAATTTATT GTAAATGCCG  
 TAGTAGAAGT GTTTTACTGT  
 GATACATTGA AACTTCTGGT  
 CAATCAGAAA AAGGTTTTTT  
 ATCAGAGATG CCAAGGTATT  
 15 ATTTGATTTT CTTTATTCGC  
 CGTGAAGAGA ATTTATGATT  
 GCAAAAAGAG GAGTGTTTAC  
 ATAAACTGAT AAAAACTTG  
 AGGAATTCAG CAGAAAACAG  
 20 CCACGTGTTT CTGAACATTC  
 TTCCATAAAA GTCTCACCAT  
 GCCTGGCAGA GCCCTATTCA  
 CCTTCGCT  
 25  
 SEQ ID NO:15 (fragment of ovalbumin promoter - chicken)  
 GAGGTCAGAAAT GGTTCCTTTA CTGTTTGTCA ATTCTATTAT TTCAATACAG  
 AACAATAGCT TCTATAACTG AAATATATTT GCTATTGTAT ATTATGATTG  
 TCCCTCGAAC CATGAACACT CCTCCAGCTG AATTTCACAA TTCCTCTGTC  
 30 ATCTGCCAGG CCATTAAGTT ATTCATGGAA GATCTTTGAG GAACACTGCA  
 AGTTCATATC ATAAACACAT TTGAAATTGA GTATTGTTTT GCATTGTATG  
 GAGCTATGTT TTGCTGTATC CTCAGAAAAA AAGTTTGTTA TAAAGCATTC  
 ACACCCATAA AAAGATAGAT TTAAATATTC CAGCTATAGG AAAGAAAGTG  
 CGTCTGCTCT TCACTCTAGT CTCAGTTGGC TCCTTCACAT GCATGCTTCT  
 35 TTATTTCTCC TATTTTGTCA AGAAAATAAT AGGTCACGTC TTGTTCTCAC  
 TTATGTCCTG CCTAGCATGG CTCAGATGCA CGTTGTAGAT ACAAGAAGGA  
 TCAAATGAAA CAGACTTCTG GTCTGTTACT ACAACCATAG TAATAAGCAC  
 ACTAATAAT AATTGCTAAT TATGTTTTCC ATCTCTAAGG TTCCACATT  
 TTTCTGTTTT CTAAAGATC CCATTATCTG GTTGTAAGT AAGCTCAATG  
 40 GAACATGAGC AATATTTCCC AGTCTTCTCT CCCATCCAAC AGTCCTGATG  
 GATTAGCAGA ACAGGCAGAA AACACATTGT TACCCAGAAAT TAAAACTAA  
 TATTTGCTCT CCATTCAATC CAAAATGGAC CTATTGAAAC TAAAATCTAA  
 CCCAATCCCA TTAAATGATT TCTATGGCGT CAAAGGTCAA ACTTCTGAAG  
 45 GGAACCTGTG GGTGGGTCAC AATTCAGGCT ATATATTCCC CAGGGCTCAG

SEQ ID NO:16 (chicken ovalbumin enhancer)  
 ccgggctgca gaaaaatgcc aggtggacta tgaactcaca tccaaaggag  
 cttgacctga tacctgattt tcttcaaact ggggaaacaa cacaatccca caaaacagct  
 50 cagagagaaa ccactactga tggctacagc accaagggtat gcaatggcaa tccattcgac  
 attcatctgt gacctgagca aaatgattta tctctccatg aatgggttgc tctttccctc  
 atgaaaaggc aatttcacaca ctcacaatat gcaacaaaga caaacagaga acaattaatg  
 tgctccttcc taatgtcaaa attgtagtgg caaagaggag aacaaaatct caagttctga  
 gtaggtttta gtgattggat aagaggcttt gacctgtgag ctcacctgga cttcatatcc  
 55 ttttggataa aaagtgcctt tataactttc aggtctccga gtctttatcc atgagactgt  
 tgggtttagg acagacccac aatgaaatgc ctggcatagg aaagggcagc agagccttag  
 ctgacctttt cttgggacaa gcattgtcaa acaatgtgtg acaaaactat ttgtactgct  
 ttgcacagct gtgctgggca gggcaatcca ttgccaccta tcccaggtaa cttccaact  
 60 gcaagaagat tgttgcttac tctctctaga

SEQ ID NO:17 (5' untranslated region)  
GTGGATCAACATACAGCTAGAAAGCTGTATTGCCCTTTAGCACTCAAGCTCAAAAGACAAC TCAGAGTTC  
ACC

5

SEQ ID NO:18 (putative cap site)  
ACATACAGCTAG AAAGCTGTAT TGCCTTTAGC ACTCAAGCTC AAAAGACAAC TCAGAGTTCA

10

SEQ ID NO:19 (Chicken Ovalbumin Signal Sequence)  
ATG GGCTCCATCG GCGCAGCAAG CATGGAATTT TGTTTTGATG TATTCAAGGA GCTCAAAGTC  
CACCATGCCA ATGAGAACAT CTTCTACTGC CCCATTGCCA TCATGTCAGC TCTAGCCATG  
GTATACCTGG GTGCAAAAGA CAGCACCAGG ACACAGATAA ATAAGGTTGT TCGCTTTGAT  
AAACTTCCAG GATTTCGGAGA CAGTATTGAA GCTCAGTGTG GCACATCTGT AAACGTTTAC  
15 TCTTCACTTA GAGACATCCT CAACCAAATC ACCAAACCAA ATGATGTTTA TTCGTTTACG  
CTTGCCAGTA GACTTTATGC TGAAGAGAGA TACCCAATCC TGCCAGAATA CTGTCAGTGT  
GTGAAGGAAC TGTATAGAGG AGGCTTGGAA CCTATCAACT TTCAAACAGC TGCAGATCAA  
GCCAGAGAGC TCATCAATTC CTGGGTAGAA AGTCAGACAA ATGGAATTAT CAGAAATGTC  
CTTCAGCCAA GCTCCGTGGA TTCTCAAAC GCAATGGTTC TGGTTAATGC CATTGTCCTC  
20 AAAGGACTGT GGGAGAAAAC ATTTAAGGAT GAAGACACAC AAGCAATGCC TTTCAGAGTG  
ACTGAGCAAG AAAGCAAACC TGTGCAGATG ATGTACCAGA TTGGTTTATT TAGAGTGGCA  
TCAATGGCTT CTGAGAAAAT GAAGATCCTG GAGCTTCCAT TTGCCAGTGG GACAATGAGC  
ATGTTGGTGC TGTTGCCCTGA TGAAGTCTCA GGCCTTGAGC AGCTTGAGAG TATAATCAAC  
TTTGAAAAAC TGACTGAATG GACCAGTTCT AATGTTATGG AAGAGAGGAA GATCAAAGTG  
25 TACTTACCTC GCATGAAGAT GGAGGAAAAA TACAACCTCA CATCTGTCTT AATGGCTATG  
GGCATTACTG ACGTGTTTAG CTCTTCAGCC AATCTGTCTG GCATCTCCTC AGCAGAGAGC  
CTGAAGATAT CTCAAGCTGT CCATGCAGCA CATGCAGAAA TCAATGAAGC AGGCAGAGAG  
GTGGTAGGGT CAGCAGAGGC TGGAGTGGAT GCTGCAAGCG TCTCTGAAGA ATTTAGGGCT  
GACCATCCAT TCCTCTTCTG TATCAAGCAC ATCGCAACCA ACGCCGTTCT CTCTTTGGC  
30 AGATGTGTTT CCCCT

35

SEQ ID NO:20 (Chicken Ovalbumin Signal Sequence - shortened 50bp)  
ATG GGCTCCATCG GCGCAGCAAG CATGGAATTT TGTTTTGATG TATTCAAGGA

40

SEQ ID NO:21 (Chicken Ovalbumin Signal Sequence - shortened 100bp)  
ATG GGCTCCATCG GCGCAGCAAG CATGGAATTT TGTTTTGATG TATTCAAGGA GCTCAAAGTC  
CACCATGCCA ATGAGAACAT CTTCTACTGC CCCATTGCCA

45

SEQ ID NO:22 (vitellogenin targeting sequence)  
ATGAGGGGGATCATACTGGCATTAGTGCTCACCTTGTAGGCAGCCAGAAGTTTGACATTGGT

50

SEQ ID NO:23 (pro-insulin sequence)  
TTTGTGAACCAACACCTGTGCGGCTCACACCTGGTGGAAGCTCTCTACCTAGTGTGCGGGGAACGAGGC  
TTCTTCTACACACCAAGACCCGCGGGAGGCAGAGGACCTGCAGGTGGGGCAGGTGGAGCTGGGCGGG  
GGCCCTGGTGCAGGCAGCCTGCAGCCCTTGGCCCTGGAGGGTCCCTGCAGAAGCGTGGCATTGTGGAA  
CAATGCTGTACCAGCATCTGCTCCCTCTACCAGCTGGAGAACTCTGCAACTAG

55

SEQ ID NO:24 (p146 protein)  
KYKKALKKLAKLL

60

SEQ ID NO:25 (p146 coding sequence)  
AAATACAAAAAGCACTGAAAAAACTGGCAAACTGCTG

SEQ ID NO:26 (spacer)

- (GPGG)<sub>x</sub>
- 5 SEQ ID NO:27 (spacer)  
GPGGGPGGGPGG
- 10 SEQ ID NO:28 (spacer)  
GGGSGGGSGGGGS
- 15 SEQ ID NO:29 (spacer)  
GGGSGGGSGGGSGGGGS
- 20 SEQ ID NO:30 (repeat domain in TAG spacer sequence)  
Pro Ala Asp Asp Ala
- 25 SEQ ID NO:31 (TAG spacer sequence)  
Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp  
Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp
- 30 SEQ ID NO:32 (gp41 epitope)  
Ala Thr Thr Cys Ile Leu Lys Gly Ser Cys Gly Trp Ile Gly Leu Leu
- 35 SEQ ID NO:33 (polynucleotide sequence encoding gp41 epitope)  
Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Thr Thr Cys Ile Leu Lys Gly  
Ser Cys Gly Trp Ile Gly Leu Leu Asp Asp Asp Asp Lys
- 40 SEQ ID NO:34 (enterokinase cleavage site)  
DDDDK
- 45 SEQ ID NO:35 (TAG sequence)  
Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp  
Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Thr Thr Cys Ile Leu Lys Gly Ser Cys  
Gly Trp Ile Gly Leu Leu Asp Asp Asp Asp Lys
- 50 SEQ ID NO:36 (altered transposase Hef forward primer)  
ATCTCGAGACCATGTGTGAAGTTGATATTTTACATGATTCTCTTTACC
- 55 SEQ ID NO:37 (altered transposase Her reverse primer)  
GATTGATCATTATCATAATTTCCCAAAGCGTAACC
- 60 SEQ ID NO:38 (Xho I restriction site)  
CTCGAG
- 65 SEQ ID NO:39 (Bcl I restriction site)  
TGATCA



SEQ ID NO:40 (CMVf-NgoM IV primer)  
TTGCCGGCATCAGATTGGCTAT

5

SEQ ID NO:41 (Syn-polyAr-BstE II primer)  
AGAGGTCACCGGTCAATTCTTCAGCACCTGGTA

10 SEQ ID NO:42 (pTnMod(Oval/ENT tag/Proins/PA) - Chicken)  
CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50  
CGCAGCGTGA CCGGTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTTCGC 100  
TTTCTTCCCT TCCTTTCTCG CCACGTTTCGC CGGCATCAGA TTGGCTATTG 150  
GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200  
15 CATGTCCAAC ATTACCGCCA TGTTGACATT GATTATTGAC TAGTTATTAA 250  
TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG 300  
CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 350  
CCCGCCCAT TACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA 400  
GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AAAGTGGCCA 450  
20 CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 500  
TCAATGACGG TAAATGGCCC GCCTGCGATT ATGCCAGTA CATGACCTTA 550  
TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC 600  
CATGGTGATG CGGTTTGGC AGTACATCAA TGGGCGTGGG TAGCGGTTTG 650  
ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG 700  
25 TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC 750  
CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 800  
GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850  
TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG 900  
GGAACGGTGC ATTGGAACGC GGATTCCCCG TGCCAAGAGT GACGTAAGTA 950  
30 CCGCCTATAG ACTCTATAGG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000  
CTGTTTTTGG CTTGGGGCCT ATACACCCCC GCTTCCTTAT GCTATAGGTG 1050  
ATGGTATAGC TTAGCCTATA GGTGTGGGT ATTGACCATT ATTGACCATT 1100  
CCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150  
GCCACAATA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTGAGAGAC 1200  
35 TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATTT ATTATTTACA 1250  
AATTACACATA TACAACAACG CCGTCCCCCG TGCCCGCAGT TTTTATTAAA 1300  
CATAGCGTGG GATCTCCACG CGAATCTCGG GTACGTGTTT CCGACATGGG 1350  
CTCTTCTCCG GTAGCGGCGG AGCTTCCACA TCCGAGCCCT GGTCCCATGC 1400  
CTCCAGCGGC TCATGGTCGC TCGGCAGCTC CTTGCTCCTA ACAGTGGAGG 1450  
40 CCAGACTTAG GCACAGCACA ATGCCACCA CCACAGTGT GCCGCACAAG 1500  
GCCGTGGCGG TAGGGTATGT GTCTGAAAAT GAGCGTGGAG ATTGGGCTCG 1550  
CACGGCTGAC GCAGATGGAA GACTTAAGGC AGCGGCAGAA GAAGATGCAG 1600  
GCAGCTGAGT TGTGTATTG TGATAAGAGT CAGAGGTAAC TCCCGTTGCG 1650  
GTGCTGTTAA CGGTGGAGG CAGTGTAGT TGAGCAGTAC TCGTTGCTGC 1700  
45 CGCGCGCGCC ACCAGACATA ATAGCTGACA GACTAACAGA CTGTTCCCTT 1750  
CCATGGGTCT TTTCTGCAGT CACCGTCGGA CCATGTGTGA ACTTGATATT 1800  
TTACATGATT CTCTTTACCA ATTCTGCCCC GAATTACACT TAAAACGACT 1850  
CAACAGCTTA ACGTTGGCTT GCCACGCATT ACTTGACTGT AAAACTCTCA 1900  
CTCTTACCGA ACTTGGCCGT AACCTGCCAA CCAGAGCGAG AACAAAACAT 1950  
50 AACATCAAAC GAATCGACCG ATTGTTAGGT AATCGTCACC TCCACAAAGA 2000  
GCGACTCGCT GTATACCGTT GGCATGCTAG CTTTATCTGT TCGGGAATAC 2050  
GATGCCCATT GTACTTGTG ACTGCTCTGA TATTCGTGAG CAAAAACGAC 2100  
TTATGGTATT GCGAGCTTCA GTCGCACTAC ACGTCTGTTT TGTTACTCTT 2150  
TATGAGAAAG CGTTCCCGCT TTCAGAGCAA TGTTCAAAGA AAGCTCATGA 2200  
55 CCAATTTCTA GCCGACCTTG CGAGCATTCT ACCGAGTAAC ACCACACCGC 2250  
TCATTGTCAG TGATGCTGGC TTAAAGTGC CATGGTATAA ATCCGTTGAG 2300  
AAGCTGGGTT GGTACTGGTT AAGTCGAGTA AGAGGAAAAG TACAATATGC 2350  
AGACCTAGGA GCGGAAAAC GGAACCTAT CAGCAACTTA CATGATATGT 2400  
CATCTAGTCA CTCAAAGACT TTAGGCTATA AGAGGCTGAC TAAAAGCAAT 2450  
60 CCAATCTCAT GCCAAATTCT ATTGTATAAA TCTCGCTCTA AAGGCCGAAA 2500  
AAATCAGCGC TCGACACGGA CTCATTGTCA CCACCGTCA CCTAAAATCT 2550

	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTT	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTCGAA	CACCCAAACA	ACTTGTTAAT	ATCTATTGGA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTGTGATAT	CATGCTGCTA	2750
5	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTCGC	TTAGGCATGG	AAGTTTTCGC	GCATTCTGGC	2900
	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
	AAATTTATTC	ACACATGGTT	ACGCTTTGGG	GAAATTATGA	TAATGATCCA	3000
10	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
	CCCTCCCCCG	TGCCCTCCTT	GACCCTGGAA	GGTGCCACTC	CCACTGTCCT	3150
	TTCTTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3200
	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
15	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
20	CATCACAACA	AAACTGATT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATG	ATAATAATAA	AAACCTTATC	3600
	CCTATCCAAG	AAGTGATGCC	TATCATTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
25	GACCCTGAGC	ACTGATGAAT	CCCCAATGA	TTTTGGTAAA	AATCATTAA	3800
	TTAAGGTGGA	TACACATCTT	GTCAATATG	CCCGGTAATG	TGAGTTAGCT	3850
	CACCTCATTAG	GCACCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTC	ACACAGGAAA	CAGCTATGAC	3950
	CATGATTACG	CCAAGCGCGC	AATTAACCCT	CACTAAAGGG	AACAAAAGCT	4000
30	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGA	TCCCCCGGGG	4050
	AGGTGAGAAT	GGTTTCTTTA	CTGTTTGTCA	ATTCTATTAT	TTCAATACAG	4100
	AACAATAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTTACAA	TTCTCTGTCT	4200
	ATCTGCCAGG	CCATTAAAGT	ATTCAATGAA	GATCTTTGAG	GAACACTGCA	4250
35	AGTTCAATATC	ATAAACACAT	TTGAAATTGA	GTATTGTTTT	GCATTGTATG	4300
	GAGCTATGTT	TTGCTGTATC	CTCAGAAAAA	AAGTTTGTGA	TAAAGCATTTC	4350
	ACACCCATAA	AAAGATAGAT	TTAAATATTC	CAGCTATAGG	AAAGAAAGTG	4400
	CGTCTGCTCT	TCACTCTAGT	CTCAGTTGGC	TCCTTCACAT	GCATGCTTCT	4450
	TTATTTCTCC	TATTTTGTCA	AGAAAATAAT	AGGTACAGTC	TTGTTCTCAC	4500
40	TTATGTCTCG	CCTAGCATGG	CTCAGATGCA	CGTTGTAGAT	ACAAGAAGGA	4550
	TCAAATGAAA	CAGACTTCTG	GTCTGTTACT	ACAACCATAG	TAATAAGCAC	4600
	ACTAACTAAT	AATTGCTAAT	TATGTTTTTC	ATCTCTAAGG	TTCCACATT	4650
	TTTCTGTTTT	CTTAAAGATC	CCATTATCTG	GTTGTAACCTG	AAGCTCAATG	4700
	GAACATGAGC	AATATTTCCC	AGTCTTCTCT	CCCATCCAAC	AGTCCCTGATG	4750
45	GATTAGCAGA	ACAGGCAGAA	AACACATTGT	TACCCAGAAT	TAAAACTAA	4800
	TATTTGCTCT	CCATTCAATC	CAAAATGGAC	CTATTGAAAC	TAAAACTAA	4850
	CCCAATCCCA	TTAAATGATT	TCTATGGCGT	CAAAGGTCAA	ACTTCTGAAG	4900
	GGAACCTGTG	GGTGGGTCAC	AATTCAGGCT	ATATATTCCC	CAGGGCTCAG	4950
	CGGATCCATG	GGCTCCATCG	GCGCAGCAAG	CATGGAATTT	TGTTTTGATG	5000
50	TATTCAAGGA	GCTCAAAGTC	CACCATGCCA	ATGAGAACAT	CTTCTACTGC	5050
	CCCATTGCCA	TCATGTCAGC	TCTAGCCATG	GTATACCTGG	GTGCAAAAAGA	5100
	CAGCACCAGG	ACACAGATAA	ATAAGGTTGT	TCGCTTTGAT	AAACTTCCAG	5150
	GATTCCGGAGA	CAGTATTGAA	GCTCAGTGTG	GCACATCTGT	AAACGTTTAC	5200
	TCTTCACTTA	GAGACATCCT	CAACCAAATC	ACCAAACCAA	ATGATGTTTA	5250
55	TTGTTTCAAGC	CTTGCCAGTA	GACTTTATGC	TGAAGAGAGA	TACCCATCC	5300
	TGCCAGAAATA	CTTGCAAGTGT	GTGAAGGAAC	TGTATAGAGG	AGGCTTGGAA	5350
	CCTATCAACT	TTCAAACAGC	TGCAGATCAA	GCCAGAGAGC	TCATCAATTTC	5400
	CTGGGTAGAA	AGTCAGACAA	ATGGAATTAT	CAGAAATGTC	CTTCAGCCAA	5450
	GATCCGTGGA	TTCTCAAAC	GCAATGGTTC	TGGTTAATGC	CATTGTCTTC	5500
60	AAAGCACTGT	GGGAGAAAAC	ATTTAAGGAT	GAAGACACAC	AAGCAATGCC	5550
	TTTCAGAGTG	ACTGAGCAAG	AAAGCAAACC	TGTGCAGATG	ATGTACCAGA	5600

	TTGGTTTATT	TAGAGTGGCA	TCAATGGCTT	CTGAGAAAAT	GAAGATCCTG	5650
	GAGCTTCCAT	TTGCCAGTGG	GACAATGAGC	ATGTTGGTGC	TGTTGCCTGA	5700
	TGAAGTCTCA	GGCCTTGAGC	AGCTTGAGAG	TATAATCAAC	TTTGAAAAAC	5750
	TGACTGAATG	GACCAATTCT	AATGTTATGG	AAGAGAGGAA	GATCAAAGTG	5800
5	TACTTACCTC	GCATGAAGAT	GGAGGAAAAA	TACAACCTCA	CATCTGTCTT	5850
	AATGGCTATG	GGCATTACTG	ACGTGTTTAG	CTCTTCAGCC	AATCTGTCTG	5900
	GCATCTCCTC	AGCAGAGAGC	CTGAAGATAT	CTCAAGCTGT	CCATGCAGCA	5950
	CATGCAGAAA	TCAATGAAGC	AGGCAGAGAG	GTGGTAGGGT	CAGCAGAGGC	6000
	TGGAGTGGAT	GCTGCAAGCG	TCTCTGAAGA	ATTAGGGCT	GACCATCCAT	6050
10	TCCTCTTCTG	TATCAAGCAC	ATCGCAACCA	ACGCCGTTC	CTTCTTTGGC	6100
	AGATGTGTTT	CCCCCTCCG	GCCAGCAGAT	GACGCACCAG	CAGATGACGC	6150
	ACCAGCAGAT	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	GACGCACCAG	6200
	CAGATGACGC	AACAACATGT	ATCCTGAAAG	GCTCTGTGG	CTGGATCGGC	6250
	CTGCTGGATG	ACGATGACAA	ATTTGTGAAC	CAACACCTGT	GCGGCTCACA	6300
15	CCTGGTGGAA	GCTCTCTACC	TAGTGTGCGG	GGAACGAGGC	TTCTTCTACA	6350
	CACCCAAGAC	CCGCCGGGAG	GCAGAGGACC	TGCAGGTGGG	GCAGGTGGAG	6400
	CTGGGCGGGG	CCCCTGGTGC	AGGCAGCCTG	CAGCCCTTGG	CCCTGGAGGG	6450
	GTCCCTGCAG	AAGCGTGGCA	TTGTGGAACA	ATGCTGTACC	AGCATCTGCT	6500
	CCCTCTACCA	GCTGGAGAAC	TACTGCAACT	AGGGCGCCTG	GATCCAGATC	6550
20	ACTTCTGGCT	AATAAAAGAT	CAGAGCTCTA	GAGATCTGTG	TGTTGGTTTT	6600
	TTGTGGATCT	GCTGTGCCCT	CTAGTTGCCA	GCCATCTGTT	GTTTGCCCTT	6650
	CCCCCGTGCC	TTCTTGAC	CTGGAAGGTG	CCACTCCAC	TGTCCTTTCC	6700
	TAATAAAATG	AGGAAATTGC	ATCGCATTGT	CTGAGTAGGT	GTCATTCTAT	6750
	TCTGGGGGGT	GGGGTGGGGC	AGCACAGCAA	GGGGGAGGAT	TGGGAAGACA	6800
25	ATAGCAGGCA	TGCTGGGGAT	GCGGTGGGCT	CTATGGGTAC	CTCTCTCTCT	6850
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCTCT	CTCGAGGGGG	6900
	GGCCCCGTAC	CCAATTCGCC	CTATAGTGAG	TCGTATTACG	CGCGCTCACT	6950
	GGCCGTCGTT	TTACAACGTC	GTGACTGGGA	AAACCTTGGC	GTTACCCAAC	7000
	TTAATCGCCT	TGCAGCACAT	CCCCCTTTTC	CCAGCTGGCG	TAATAGCGAA	7050
30	GAGGCCCGCA	CCGATCGCCC	TTCCCAACAG	TTGCGCAGCC	TGAATGGCGA	7100
	ATGGAAATTG	TAAGCGTTAA	TATTTTGTTA	AAATTCGCGT	TAAATTTTGT	7150
	TTAAATCAGC	TCATTTTTTA	ACCAATAGGC	CGAAATCGGC	AAAATCCCTT	7200
	ATAAATCAAA	AGAATAGACC	GAGATAGGGT	TGAGTGTGT	TCCAGTTTGG	7250
	AACAAGAGTC	CACTATTAAA	GAACGTGGAC	TCCAACGTCA	AAGGGCGAAA	7300
35	AACCGTCTAT	CAGGGCGATG	GCCCACTACT	CCGGGATCAT	ATGACAAGAT	7350
	TGATATCCAC	CTTAACCTTA	TGATTTTTAC	CAAAATCATT	AGGGGATPCA	7400
	TCAGTGCTCA	GGGTCAACGA	GAATTAACAT	TCCGTCAGGA	AAGCTTATGA	7450
	TGATGATGTG	CTTAAAAACT	TACTCAATGG	CTGGTTATGC	ATATCGCAAT	7500
	ACATGCGAAA	AACCTAAAAG	AGCTTGCCGA	TAAAAAAGGC	CAATTTATTG	7550
40	CTATTTACCG	CGGCTTTTTA	TTGAGCTTGA	AAGATAAATA	AAATAGATAG	7600
	GTTTTATTGT	AAGCTAAATC	TTCTTTATCG	TAAAAAATGC	CCTCTTGGGT	7650
	TATCAAGAGG	GTCATTATAT	TTGCGGGAAT	AACATCATT	GGTGACGAAA	7700
	TAACTAAGCA	CTTGCTCCTT	GTTTACTCCC	CTGAGCTTGA	GGGGTTAACA	7750
	TGAAGGTCAT	CGATAGCAGG	ATAATAATAC	AGTAAAACGC	TAAACCAATA	7800
45	ATCCAAATCC	AGCCATCCCA	AATTGGTAGT	GAATGATTAT	AAATAACAGC	7850
	AAACAGTAAT	GGGCCAATAA	CACCGTTGTC	ATTGGTAAGG	CTCACCAATA	7900
	ATCCCTGTAA	AGCACCTTGC	TGATGACTCT	TTGTTTGGAT	AGACATCACT	7950
	CCCTGTAATG	CAGGTAAAGC	GATCCCACCA	CCAGCCAATA	AAATTAAAC	8000
	AGGGAAAACT	AACCAACCTT	CAGATATAAA	CGCTAAAAAG	GCAAAATGCAC	8050
50	TACTATCTGC	AATAAATCCG	AGCAGTACTG	CCGTTTTTTC	GCCCCATTTA	8100
	GTGGCTATTC	TTCTTGCCAC	AAAGGCTTGG	AATACTGAGT	GTAAAAGACC	8150
	AAGACCCGAT	AATGAAAAGC	CAACCATCAT	GCTATTCCAT	CCAAAACGAT	8200
	TTTCGGTAAA	TAGCACCCAC	ACCGTTGCGG	GAATTTGGCC	TATCAATTGC	8250
	GCTGAAAAAT	AAATAATCAA	CAAAATGGCA	TCGTTTTAAA	TAAAGTGATG	8300
55	TATACCGAAT	TCAGCTTTTG	TTCCCTTTAG	TGAGGGTTAA	TTGCGCGCTT	8350
	GGCGTAATCA	TGGTCATAGC	TGTTTCCTGT	GTGAAATTGT	TATCCGCTCA	8400
	CAATTCCACA	CAACATACGA	GCCGGAAGCA	TAAAGTGTA	AGCCTGGGGT	8450
	GCCTAATGAG	TGAGCTAACT	CACATTAATT	GCGTTGCGCT	CAC'TGCCCGC	8500
	TTTCCAGTCG	GGAAACCTGT	CGTGCCAGCT	GCATTAATGA	ATCGGCCAAC	8550
60	GCGCGGGGAG	AGGCGGTTTG	CGTATTGGGC	GCTCTCCGCT	TTCTTCGCTC	8600
	ACTGACTCGC	TGCGCTCGGT	CGTTCGGCTG	CGGCGAGCGG	TATCAGCTCA	8650

CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT AACGCAGGAA 8700  
 AGAACATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC 8750  
 CGGTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCTGACG AGCATCACAA 8800  
 AAATCGACGC TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT 8850  
 5 ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TCGCTCTCC TGTTCGACC 8900  
 CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC 8950  
 GCTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG TAGGTCGTTT 9000  
 GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC 9050  
 GCCTTATCCG GTAACATATCG TCTTGAGTCC AACCCGGTAA GACACGACTT 9100  
 10 ATCGCCACTG GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG 9150  
 TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA CGGCTACACT 9200  
 AGAAGGACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG 9250  
 AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG 9300  
 GTGGTTTTTT TGTTCGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT 9350  
 15 CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGAACGA 9400  
 AAATCAGCT TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA 9450  
 CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT CTAAAGTATA 9500  
 TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC 9550  
 TATCTCAGCG ATCTGTCTAT TTCGTTTATC CATAGTTGCC TGACTCCCCG 9600  
 20 TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG CCCAGTGCT 9650  
 GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT TATCAGCAAT 9700  
 AAACCAGCCA GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT 9750  
 CCGCTCCAT CCAGTCTATT AATTGTTGCC GGAAGCTAG AGTAAGTAGT 9800  
 TCGCCAGTTA ATAGTTTGGC CAACGTTGTT GCCATTGCTA CAGGCATCGT 9850  
 25 GGTGTCACGC TCGTCGTTT GTATGGCTTC ATTGAGCTCC GGTTCCTAAC 9900  
 GATCAAGGCG AGTTACATGA TCCCCATGT TGTGCAAAA AGCGGTTAGC 9950  
 TCCTTCGGTC CTCCGATCGT TGTCAGAGT AAGTTGGCCG CAGTGTTATC 10000  
 ACTCATGGTT ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCCG 10050  
 TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC ATTCTGAGAA 10100  
 30 TAGTGTATGC GGCGACCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA 10150  
 TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT GGAAAACGTT 10200  
 CTTCCGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTTCG 10250  
 ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT TACTTTTCAC 10300  
 CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAGG 10350  
 35 GAATAAGGCG GACACGGAAA TGTTGAATAC TCATACTCTT CCTTTTTCAA 10400  
 TATTATGAA GCATTATCA GGGTTATTGT CTCATGAGCG GATACATATT 10450  
 TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCGCGC ACATTTCCCC 10500  
 GAAAGTGCC AC 10512

40

SEQ ID NO:43 (pTnMOD (CMV-CHOVg-ent-ProInsulin-synPA))

1 ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga  
 61 ccgtacact tgccagcgcc ctagegcgcg ctcccttcgc tttcttccct tcccttcgcg  
 45 121 ccacgttcgc cggcatcaga ttggctattg gccattgcat acgttgatc catatcataa  
 181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac  
 241 tagttattaa tagtaataa ttacggggc attagttcat agcccatata tggagttccg  
 301 cggtacataa cttacggtta atggcccgcc tggctgaccg cccaacgacc cccgcccatt  
 361 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca  
 50 421 atgggtggag tatttacggt aaactgccc cttggcagta catcaagtgt atcatatgcc  
 481 aagtagcgcc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta  
 541 catgacctta tgggactttc ctacttgga gtacatctac gtattagtca tcgctattac  
 601 catggtgatg cggttttggc agtacatcaa tggcggtgga tagcggtttg actcacgggg  
 661 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg  
 55 721 ggactttcca aaatgtcgta acaactccg cccattgacg caaatggcg gtaggcgtgt  
 781 acggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg  
 841 ccatccacgc tgttttgacc tccatagaag acaccgggac cgtccagcc tccgcgccg  
 901 ggaacgggtg attggaacgc ggattcccg tgccaagagt gacgtaaata ccgctatag  
 961 actctatagg cacacccctt tggctcttat gcatgctata ctgttttttg cttggggcct  
 60 1021 atacaccccc gcttccctat gctatagggt atggtatagc ttagcctata ggtgtgggtt  
 1081 attgaccatt attgaccact cccctattgg tgacgatact ttccattact aatccataac  
 1141 atggctcttt gccacaacta tctctattgg ctatatgcca atactctgtc cttcagagac  
 1201 tgacaaggac tctgtatttt tacaggatgg ggtcccattt attatttaca aattcacata

1261 tacaacaacg ccgtcccccg tgcccgcagt ttttattaaa catagcgtgg gatctccacg  
 1321 cgaatctcgg gtaogtgttc cggacatggg ctcttctccg gtagcggcgg agcttccaca  
 1381 tccgagccct ggtcccatgc ctccagcggc tcatgggtcg tggcagctc cttgctccta  
 1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag  
 1501 gccgtggcgg taggggtatgt gtctgaaaat gagcgtggag attgggctcg cacggctgac  
 1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgttgtatcc  
 1621 tgataagagt cagaggtaac tcccggttgc gtgctgttaa cgggtggagg cagtgtagtcc  
 1681 tgagcagtag tcgttgctgc cgcgcgcgcc accagacata atagctgaca gactaacaga  
 1741 ctgttccttt ccatgggtct tttctgcagt caccgtcgga ccatgtgtga acttgatatt  
 1801 ttacatgatt ctctttacca attctgcccc gaattacact taaaacgact caacagctta  
 1861 acgttggctt gccacgcatt acttgactgt aaaactctca ctcttaccga acttggccgt  
 1921 aacctgccaa ccaagcgcag aacaaaacat aacatcaaac gaatcgaccg attggtagggt  
 1981 aatcgtcacc tccacaaaga ggcactcgct gtataccggt ggcatgctag ctttatctgt  
 2041 tccggcaata cgatgcccat tgtacttgtt gactggtctg atattcgtga gcaaaaacga  
 2101 cttatggtat tgcgagcttc agtcgcacta caccgtcggt ctgttactct ttatgagaaa  
 2161 gcgttcccgcc tttcagagca atggtcaaag aaagctcatg accaattctc agccagctct  
 2221 gcgagcattc taccgagtaa caccacaccg ctcatgttca gtgatgtggt ctttaagtg  
 2281 ccatgggtata aatccgttga gaagctgggt tggtagctgt taagtcgagt aagaggaaaa  
 2341 gtacaatatg cagacctagg agcggaaaac tggaaaacct tcagcaactt acatgatatg  
 2401 tcacttagtc actcaaagac ttttaggtat aagaggctga ctaaaagcaa tccaatctca  
 2461 tgccaaatcc tattgtataa atctcgcctc aaaggccgaa aaaatcagcg ctgcacacgg  
 2521 actcattgtc accaccgctc acctaaaatc tactcagcgt cggcaaaagg gccatgggtt  
 2581 ctacgaacta acttacctgt tgaatttcga acacccaaac aacttgtaa tatctattcg  
 2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtccctgccta cggactaggc  
 2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg  
 2761 atgcttcaac taacatgttg gcttgcgggc gtccatgctc agaaaacaag ttgggacaag  
 2821 cacttccagg ctaacacagt cagaaaatcga aacgtactct caacagttcg cttaggcatg  
 2881 gaagttttgc ggcattcttg ctacacaata acaagggaag acttactcgt ggctgcaacc  
 2941 ctactagctc aaaattttatt cacacatggt tacgctttgg ggaaattatg ataagatcc  
 3001 agatcacttc tggctaataa aagatcagag ctctagagat ctgtgtgttg gttttttgtg  
 3061 gatctgctgt gccttctagt tggcagccat ctggtgtttg cccctccccc gtgcttccct  
 3121 tgacctgga aggtgccact ccactgttc tttcttaata aaatgaggaa attgcatcgc  
 3181 attgtctgag taggtgtcat totattctgg ggggtggggg ggggcagcac agcaaggggg  
 3241 aggattggga agacaatagc aggcattgct gggatgagg gggctctatg ggtacctctc  
 3301 tctctctctc tctctctctc tctctctctc tctctctctc cctctctctc tctctctctc  
 3361 tctctctctc tctctctctc tctctctctc tctctctctc tctctctctc tctctctctc  
 3421 tgccttttat catcacttta aaaataaaaa acaattactc agtgccctgt ataagcagca  
 3481 attaatatg attgatgctt acatcacaaac aaaaactgat ttaacaaatg gttggtctgc  
 3541 cttagaaagt atatttgaac attatcttga ttatattatt gataataata aaaacottat  
 3601 cctatccaa gaagtgtatg ctactattgg ttggaatgaa cttgaaaaaa cttagccttg  
 3661 aatacattac tggtaaggta aacgccattg tcagcaaat gatccaagag aaccaactta  
 3721 aagctttcct gacggaatgt taattctcgt tgacctgag cactgatgaa tcccctaattg  
 3781 attttggtaa aaatcattaa gtttaagggtg atacacatct tgtcatatga tcccggtaat  
 3841 gtgagttagc tactcatta ggcaccccg gctttactc ttatgcttcc ggctcgatg  
 3901 ttgtgtggaa ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac  
 3961 gccaaagcgc caattaaccc tcaataaagg gaacaaaagc tggagctcca ccgcggtggc  
 4021 ggccgctcta gaactagtgg atcccccg gcatcagattg gctattggcc attgcatacg  
 4081 ttgtatccat atcataatat gtacatttat attggctcat gtccaacatt accgcatgt  
 4141 tgacattgat tattgactag ttattaatag taatcaatta cggggctatt agttcatagc  
 4201 ccataatagg agttccgcgt tacataactt acggtaaatg gcccgccctg ctgaccgccc  
 4261 aacgaccccc gccattgac gtcaataatg acgtatgttc ccatagtaac gccaataggg  
 4321 actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgcccactt ggcagtaacat  
 4381 caagtgtatc atatgccaag tacgccccct attgacgtca atgacggtaa atggcccgcc  
 4441 tggcattatg cccagtacat gaccttatgg gactttccta cttggcagta catctacgta  
 4501 ttagtcatcg ctattaccat ggtgatgcgg ttttggcagt acatcaatgg gcgtggatag  
 4561 cggtttgact cagggggatt tccaagtctc caccctattg acgtcaatgg gagtttgttt  
 4621 tggcaccaaa atcaacggga ctttccaaaa tgtcgtaaca actcgcgcc atttgacgaa  
 4681 atggcgggta ggcgtgtacg gtgggaggtc tatataagca gagctcgttt agtgaacgt  
 4741 cagatcgctc ggagacgcca tccacgctgt tttgacctcc atagaagaca ccgggaccga  
 4801 tccagcctcc gcggccggga acggtgcatt ggaacgcgga ttccccgtgc caagagtgc  
 4861 gtaagtaccg cctatagact ctataggcac acccctttgg ctcttatgca tgctatactg  
 4921 tttttggctt ggggcctata ccccccgct tccttatgct ataggtgatg gtatagctta  
 4981 gcctataggt gtgggttatt gaccattatt gaccactccc ctattgggtg cgatacttcc  
 5041 cattaactaat ccataacatg gctctttggc acaactatct ctattgggta tatgccaata  
 5101 ctctgtcctt cagagactga caccgactct gtatttttac aggatggggg cccatttatt  
 5161 atttacaaat tcacatatat aacaacgcgc tcccccgctc ccgcagtttt tattaaacat  
 5221 agcgtgggat ctccacgcga atctcgggta cgtgttccgg acatgggctc ttctccggta  
 5281 gggcgggagc ttccacatcc gagccctggg cccatgctc cagcggctca tggctgctcg

5341 gcagctcctt gctcctaaca gtggaggcca gacttaggca cagcacaatg cccaccacca  
 5401 ccagtggtgcc gcacaaggcc gtggcggtag ggtatgtgtc tgaaaatgag cgtggagatt  
 5461 gggctcgcac ggctgacgca gatggaagac ttaaggcagc ggcagaagaa gatgcaggca  
 5521 gctgagttgt tgtattctga taagagtcag aggtaactcc cgttgccggtg ctgttaacgg  
 5581 tggagggcag tgtagtctga gcagtactcg ttgctgccgc gcgcgccacc agacataata  
 5641 gctgacagac taacagactg ttccctttcca tgggtctttt ctgcagtcac cgtcggatca  
 5701 atggggtcca tcgggtgcagc aagcatggaa ttttgttttg atgtattcaa gtagctcaaa  
 5761 gtccaccatg ccaatgagaa catcttctac tgccccattg ccatcatgtc agctctagcc  
 5821 atgggtatacc tgggtgcaaa agacagcacc aggacacaaa taaataagggt tgttcgcttt  
 5881 gataaacttc caggattcgg agacagtatt gaagctcagt gtggcacatc tgtaaacgtt  
 5941 cactcttcac ttagagacat cctcaaccaa atcaccaaac caaatgatgt ttattcgttc  
 6001 agccttgcca gtagacttta tgctgaagag agatacccaa tcctgccaga taaactgcag  
 6061 tgtgtgaagg aactgtatag aggaggcttg gaacctatca actttcaaac agctgcagat  
 6121 caagccagag agctcatcaa ttctgggta gaaagtcaga caaatggaat tatcagaat  
 6181 gtcccttcagc caagctccgt ggattctcaa actgcaatgg ttctgggtta tgccattgtc  
 6241 ttcaaaggac tgtgggagaa agcatttaag atgaaagaca cacaagcaat gcctttcaga  
 6301 gtgactgagc aagaaagcaa acctgtgcag atgatgtacc agattggttt atttagagt  
 6361 gcatcaatgg ctctgagaa aatgaagtc ctggagcttc catttgccag tgggacaatg  
 6421 agcatgttgg tgctgttggc tgatgaagtc tcaggccttg agcagcttga gagtataatc  
 6481 aactttgaaa aactgactga atggaccagt tctaattgta tggaaagagag aagatcaaa  
 6541 tgtacttacc tcgcatgaag atggaggaaa aatacaacct cacatctgtc ttaattggcta  
 6601 tgggcattac tgacgtgttt agctcttcag ccaatctgtc tggcatctcc tcagcagaga  
 6661 gctgaagat atctcaagct gtccatgcag cacatgcaga aatcaatgaa gcaggcagag  
 6721 aggtggttagg gtcagcagag gctggagtgg atgctgcaag cgtctctgaa gaatttaggg  
 6781 ctgaccatcc attctctctc tgtatcaagc acatcgcaac caacgcggtt ctctctcttt  
 6841 ggcagatgtg ttcccgcgcg ccagcagatg acgcaccagc agatgacgca ccagcagatg  
 6901 acgcaccagc agatgacgca ccagcagatg acgcaacaac atgtatcctg aaaggctctt  
 6961 gtggctggat cggcctgctg gatgacgatg acaaatgtgt gaaccaacac ctgtgcggct  
 7021 cacacctggg ggaagctctc tacctagtgt gcggggaacg aggtctcttc tacacacca  
 7081 agaccgcgcg ggaggcagag gacctgcagg tggggcagggt ggagctgggc gggggccctg  
 7141 gtgcaggcag cctgcagccc ttggccctgg aggggtccct gcagaagcgt ggcattgtgg  
 7201 aacaatgctg taccagcatc tgctccctct accagctgga gaactactgc aactaggcgc  
 7261 cctaaagggc gaattatcgc ggccgctcta gaccaggcgc ctggatccag atcacttctg  
 7321 gctaataaaa gatcagagct cttagagatct gtgtgttggg tttttgtgga tctgtgtg  
 7381 ctctagtgtg ccagccatct gttgtttgccc cctcccccgt accctggaaag  
 7441 gtgccactcc cactgtcctt tccataaaa atgaggaaat tgcacgcacat tgtctgagta  
 7501 ggtgtcattc tattctgggg ggtgggggtgg ggcagcacag caagggggag gattgggaag  
 7561 acaatagcag gcatgtggg gatgcggtgg gctctatggg tactctctctc tctctctctc  
 7621 tctctctcac tctctctctc tctcggatcc tctcctcgag gggggggccc gtacccaatt  
 7681 cgccctatag tgagtcgatg taacgcgcgt cactggcgt cgttttacaa cgtctgtgact  
 7741 gggaaaaccc tggcggtacc caacttaate gccttgacgc acatccccct ttccgcagct  
 7801 ggcgtaatat cgaagaggcc cgcaccgacg gcccttccca acagttgcgc agcctgaatg  
 7861 gcgaatggaa attgtaagcg ttaatatattt gttaaaattc gcgttaaat tttgttaaat  
 7921 cagctcattt tttaaccaat aggcggaat cggcaaaatc ccttataaat caaaagaata  
 7981 gaccagataa ggggttgagt ttgttccagt ttggaacaag agtccactat taaagaacgt  
 8041 ggactccaac gtcaaaaggcg gaaaaaccgt ctatcagggc gatggccac tactccggga  
 8101 tcatatgaca agatgtgtat ccaccttaac ttaattgattt ttacaaaaat cattagggga  
 8161 ttcatcagtg ctccagggtca acgagaatta acattccgtc aggaagagct atgatgatga  
 8221 tgtgcttaaa aacttactca atggctgggt atgcatatcg caatacatgc gaaaaacctc  
 8281 aaagagcttg ccgataaaaa aggccaattt attgctattt accgcggctt tttattgagc  
 8341 ttgaaagata aataaaatag ataggtttta tttgaagcta aatcttcttt atcgtaaaaa  
 8401 atgccctctt ggggttatcaa gagggtcatt atatttcgcy gaataacatc atttgggtgac  
 8461 gaaataacta agcacttgtc tctgttttac tcccctgagc ttgagggggt aacatgaagg  
 8521 tcatcgatag caggataata atacagtaaa acgctaacc aataatccaa atccagccat  
 8581 cccaaattgg tagtgaatga ttataaataa cagcaaacag taatgggcca ataaccggg  
 8641 ttgcattggg aaggctcacc aataatccct gtaaaagcacc ttgctgatga ctctttgttt  
 8701 ggatagacat cactccctgt aatgcaggta aagcgatccc accaccagcc aataaaatta  
 8761 aaacagggaa aactaaccaa ccttcagata taaacgctaa aaaggcaaat gcactactat  
 8821 ctgcaataaa tccgagcagt actgcggttt tttcggccat ttagtggcta ttcttctg  
 8881 cacaaggct tggaatactg agtgtaaaag accaagaccc gtaatgaaaa gccaaacctc  
 8941 atgctattca tcatcacgat ttctgtaata gcaccacacc gtgctggatt ggctatcaat  
 9001 gcgctgaaat aataatcaac aaatggcatc gttaaataag tgatgtatc cgtacagctt  
 9061 ttgttccctt tagtgagggt taattgcgcg cttggcgtaa tcatgggtat agctgtttcc  
 9121 tgtgtgaaat tgttatccgc tcacaattcc acacaacata cgagccggaa gcataaagt  
 9181 taaagcctgg ggtgcctaact gagtgcgcta actcacatta attgcgttgc gctcactgcc  
 9241 cgctttccag tccggaaacc tgcgtgcca gctgcattaa tgaatccggc aacgcgcggg  
 9301 gagaggcggt ttgcgtattg ggcgctcttc cgcttctcg ctccactgact cgtgcgctc  
 9361 ggtcgttcgg ctgcggcgag cgggtatcag tcactcaaa gcggaataac ggttatccac

5 9421 agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa  
 9481 ccgtaaaaag gccgcgttgc tggcggtttt ccataggctc cccccctg acgagcatca  
 9541 caaaaaatcga cgctcaagtc agaggtggcg aaaccgcaga ggactataaa gataccaggc  
 9601 gtttccccct ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata  
 9661 cctgtccgcc tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta  
 9721 tctcagttcg gtgtaggctg ttcgctccaa gctgggctgt gtgcacgaac ccccggttca  
 9781 gcccgaccgc tgcgccttat ccggttaacta tcgtcttgag tccaaccgg taagacacga  
 9841 cttatcgcca ctggcagcag ccaactggtaa caggattagc agagcgagg atgtaggcgg  
 10 9901 tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagga cagtatttgg  
 9961 tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg  
 10021 caaacaacc accgctggta gcggtggtt ttttgttgc aagcagcaga ttacgcgcag  
 10081 aaaaaaagg tctcaagaag atcctttgat ctttctacg gggctctgac ctcagtggaa  
 10141 cgaaaaactca cgtaaggga ttttggcat gagattatca aaaaggatct tcacctagat  
 10201 ccttttaaat taaaaatgaa gttttaatc aatctaaagt atatatgagt aaacttggtc  
 15 10261 tgacagttac caatgcttaa tcagtgggc acctatctca gcgatctgtc tatttcgttc  
 10321 atccatagtt gcctgactcc cgtcgtgta gataactacg atacgggagg gcttaccatc  
 10381 tggcccgagt gctgcaatga taccgcgaga cccacgctca ccggctccag atttatcagc  
 10441 aataaaccag ccagccggaa gggccgagcg cagaagtggc cctgcaactt tatccgctc  
 20 10501 catccagttc attaatgtt gcgggaagc tagagtaagt agttcgccag ttaatagttt  
 10561 gcgcaacggt gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc  
 10621 ttcattcagc tccggttccc aacgatcaag gcgagttaca tgatccccc tggtgtgcaa  
 10681 aaaagcgggt agctccttcg gtctccgat cgtgtcaga agtaagtgg ccgagtggt  
 10741 atcactcatg gttatggcag cactgcataa ttctottact gtcatgcat ccgtaagatg  
 25 10801 cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtgtg tgccgggacc  
 10861 gagttgctct tgcccgcggt caatacggga taataccgcy ccacatagca gaactttaaa  
 10921 agtgcctate attggaatac gttcttcggg gcgaaaaactc tcaaggatct taccgctggt  
 10981 gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt  
 11041 caccagcgtt tctgggtgag caaaaacagg aaggcaaaat gccgcaaaa aggggaataag  
 30 11101 ggcgacacgg aaatgttgaa tactcatact cttcctttt caatattatt gaagcattta  
 11161 tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaat  
 11221 aggggttccg cgcacatttc ccgaaaaagt gccac

SEQ ID NO:44 (pTnMod(Oval/ENT tag/Proins/PA) - QUAIL)

35 CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50  
 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCCG 100  
 TTTCTTCCCT TCCTTTCTCG CCACGTTCCG CGGCATCAGA TTGGCTATTG 150  
 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200  
 CATGTCCAAC ATTACCGCCA TGTGACATT GATTATTGAC TAGTTATTAA 250  
 40 TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG 300  
 CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 350  
 CCCGCCCAT TACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA 400  
 GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AAAGTGCCCA 450  
 CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCC CCTATTGACG 500  
 45 TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCAGTA CATGACCTTA 550  
 TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC 600  
 CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGG TAGCGGTTTG 650  
 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG 700  
 TTTTGGCACC AAAATCAACG GGAATTTCCA AAATGTCGTA ACAACTCCGC 750  
 50 CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 800  
 GCAGAGCTCG TTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850  
 TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG 900  
 GGAACGGTGC ATTGGAACGC GGATTCCTCC TGCCAAGAGT GACGTAAGTA 950  
 CCGCCTATAG ACTCTATAG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000  
 55 CTGTTTTTGG CTTGGGGCCT ATACACCCCG GCTTCCTTAT GCTATAGGTG 1050  
 ATGGTATAGC TTAGCCTATA GGTGTGGGTT ATTGACCATT ATTGACCACT 1100  
 CCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150  
 GCCACAATA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTGAGAGAC 1200  
 TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATTT ATTATTTACA 1250  
 60 AATTCACATA TACAACAACG CCGTCCCCCG TGCCCGCAGT TTTTATTAAA 1300  
 CATAGCGTGG GATCTCCAGC CGAATCTCGG GTACGTGTTT CGGACATGGG 1350  
 CTCTTCTCCG GTAGCGGCGG AGCTTCACA TCCGAGCCCT GGTCCCATGC 1400  
 CTCCAGCGGC TCATGGTCGC TCGGCAGCTC CTTGCTCCTA ACAGTGGAGG 1450  
 CCAGACTTAG GCACAGCACA ATGCCACCA CCACAGTGT GCCGCACAAG 1500



	GCCGTGGCGG	TAGGGTATGT	GTCTGAAAAT	GAGCGTGGAG	ATTGGGCTCG	1550
	CACGGCTGAC	GCAGATGGAA	GACTTAAGGC	AGCGGCAGAA	GAAGATGCAG	1600
	GCAGCTGAGT	TGTTGTATTC	TGATAAGAGT	CAGAGGTAAC	TCCCGTTGCG	1650
	GTGCTGTTAA	CGGTGGAGGG	CAGTGTAGTC	TGAGCAGTAC	TCGTTGCTGC	1700
5	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GACTAACAGA	CTGTTCTTTT	1750
	CCATGGGTCT	TTTCTGCAGT	CACCGTCGGA	CCATGTGTGA	ACTTGATATT	1800
	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAACGACT	1850
	CAACAGCTTA	ACGTTGCTTT	GCCACGCATT	ACTTGACTGT	AAAACCTCTA	1900
	CTCTTACCGA	ACTTGCGCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
10	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCACC	TCCACAAAGA	2000
	GCGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
	GATGCCCCATT	GTACTTGTTC	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAC	2100
	TTATGGTATT	GCGAGCTTCA	GTCGCACTAC	ACGGTCGTTT	TGTTACTCTT	2150
	TATGAGAAAG	CGTTCCCGCT	TTCAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
15	CCAATTTCTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
	TCATTGTCTAG	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAATATGC	2350
	AGACCTAGGA	GCGGAAAAC	GGAAACCTAT	CAGCAACTTA	CATGATATGT	2400
	CATCTAGTCA	CTCAAAGACT	TTAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
20	CCAATCTCAT	GCCAAATTCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
	AAATCAGCGC	TCGACACGGA	CTCATTGTCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTC	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTCGAA	CACCCAAACA	ACTTGTTAAT	ATCTATTCTA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
25	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTCGC	TTAGGCATGG	AAGTTTTGCG	GCATTCTGGC	2900
	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
30	AAATTTATTC	ACACATGGTT	ACGCTTTGGG	GAAATTATGA	TAATGATCCA	3000
	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
	CCCTCCCCCG	TGCTTCTCTT	GACCTGGAA	GGTGCCACTC	CCACTGTCTT	3150
	TTCCTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3200
35	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
40	CAATTACTCA	GTGCTGTGTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
	CATCACAACA	AAAACCTGAT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
	CCTATCCAAG	AAGTGATGCC	TATCATTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
45	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
	GACCCTGAGC	ACTGATGAAT	CCCCTAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCATATGAT	CCCGGTAATG	TGAGTTAGCT	3850
	CACTCATTAG	GCACCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
50	CATGATTACG	CCAAGCGCGC	AATTAACCCT	CACTAAAGGG	AACAAAAGCT	4000
	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGA	TCCCCGGGG	4050
	AGGTCTCAAT	GGTTTCTTTA	CTGTTTGTCA	ATTCTATTAT	TTCAATACAG	4100
	AACAAAAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTTCAACA	TTCTCTGTCT	4200
55	ATCTGCCAGG	CTGGAAGATC	ATGGAAGATC	TCTGAGGAAC	ATTGCAAGTT	4250
	CATACCATAA	ACTCATTTGG	AATTGAGTAT	TATTTTGTCT	TGAATGGAGC	4300
	TATGTTTTGC	AGTCCCTCA	GAAGAAAAGC	TTGTTATAAA	GCGTCTACAC	4350
	CCATCAAAG	ATATATTTAA	ATATTCCAAC	TACAGAAAAG	TTTTGTCTGC	4400
	TCTTCACTCT	GATCTCAGTT	GGTTTCTTCA	CGTACATGCT	TCTTTATTTG	4450
60	CCTATTTTGT	CAAGAAAATA	ATAGGTCAAG	TCCTGTTCTC	ACTTATCTCC	4500
	TGCCTAGCAT	GGCTTAGATG	CACGTTGTAC	ATTCAAGAAG	GATCAAATGA	4550



	AACAGACTTC	TGGTCTGTTA	CAACAACCAT	AGTAATAAAC	AGACTAACTA	4600
	ATAATTGCTA	ATTATGTTTT	CCATCTCTAA	GGTCCCACA	TTTTTCTGTT	4650
	TTAAGATCCC	ATTATCTGGT	TGTAAC TGAA	GCTCAATGGA	ACATGAACAG	4700
	TATTTCTCAG	TCTTTTCTCC	AGCAATCCTG	ACGGATTAGA	AGAACTGGCA	4750
5	GAAAAACTTT	TGTTACCCAG	AATTA AAAAC	TAATATTTGC	TCTCCCTTCA	4800
	ATCCAAAATG	GACCTATTGA	AACTAAAATC	TGACCCAATC	CCATTAAATT	4850
	ATTTCTATGG	CGTCAAAGGT	CAAAC TTTTG	AAGGGAACCT	GTGGGTGGGT	4900
	CCCAATT CAG	GCTATATATT	CCCCAGGGCT	CAGCCAGTGG	ATCCATGGGC	4950
	TCCATCGGTG	CAGCAAGCAT	GGAATTTTGT	TTTGATGTAT	TCAAGGAGCT	5000
10	CAAAGTCCAC	CATGCCAATG	ACAACATGCT	CTACTCCCCC	TTTGCCATCT	5050
	TGTCAACTCT	GGCCATGGTC	TTCCTAGGTG	CAAAAGACAG	CACCAGGACC	5100
	CAGATAAATA	AGGTTGTTCA	CTTTGATAAA	CTTCCAGGAT	TCGGAGACAG	5150
	TATTGAAGCT	CAGTGTGGCA	CATCTGTAAA	TGTTCACTCT	TCACTTAGAG	5200
	ACATACTCAA	CCAAATCACC	AAACAAAATG	ATGCTTATTC	GTTTCAGCCTT	5250
15	GCCAGTAGAC	TTTATGCTCA	AGAGACATAC	ACAGTCGTGC	CGGAATACTT	5300
	GCAATGTGTG	AAGGAACTGT	ATAGAGGAGG	CTTAGAATCC	GTCAACTTTC	5350
	AAACAGCTGC	AGATCAAGCC	AGAGGCCTCA	TCAATGCCTG	GGTAGAAAGT	5400
	CAGACAAACG	GAATTATCAG	AAACATCCTT	CAGCCAAGCT	CCGTGGATTTC	5450
	TCAAAC TGCA	ATGGTCC TGG	TTAATGCCAT	TGCC TTTCAAG	GGACTGTGGG	5500
20	AGAAAGCATT	TAAGGCTGAA	GACACGCAAA	CAATACCTTT	CAGAGTGACT	5550
	GAGCAAGAAA	GCAAACCTGT	GCAGATGATG	TACCAGATTG	GTTCA TTTAA	5600
	AGTGGCATCA	ATGGCTTCTG	AGAAAATGAA	GATCCTGGAG	CTTCCATT TG	5650
	CCAGTGGAAC	AATGAGCATG	TTGGTGTCTGT	TGCCTGATGA	TGTCTCAGGC	5700
	CTTGAGCAGC	TTGAGAGTAT	AATCAGCTTT	GAAAACTGA	CTGAATGGAC	5750
25	CAGTTCTAGT	ATTATGGAAG	AGAGGAAAGT	CAAAGTG TAC	TTACCTCGCA	5800
	TGAAGATGGA	GGAGAAATAC	AACCTCACAT	CTCTCTTAAT	GGCTATGGGA	5850
	ATTACTGACC	TGTT CAGCTC	TT CAGCCAAT	CTGTCTGGCA	TCTCCTCAGT	5900
	AGGGAGCCTG	AAGATATCTC	AAGCTGTCCA	TGCAGCACAT	GCAGAAATCA	5950
	ATGAAGCGGG	CAGAGATGTG	GTAGGCTCAG	CAGAGGCTGG	AGTGGATGCT	6000
30	ACTGAAGAAT	TTAGGGCTGA	CCATCCATTC	CTCTTCTGTG	TCAAGCACAT	6050
	CGAAACCAAC	GCCATTCTCC	TCTTTGGCAG	ATGTGTTTCT	CCGCGGCCAG	6100
	CAGATGACGC	ACCAGCAGAT	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	6150
	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	GACGCAACAA	CATGTATCCT	6200
	GAAAGGCTCT	TGTGGCTGGA	TCGGCCTGCT	GGATGACGAT	GACAAATT TG	6250
35	TGAACCAACA	CTGTGCGGC	TCACACCTGG	TGGAAGCTCT	CTACCTAGTG	6300
	TGCGGGGAAC	GAGGCTTCTT	CTACACACCC	AAGACCCGCC	GGGAGGCAGA	6350
	GGACCTGCAG	GTGGGGCAGG	TGGAGCTGGG	CGGGGGCCCT	GGTGCAGGCA	6400
	GCCTGCAGCC	CTTGCCCTTG	GAGGGGTCCC	TGCAGAAGCG	TGGCATTGTG	6450
	GAACAATGCT	GTACCAGCAT	CTGCTCCCTC	TACCAGCTGG	AGAACTACTG	6500
40	CAACTAGGGC	GCCTGGATCC	AGATCACTTC	TGGCTAATAA	AAGATCAGAG	6550
	CTCTAGAGAT	CTGTGTGTTG	GTTTTTTGTG	GATCTGCTGT	GCCTTCTAGT	6600
	TGCCAGCCAT	CTGTGTGTTG	CCCC TCCCCC	GTGCCTTCCT	TGACCCTGGA	6650
	AGGTGCCACT	CCCAGTGTCC	TTTCCTAATA	AAATGAGGAA	ATTGCATCGC	6700
	ATTGTCTGAG	TAGGTGT CAT	TCTATTCTGG	GGGGTGGGGT	GGGGCAGCAC	6750
45	AGCAAGGGGG	AGGATTGGGA	AGACAATAGC	AGGCATGCTG	GGGATGCGGT	6800
	GGGCTCTATG	GGTACCTCTC	TCTCTCTCTC	TCTCTCTCTC	TCTCTCTCTC	6850
	TCTCTCGGTA	CCTCTCTCGA	GGGGGGGCCC	GGTACCCAAT	TCGCCCTATA	6900
	GTGAGTCGTA	TTACGCGCGC	TCACTGGCCG	TCGTTTTTACA	ACGTCTGTGAC	6950
	TGGGAAAACC	CTGGCGTTAC	CCAAC TTAAT	CGCCTTG CAG	CACATCCCCC	7000
50	TTTCGCCAGC	TGGCGTAATA	GCGAAGAGGC	CCGCACCGAT	CGCCCTTCCC	7050
	AACAGTTGCG	CAGCCTGAAT	GGCGAATGGA	AATTGTAAGC	GTTAATATTT	7100
	TGTTAAAATT	CGCGTTAAAT	TTTTGT TAAA	TCAGCTCATT	TTTTAACC AA	7150
	TAGGCCGAAA	TCGGCAAAAT	CCCTTATAAA	TCAAAAGAAT	AGACCGAGAT	7200
	AGGGTTGAGT	GTTGTTCCAG	TTTGGAACAA	GAGTCCACTA	TTAAAGAACG	7250
55	TGGACTCCAA	CGTCAAAGGG	CGAAAAACCG	TCTATCAGGG	CGATGGCCCA	7300
	CTACTCCGGG	ATCATATGAC	AAGATGTGTA	TCCACCTTAA	CTTAATGATT	7350
	TTTACCAAAA	TCATTAGGGG	ATTCATCAGT	GCTCAGGGTC	AACGAGAATT	7400
	AACATTCCGT	CAGGAAAGCT	TATGATGATG	ATGTGCTTAA	AAACTTACTC	7450
	AATGGCTAGT	TATGCAATATC	GCAATACATG	CGAAAAACCT	AAAAGAGCTT	7500
60	GCCGATAAAA	AAGGCCAATT	TATTGCTATT	TACCGCGGCT	TTTTATTGAG	7550
	CTTGAAAGAT	AAATAAAAATA	GATAGGTTTT	ATTTGAAGCT	AAATCTTCTT	7600

	TATCGTAAAA	AATGCCCTCT	TGGGTTATCA	AGAGGGTCAT	TATATTTTCGC	7650
	GGAATAACAT	CATTGGGTGA	CGAAATAACT	AAGCAC TTGT	CTCCTGTTTA	7700
	CTCCCCTGAG	CTTGAGGGGT	TAACATGAAG	GTCATCGATA	GCAGGATAAT	7750
5	AATACAGTAA	AACGCTAAAC	CAATAATCCA	AATCCAGCCA	TCCCAAATTG	7800
	GTAGTGAATG	ATTATAAATA	ACAGCAAACA	GTAATGGGCC	AATAACACCG	7850
	GTTGCATTGG	TAAGGCTCAC	CAATAATCCC	TGTAAAGCAC	CTTGCTGATG	7900
	ACTCTTTGTT	TGGATAGACA	TCACTCCCTG	TAATGCAGGT	AAAGCGATCC	7950
	CACCACCAGC	CAATAAAATT	AAAACAGGGA	AAACTAACCA	ACCTTCAGAT	8000
	ATAAACGCTA	AAAAGGCAAA	TGCACTACTA	TCTGCAATAA	ATCCGAGCAG	8050
10	TACTGCCGTT	TTTTTCGCCCC	ATTTAGTGGC	TATTCTTCCT	GCCACAAAGG	8100
	CTTGGGAATAC	TGAGTGTAAG	AGACCAAGAC	CCGCTAATGA	AAAGCCAACC	8150
	ATCATGCTAT	TCCATCCAAA	ACGATTTTCG	GTAAATAGCA	CCCACACCGT	8200
	TGCGGGAATT	TGGCCTATCA	ATTGCGCTGA	AAAATAAATA	ATCAACAAAA	8250
	TGGCATCGTT	TTAAATAAAG	TGATGTATAC	CGAATTCAGC	TTTTGTTCCC	8300
15	TTTAGTGAGG	GTTAATTGCG	CGCTTGGCGT	AATCATGGTC	ATAGCTGTTT	8350
	CCTGTGTGAA	ATTGTTATCC	GCTCACAATT	CCACACAACA	TACGAGCCGG	8400
	AAGCATAAAG	TGTAAAGCCT	GGGGTGCCTA	ATGAGTGAGC	TAACCTCACAT	8450
	TAATTGCGTT	GCGCTCACTG	CCCGCTTTCC	AGTCGGGAAA	CCTGTCTGTC	8500
	CAGCTGCATT	AATGAATCGG	CCAACGCGCG	GGGAGAGGCG	GTTTGCGTAT	8550
20	TGGGCGCTCT	TCCGCTTCCT	CGCTCACTGA	CTCGCTGCGC	TCGGTTCGTC	8600
	GGCTGCGGCG	AGCGGTATCA	GCTCACTCAA	AGGCGGTAAT	ACGGTTATCC	8650
	ACAGAATCAG	GGGATAACGC	AGGAAGAAGC	ATGTGAGCAA	AAGGCCAGCA	8700
	AAAGGCCAGG	AACCGTAAAA	AGGCCGCGTT	GCTGGCGTTT	TTCCATAGGC	8750
	TCCGCCCCCC	TGACGAGCAT	CACAAAAATC	GACGCTCAAG	TCAGAGGTGG	8800
25	CGAAACCCGA	CAGGACTATA	AAGATACCAG	GCGTTTCCCC	CTGGAAGCTC	8850
	CCTCGTGCGC	TCTCTGTTC	CGACCCTGCC	GCTTACCGGA	TACCTGTCCG	8900
	CCTTTCTCCC	TTGCGGAAGC	GTGGCGCTTT	CTCATAGCTC	ACGCTGTAGG	8950
	TATCTCAGTT	CGGTGTAGGT	CGTTGCGTCC	AAGCTGGGCT	GTGTGCACGA	9000
	ACCCCCCGTT	CAGCCCCACC	GCTGCGCCTT	ATCCGGTAAC	TATCGTCTTG	9050
30	AGTCCAACCC	GGTAAGACAC	GACTTATCGC	CACTGGCAGC	AGCCACTGGT	9100
	AACAGGATTA	GCAGAGCGAG	GTATGTAGGC	GGTGCTACAG	AGTTCTTGAA	9150
	GTGGTGCCCT	AACTACGGCT	ACACTAGAAG	GACAGTATTT	GGTATCTGCG	9200
	CTCTGCTGAA	GCCAGTTACC	TTGCGAAAAA	GAGTTGGTAG	CTCTTGATCC	9250
	GGCAACAAAA	CCACCGCTGG	TAGCGGTGGT	TTTTTTGTTT	GCAAGCAGCA	9300
35	GATTACGCGC	AGAAAAAAG	GATCTCAAGA	AGATCCTTTG	ATCTTTTCTA	9350
	CGGGGTCTGA	CGCTCAGTGG	AACGAAAACT	CACGTTAAGG	GATTTTGGTC	9400
	ATGAGATTAT	CAAAAAGGAT	CTTCACCTAG	ATCCTTTTAA	ATTAAAAATG	9450
	AAGTTTAAAT	TCAATCTAAA	GTATATATGA	GTAAACTTGG	TCTGACAGTT	9500
	ACCAATGCTT	AATCAGTGAG	GCACCTATCT	CAGCGATCTG	TCTATTTCTG	9550
40	TCATCCATAG	TTGCCTGACT	CCCCGTCTGT	TAGATAACTA	CGATACGGGA	9600
	GGGCTTACCA	TCTGGCCCCA	GTGCTGCAAT	GATACCGCGA	GACCCACGCT	9650
	CACCGGCTCC	AGATTTATCA	GCAATAAACC	AGCCAGCCGG	AAGGGCCGAG	9700
	CGCAGAAGTG	GTCCTGCAAC	TTTATCCGCC	TCCATCCAGT	CTATTAATTG	9750
	TTGCCGGGAA	GCTAGAGTAA	GTAGTTCGCC	AGTTAATAGT	TTGCGCAACG	9800
45	TTGTTGCCAT	TGCTACAGGC	ATCGTGGTGT	CACGCTCGTC	GTTTGGTATG	9850
	GCTTCATTCA	GCTCCGGTTC	CCAACGATCA	AGGCGAGTTA	CATGATCCCC	9900
	CATGTTGTGC	AAAAAAGCGG	TTAGCTCCTT	CGGTCCTCCG	ATCGTTGTCA	9950
	GAAGTAAGTT	GGCCGCAGTG	TTATCACTCA	TGGTTATGGC	AGCACTGCAT	10000
	AATTCTCTTA	CTGTCTATGC	ATCCGTAAGA	TGCTTTTCTG	TGACTGGTGA	10050
50	GTACTCAACC	AAGTCATTCT	GAGAATAGTG	TATGCGGCGA	CCGAGTTGCT	10100
	CTTGCCCGGC	GTCAATACGG	GATAATACCG	CGCCACATAG	CAGAACTTTA	10150
	AAAGTGCTCA	TCATTGGAAG	ACGTTCTTCG	GGGCGAAAAA	TCTCAAGGAT	10200
	CTTACCCTCG	TTGAGATCCA	GTTTCGATGA	ACCCACTCGT	GCACCCAACT	10250
	GATCTTTCAG	ATCTTTTACT	TTACCCAGCG	TTTCTGGGTG	AGCAAAAACA	10300
55	GGAAGGCAAA	ATGCCGCAAA	AAAGGGAATA	AGGGCGACAC	GGAAATGTTG	10350
	AATACTCATA	CTCTTCCTTT	TTCAATATTA	TTGAAGCATT	TATCAGGGTT	10400
	ATTGTCTCAT	GAGCGGATAC	ATATTTGAAT	GTATTTAGAA	AAATAAACAA	10450
	ATAGGGGTTC	CGCGCACATT	TCCCCGAAAA	GTGCCAC		10487
60	SEQ ID NO:45 (pTnMod(Oval/ENT tag/P146/PA) - Chicken)					

	CTGACGCGCC	CTGTAGCGGC	GCATTAAGCG	CGGCGGGTGT	GGTGGTTACG	50
	CGCAGCGTGA	CCGCTACACT	TGCCAGCGCC	CTAGCGCCCG	CTCCTTTTCG	100
	TTTCTTCCCT	TCCTTCTCG	CCACGTTTCG	CGGCATCAGA	TTGGCTATTG	150
5	GCCATTGCAT	ACGTTGTATC	CATATCATAA	TATGTACATT	TATATTGGCT	200
	CATGTCCAAC	ATTACCGCCA	TGTTGACATT	GATTATTGAC	TAGTTATTAA	250
	TAGTAATCAA	TTACGGGGTC	ATTAGTTCAT	AGCCCATATA	TGGAGTTCCT	300
	CGTTACATAA	CTTACGGTAA	ATGGCCCGCC	TGGCTGACCG	CCCAACGACC	350
	CCCGCCCAT	GACGTCAATA	ATGACGTATG	TTCCCATAGT	AACGCCAATA	400
	GGGACTTTCC	ATTGACGTCA	ATGGGTGGAG	TATTTACGGT	AAACTGCCCA	450
10	CTTGGCAGTA	CATCAAGTGT	ATCATATGCC	AAGTACGCCC	CCTATTGACG	500
	TCAATGACGG	TAAATGGCCC	GCCTGGCATT	ATGCCAGTA	CATGACCCTTA	550
	TGGGACTTTC	CTACTTGGCA	GTACATCTAC	GTATTAGTCA	TCGCTATTAC	600
	CATGGTGTATG	CGGTTTTGGC	AGTACATCAA	TGGGCGTGA	TAGCGGTTTG	650
	ACTCACGGGG	ATTTCCAAGT	CTCCACCCCA	TTGACGTCAA	TGGGAGTTTG	700
15	TTTTTGGCACC	AAAATCAACG	GGACTTTCCA	AAATGTGTA	ACAACCTCCG	750
	CCCATTGACG	CAAAATGGGCG	GTAGGCGTGT	ACGGTGGGAG	GTCTATATAA	800
	GCAGAGCTCG	TTTAGTGAAC	CGTCAGATCG	CCTGGAGACG	CCATCCACGC	850
	TGTTTTTGACC	TCCATAGAAG	ACACCGGGAC	CGATCCAGCC	TCCGCGGCCG	900
	GGAAACGGTGC	ATTGGAACGC	GGATTCCCCG	TGCCAAGAGT	GACGTAAGTA	950
20	CCGCCTATAG	ACTCTATAGG	CACACCCCTT	TGGCTCTTAT	GCATGCTATA	1000
	CTGTTTTTGG	CTTGGGGCCT	ATACACCCCC	GCTTCTTAT	GCTATAGGTG	1050
	ATGGTATAGC	TTAGCCTATA	GGTGTGGGT	ATTGACCATT	ATTGACCACT	1100
	CCCCTATTGG	TGACGATACT	TTCCATTACT	AATCCATAAC	ATGGCTCTTT	1150
	GCCACAACATA	TCTCTATTGG	CTATATGCCA	ATACTCTGTC	CTTCAGAGAC	1200
25	TGACACGGAC	TCTGTATTTT	TACAGGATGG	GGTCCCATT	ATTATTTACA	1250
	AATTACACATA	TACAACAACG	CCGTCCCCCG	TGCCCGCAGT	TTTTATTAAA	1300
	CATAGCGTGG	GATCTCCACG	CGAATCTCGG	GTACGTGTTT	CGGACATGGG	1350
	CTCTTCTCCG	GTAGCGGCGG	AGCTTCCACA	TCCGAGCCCT	GGTCCCATGC	1400
	CTCCAGCGGC	TCATGGTCGC	TCGGCAGCTC	CTTGCTCCTA	ACAGTGGAGG	1450
30	CCAGACTTAG	GCACAGCACA	ATGCCACCA	CCACCAGTGT	GCCGCACAAG	1500
	GCCGTGGCGG	TAGGGTATGT	GTCTGAAAAT	GAGCGTGGAG	ATTGGGCTCG	1550
	CACGGCTGAC	GCAGATGGAA	GACTTAAGGC	AGCGGCAGAA	GAAGATGCAG	1600
	GCAGCTGAGT	TGTTGTATTC	TGATAAGAGT	CAGAGGTAAC	TCCCGTTGCG	1650
	GTGCTGTAA	CGGTGGAGGG	CAGTGTAGTC	TGAGCAGTAC	TCGTTGCTGC	1700
35	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GACTAACAGA	CTGTTCTCTT	1750
	CCATGGGTCT	TTTCTGCAGT	CACCGTCCGA	CCATGTGTGA	ACTTGATATT	1800
	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAACGACT	1850
	CAACAGCTTA	ACGTTGGCTT	GCCACGCATT	ACTTGACTGT	AAAACCTCTA	1900
	CTCTTACCGA	ACTTGGCCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
40	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCACC	TCCACAAAGA	2000
	GCGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
	GATGCCCATT	GTACTTGTG	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAC	2100
	TTATGGTATT	GCGAGCTTCA	GTGCACTAC	ACGGTTCGTT	TGTTACTCTT	2150
	TATGAGAAAG	CGTTCCCGCT	TTGAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
45	CCAATTTCTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
	TCATTGTGAG	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAATATGC	2350
	AGACCTAGGA	GCGGAAAAC	GGAAACCTAT	CAGCAACTTA	CATGATATGT	2400
	CATCTAGTCA	CTCAAAGACT	TTAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
50	CCAATCTCAT	GCCAAATTCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
	AAATCAGCGC	TCGACACGGA	CTCATGTGCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTT	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTCGAA	CACCCAAACA	ACTTGTAAAT	ATCTATTGCA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAGAG	TCCTGCCTAC	GGACTAGGCC	2700
55	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTGCG	TTAGGCATGG	AAGTTTTCGG	GCATTCTGGC	2900
	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
60	AAATTTATTC	ACACATGGTT	ACGCTTTGGG	GAAATTATGA	TAATGATCCA	3000
	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTTG	3050

	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
	CCCTCCCCCG	TGCCTTCCTT	GACCTTGGAA	GGTGCCACTC	CCACTGTCCCT	3150
	TTCCTAATAA	AATGAGGAAA	TTGCATCGCA	TTGCTGAGT	AGGTGTCATT	3200
	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
5	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
10	CATCACAACA	AAAACCTGAT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
	CCTATCCAAG	AAGTGATGCC	TATCATTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
15	GACCTTGAGC	ACTGATGAAT	CCCCTAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCATATGAT	CCCGTAATG	TGAGTTAGCT	3850
	CACTCATTAG	GCACCCAGG	CTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
20	CATGATTACG	CCAAGCGCGC	AATTAACCTT	CACTAAAGGG	AACAAAAGCT	4000
	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGG	TCCCCCGGGG	4050
	AGGTCAGAAT	GGTTTCTTTA	CTGTTTGTCA	ATTCTATTAT	TTCAATACAG	4100
	AACAATAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTTACAAA	TTCTCTGTCT	4200
	ATCTGCCAGG	CCATTAAGTT	ATTATGGAAT	GATCTTTGAG	GAACACTGCA	4250
25	AGTTTCATATC	ATAAACACAT	TTGAAATTGA	GTATTGTTTT	GCATTGTATG	4300
	GAGCTATGTT	TTGCTGTATC	CTCAGAAAAA	AAGTTTGTGA	TAAAGCATTG	4350
	ACACCCATAA	AAAGATAGAT	TTAAATATTC	CAGCTATAGG	AAAGAAAGTG	4400
	CGTCTGCTCT	TCACTCTAGT	CTCAGTTGGC	TCCTTCACAT	GCATGCTTCT	4450
	TTATTTCTCC	TATTTTGTCA	AGAAAATAAT	AGGTCACGTC	TTGTTCTCAC	4500
30	TTATGTCTCTG	CCTAGCATGG	CTCAGATGCA	CGTTGTAGAT	ACAAGAAGGA	4550
	TCAAATGAAA	CAGACTTCTG	GTCTGTACT	ACAACCATAG	TAATAAGCAC	4600
	ACTAACTAAT	AATTGCTAAT	TATGTTTCC	ATCTCTAAGG	TTCCACATT	4650
	TTTCTGTTTT	CTTAAAGATC	CCATTATCTG	GTTGTAACCTG	AAGCTCAATG	4700
	GAACATGAGC	AATATTTCCT	AGTCTTCTCT	CCCATCCAAC	AGTCCTGATG	4750
35	GATTAGCAGA	ACAGGCAGAA	AACACATTGT	TACCCAGAAT	TAAAAACTAA	4800
	TATTTGCTCT	CCATTCAATC	CAAAATGGAC	CTATTGAAAC	TAAAATCTAA	4850
	CCCAATCCCA	TTAAATGATT	TCTATGGCGT	CAAAGGTCAA	ACTTCTGAAG	4900
	GGAACCTGTG	GGTGGGTCAC	AATTCAGGCT	ATATATTCCC	CAGGGCTCAG	4950
	CGGATCCATG	GGCTCCATCG	GCGCAGCAAG	CATGGAATTT	TGTTTTGATG	5000
40	TATTCAAGGA	GCTCAAAGTC	CACCATGCCA	ATGAGAACAT	CTTCTACTGC	5050
	CCCATTGCCA	TCATGTCAGC	TCTAGCCATG	GTATACCTGG	GTGCAAAAGA	5100
	CAGCACCAGG	ACACAGATAA	ATAAGGTTGT	TCGCTTTGAT	AAACTTCCAG	5150
	GATTCGGAGA	CAGTATTGAA	GCTCAGTGTG	GCACATCTGT	AAACGTTTAC	5200
	TCTTCACTTA	GAGACATCCT	CAACCAATC	ACCAAAACCA	ATGATGTTTA	5250
45	TTGCTTCCAGC	CTTGCCAGTA	GACTTTATGC	TGAAGAGAGA	TACCCAATCC	5300
	TGCCAGAATA	CTTGCACTGT	GTGAAGGAAC	TGTATAGAGG	AGGCTTGGAA	5350
	CCTATCAACT	TTCAAACAGC	TGCAGATCAA	GCCAGAGAGC	TCATCAATTC	5400
	CTGGGTAGAA	AGTCAGACAA	ATGGAATTAT	CAGAAATGTC	CTTCAGCCAA	5450
	GCTCCGTGGA	TTCTCAAACT	GCAATGGTTC	TGGTTAATGC	CATTGTCTTC	5500
50	AAAGGACTGT	GGGAGAAAAC	ATTTAAGGAT	GAAGACACAC	AAGCAATGCC	5550
	TTTCAGAGTG	ACTGAGCAAG	AAAGCAAACC	TGTGCAGATG	ATGTACCAGA	5600
	TTGGTTTATT	TAGAGTGGCA	TCAATGGCTT	CTGAGAAAAT	GAAGATCCTG	5650
	GAGCTTCCAT	TTGCCAGTGG	GACAATGAGC	ATGTTGGTGC	TGTTGCCTGA	5700
	TGAAGTCTCA	GGCCTTGAGC	AGCTTGAGAG	TATAATCAAC	TTTGAAAAAC	5750
55	TGACTGAATG	GACCAGTTCT	AATGTTATGG	AAGAGAGGAA	GATCAAAGTG	5800
	TACTTACCTC	GCATGAAGAT	GGAGGAAAAA	TACAACCTCA	CATCTGTCTT	5850
	AATGGCTATG	GGCATTACTG	ACGTGTTTAG	CTCTTCAGCC	AATCTGTCTG	5900
	GCATCTCCTC	AGCAGAGAGC	CTGAAGATAT	CTCAAGCTGT	CCATGCAGCA	5950
	CATGCAGAAA	TCAATGAAGC	AGGCAGAGAG	GTGGTAGGGT	CAGCAGAGGC	6000
60	TGGAGTGGAT	GCTGCAAGCG	TCTCTGAAGA	ATTTAGGGCT	GACCATCCAT	6050
	TCCTCTTCTG	TATCAAGCAC	ATCGCAACCA	ACGCCGTTCT	CTTCTTTGGC	6100

	AGATGTGTTT	CCCCTCCGCG	GCCAGCAGAT	GACGCACCAG	CAGATGACGC	6150
	ACCAGCAGAT	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	GACGCACCAG	6200
	CAGATGACGC	AACAACATGT	ATCCTGAAAG	GCTCTGTGG	CTGGATCGGC	6250
	CTGCTGGATG	ACGATGACAA	AAAATACAAA	AAAGCACTGA	AAAACTGGC	6300
5	AAAACCTGCTG	TAATGAGGGC	GCCTGGATCC	AGATCACTTC	TGGCTAATAA	6350
	AAGATCAGAG	CTCTAGAGAT	CTGTGTGTTG	GTTTTTTGTG	GATCTGCTGT	6400
	GCCTTCTAGT	TGCCAGCCAT	CTGTTGTTTG	CCCCCCCC	GTGCCCTTCCT	6450
	TGACCCTGGA	AGGTGCCACT	CCCACTGTCC	TTTCCTAATA	AAATGAGGAA	6500
	ATTGCATCGC	ATTGTCTGAG	TAGGTGTCAT	TCTATTCTGG	GGGGTGGGGT	6550
10	GGGGCAGCAC	AGCAAGGGGG	AGGATTGGGA	AGACAATAGC	AGGCATGCTG	6600
	GGGATGCGGT	GGGCTCTATG	GGTACCTCTC	TCTCTCTCTC	TCTCTCTCTC	6650
	TCTCTCTCTC	TCTCTCGGTA	CCTCTCTCGA	GGGGGGGCCC	GGTACCCAAT	6700
	TCGCCCTATA	GTGAGTCGTA	TTACGCGCGC	TCACTGGCCG	TCGTTTTTACA	6750
	ACGTCGTGAC	TGGGAAAACC	CTGGCGTTAC	CCAACTTAAT	CGCCTTGCGAG	6800
15	CACATCCCCC	TTTCGCCAGC	TGGCGTAATA	GCGAAGAGGC	CCGCACCGAT	6850
	CGCCCTTCCC	AACAGTTGCG	CAGCCTGAAT	GGCGAATGGA	AATTGTAAGC	6900
	GTTAATATTT	TGTTAAAATT	CGCGTTAAAT	TTTTGTAAA	TCAGCTCATT	6950
	TTTTAACCAA	TAGGCCGAAA	TCGGCAAAAT	CCCTTATAAA	TCAAAAGAAT	7000
	AGACCGAGAT	AGGGTTGAGT	GTTGTTCCAG	TTTGAACAA	GAGTCCACTA	7050
20	TTAAGAACG	TGGACTCCAA	CGTCAAAGGG	CGAAAAACCG	TCTATCAGGG	7100
	CGATGGCCCA	CTACTCCGGG	ATCATATGAC	AAGATGTGTA	TCCACCTTAA	7150
	CTTAATGATT	TTTACCAAAA	TCATTAGGGG	ATTCAATCAGT	GCTCAGGGTC	7200
	AACGAGAATT	AACATTCCGT	CAGGAAAGCT	TATGATGATG	ATGTGCTTAA	7250
	AAACTTACTC	AATGGCTGGT	TATGCATATC	GCAATACATG	CGAAAAACCT	7300
25	AAAAGAGCTT	GCCGATAAAA	AAGGCCAATT	TATTGCTATT	TACCGCGGCT	7350
	TTTTATTGAG	CTTGAAAGAT	AAATAAAATA	GATAGGTTTT	ATTTGAAGCT	7400
	AAATCTTCTT	TATCGTAAAA	AATGCCCTCT	TGGGTTATCA	AGAGGGTCAT	7450
	TATATTTTCG	GGAATAACAT	CATTTGGTGA	CGAAATAACT	AAGCACTTGT	7500
	CTCCTGTTTA	CTCCCTGAG	CTTGAGGGGT	TAACATGAAG	GTCATCGATA	7550
30	GCAGGATAAT	AATACAGTAA	AACGCTAAAC	CAATAATCCA	AATCCAGCCA	7600
	TCCCAAATTG	GTAGTGAATG	ATTATAAATA	ACAGCAAAAC	GTAATGGGCC	7650
	AATAACACCG	GTTGCATTGG	TAAGGCTCAC	CAATAATCCC	TGTAAAGCAC	7700
	CTTGCTGATG	ACTCTTTGTT	TGGATAGACA	TCACTCCCTG	TAATGCAGGT	7750
	AAAGCCAGTC	CACCACCAGC	CAATAAAATT	AAAACAGGGA	AAACTAACCA	7800
35	ACCTTCAGAT	ATAAACGCTA	AAAAGGCAAA	TGCACTACTA	TCTGCAATAA	7850
	ATCCGAGCAG	TACTGCCGTT	TTTTCGCCCC	ATTTAGTGGC	TATTCTTCCT	7900
	GCCACAAAGG	CTTGGAATAC	TGAGTGTAAG	AGACCAAGAC	CCGCTAATGA	7950
	AAAGCCAACC	ATCATGCTAT	TCCATCCAAA	ACGATTTTCG	GTAAATAGCA	8000
	CCCACACCGT	TGCGGGAATT	TGGCCTATCA	ATTGCGCTGA	AAAATAAATA	8050
40	ATCAACAAAA	TGGCATCGTT	TTAAATAAAG	TGATGTATAC	CGAATTCAGC	8100
	TTTTGTTCCT	TTTAGTGAGG	GTTAATTGCG	CGCTTGGCGT	AATCATGGTC	8150
	ATAGCTGTTT	CCTGTGTGAA	ATTGTTATCC	GCTCACAATT	CCACACAACA	8200
	TACGAGCCGG	AAGCATAAAG	TGTAAAGCCT	GGGGTGCCTA	ATGAGTGAGC	8250
	TAATCAGCAT	TAATTGCGTT	GCGCTCACTG	CCCGCTTTCC	AGTCGGGAAA	8300
45	CCTGTGCTGC	CAGCTGCATT	AATGAATCGG	CCAACGCGCG	GGGAGAGGCG	8350
	GTTTGCGTAT	TGGGCGCTCT	TCCGCTTCCT	CGCTCACTGA	CTCGCTGCGC	8400
	TCGGTTCGTT	GGCTGCGGCG	AGCGGTATCA	GCTCACTCAA	AGGCGGTAAT	8450
	ACGGTTATCC	ACAGAATCAG	GGGATAACGC	AGGAAAGAAC	ATGTGAGCAA	8500
	AAGGCCAGCA	AAAGGCCAGG	AACCGTAAAA	AGGCCGCGTT	GCTGGCGTTT	8550
50	TTCCATAGGC	TCCGCCCCCC	TGACGAGCAT	CACAAAAATC	GACGCTCAAG	8600
	TCAGAGGTGG	CGAAACCCGA	CAGGACTATA	AAGATACCGA	GCGTTTCCCC	8650
	CTGGAAGCTC	CCTCGTGCGC	TCTCCTGTTT	CGACCCCTGCC	GCTTACCGGA	8700
	TACCTGTCCG	CCTTTCTCCC	TTGCGGAAGC	GTGGCGCTTT	CTCATAGCTC	8750
	ACGCTGTAGG	TATCTCAGTT	CGGTGTAGGT	CGTTCGCTCC	AAGCTGGGCT	8800
55	GTGTGCACGA	ACCCCCGTT	CAGCCCCACC	GCTGCGCCTT	ATCCGGTAAC	8850
	TATCGTCTTG	AGTCCAACCC	GGTAAGACAC	GACTTATCGC	CACTGGCAGC	8900
	AGCCACTGGT	AACAGGATTA	GCAGAGCGAG	GTATGTAGGC	GGTGCTACAG	8950
	AGTTCTTGAA	GTGGTGGCCT	AACTACGGCT	ACACTAGAAG	GACAGTATTT	9000
	GGTATCTGCG	CTCTGCTGAA	GCCAGTTACC	TTCGGAAAAA	GAGTTGGTAT	9050
60	CTCTTGATCC	GGCAACAAA	CCACCGCTGG	TAGCGGTGGT	TTTTTTGTTT	9100
	GCAAGCAGCA	GATTACGCGC	AGAAAAAAG	GATCTCAAGA	AGATCCTTTG	9150

ATCTTTTCTA CGGGGTCTGA CGCTCAGTGG AACGAAACT CACGTTAAGG 9200  
 GATTTTGGTC ATGAGATTAT CAAAAAGGAT CTTACCTAG ATCCTTTTAA 9250  
 ATTAAAAATG AAGTTTTAAA TCAATCTAAA GTATATATGA GTAAACTTGG 9300  
 TCTGACAGTT ACCAATGCTT AATCAGTGAG GCACCTATCT CAGCGATCTG 9350  
 5 TCTATTTCTG TCATCCATAG TTGCCTGACT CCCCCTCGTG TAGATAACTA 9400  
 CGATACGGGA GGGCTTACCA TCTGGCCCCA GTGCTGCAAT GATACCGCGA 9450  
 GACCCACGCT CACCGGCTCC AGATTTATCA GCAATAAACC AGCCAGCCGG 9500  
 AAGGGCCGAG CGCAGAAGTG GTCCTGCAAC TTTATCCGCC TCCATCCAGT 9550  
 CTATTAATTG TTGCCGGGAA GCTAGAGTAA GTAGTTCGCC AGTTAATAGT 9600  
 10 TTGCCCAACG TTGTTGCCAT TGCTACAGGC ATCGTGGTGT CACGCTCGTC 9650  
 GTTTGGTATG GCTTCATTCA GTCCGGTTC CCAACGATCA AGCGGAGTTA 9700  
 CATGATCCCC CATGTTGTGC AAAAAAGCGG TTAGCTCCTT CGGTCTCCG 9750  
 ATCGTTGTCA GAAGTAAGTT GGCCGCAGTG TTATCACTCA TGGTTATGGC 9800  
 AGCACTGCAT AATTCTCTTA CTGTCATGCC ATCCGTAAGA TGCTTTTCTG 9850  
 15 TGACTGCTGA GACTCAACC AAGTCATTCT GAGAATAGTG TATGCGGCGA 9900  
 CCGAGTTGCT CTTGCCCGGC GTCAATACGG GATAATACCG CGCCACATAG 9950  
 CAGAACTTTA AAAGTGCTCA TCATTGGAAA ACGTTCTTCG GGGCGAAAAC 10000  
 TCTCAAGGAT CTTACCGCTG TTGAGATCCA GTTCGATGTA ACCCACTCGT 10050  
 GCACCCAACG GATCTTCAGC ATCTTTTACT TTCACCAGCG TTCTGGGGTG 10100  
 20 AGCAAAAACA GGAAGGCAAA ATGCCGCAAA AAAGGGAATA AGGGCGACAC 10150  
 GGAAATGTTG AATACTCATA CTCTTCCTTT TTCAATATTA TTGAAGCATT 10200  
 TATCAGGGTT ATTGTCTCAT GAGCGGATAC ATATTTGAAT GTATTTAGAA 10250  
 AAATAAACAA ATAGGGGTTC CGCGCACATT TCCCCGAAAA GTGCCAC 10297

25

SEQ ID NO:46 (pTnMod(Oval/ENT tag/P146/PA) - QUAIL)

CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50  
 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTTCG 100  
 30 TTTCTTCCCT TCCTTTCTCG CCACGTTTCG CGGCATCAGA TTGGCTATTG 150  
 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200  
 CATGTCCAAC ATTACCGCCA TGTGACATT GATTATTGAC TAGTTATTAA 250  
 TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG 300  
 CGTTACATAA CTTACGGTAA ATGGCCCCGCG TGGCTGACCG CCCAACGACC 350  
 35 CCGGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA 400  
 GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AAAC TGCCCA 450  
 CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 500  
 TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCAGTA CATGACCTTA 550  
 TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC 600  
 40 CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 650  
 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG 700  
 TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC 750  
 CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 800  
 GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850  
 45 TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG 900  
 GGAACGGTGC ATTGGAACGC GGATTCCCCG TGCCAAGAGT GACGTAAGTA 950  
 CCGCCTATAG ACTCTATAGG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000  
 CTGTTTTTGG CTTGGGGCCT ATACACCCCC GCTTCCTTAT GCTATAGGTG 1050  
 ATGGTATAGC TTAGCCTATA GGTGTGGGTT ATTGACCATT ATTGACCACT 1100  
 50 CCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150  
 GCCACAATA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTGAGAGAC 1200  
 TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATTT ATTATTTACA 1250  
 AATTACATA TACAACAACG CCGTCCCCCG TGCCCGCAGT TTTTATTAAA 1300  
 CATAGCGTGG GATCTCCACG CGAATCTCGG GTACGTGTTT CGGACATGGG 1350  
 55 CTCTTCTCCG GTAGCGGCGG AGCTTCCACA TCCGAGCCCT GGTCCCATGC 1400  
 CTCCAGCGGC TCATGGTCGC TCGGCAGCTC CTTGCTCCTA ACAGTGGAGG 1450  
 CCAGACTTAG GCACAGCACA ATGCCACCA CCACAGTGT GCCGCACAAG 1500  
 GCCGTGGCGG TAGGGTATGT GTCTGAAAAT GAGCGTGGAG ATTGGGCTCG 1550  
 CACGGCTGAG GCAGATGGAA GACTTAAGGC AGCGGCAGAA GAAGATGCAG 1600  
 60 GCAGCTGAGT TGTGTATTTC TGATAAGAGT CAGAGGTAAC TCCCGTTGCG 1650  
 GTGCTGTTAA CGGTGGAGGG CAGTGTAGTC TGAGCAGTAC TCGTTGCTGC 1700

	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GACTAACAGA	CTGTTCCCTTT	1750
	CCATGGGTCT	TTTCTGCAGT	CACCGTCGGA	CCATGTGTGA	ACTTGATATT	1800
	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAACGACT	1850
	CAACAGCTTA	ACGTTGGCTT	GCCACGCATT	ACTTGACTGT	AAAACCTCTCA	1900
5	CTCTTACCGA	ACTTGGCCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCACC	TCCACAAAGA	2000
	GCGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
	GATGCCCAT	GTACTTGTG	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAC	2100
	TTATGGTATT	GCGAGCTTCA	GTCGCACTAC	ACGGTCGTTC	TGTTACTCTT	2150
10	TATGAGAAAG	CGTTCCCGCT	TTCAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
	CCAATTTCTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
	TCATTGTCAG	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAATATGC	2350
	AGACCTAGGA	GCGGAAAAC	GGAAACCTAT	CAGCAACTTA	CATGATATGT	2400
15	CATCTAGTCA	CTCAAAGACT	TTAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
	CCAATCTCAT	GCCAAATCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
	AAATCAGCGC	TGCACACGGA	CTCATTGTCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTT	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTCGAA	CACCCAAACA	ACTTGTTAAT	ATCTATTCTGA	AGCGAATGCA	2650
20	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTCGC	TTAGGCATGG	AAGTTTTGCG	GCAATCTGGC	2900
25	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
	AAATTTATTC	ACACATGGTT	ACGCTTTGGG	GAAATTATGA	TAATGATCCA	3000
	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
	CCCTCCCCCG	TGCCTTCTCT	GACCCTGGAA	GGTGCCACTC	CCACTGTCTT	3150
30	TTCCTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3200
	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
	GACAAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
35	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCCTA	3500
	CATCACAAACA	AAAACCTGAT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
	CCTATCCAAG	AAGTGATGCC	TATCATTGGT	TGGAATGAAC	TTGAAAAAAA	3650
40	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATCTCGTT	3750
	GACCCTGAGC	ACTGATGAAT	CCCCTAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCATATGAT	CCCGGTAATG	TGAGTTAGCT	3850
	CACTCATTAG	GCACCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
45	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
	CATGATTACG	CCAAGCGCGC	AATTAACCCT	CACTAAAGGG	AACAAAAGCT	4000
	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGA	TCCCCCGGGG	4050
	AGGTCAGAAT	GGTTTCTTTA	CTGTTTGTCA	ATTCTATTAT	TTCAATACAG	4100
	AACAAAAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
50	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTTACAAA	TTCTCTGTCT	4200
	ATCTGCCAGG	CTGGAAGATC	ATGGAAGATC	TCTGAGGAAC	ATTGCAAGTT	4250
	CATACCATAA	ACTCATTTTG	AATTGAGTAT	TATTTTGCTT	TGAATGGAGC	4300
	TATGTTTTGC	AGTTCCCTCA	GAAGAAAAGC	TTGTTATAAA	GCGTCTACAC	4350
	CCATCAAAG	ATATATTTTAA	ATATTCCAAC	TACAGAAAAG	TTTTGTCTGC	4400
55	TCTTCACTCT	GATCTCAGTT	GGTTTCTTCA	CGTACATGCT	TCTTTATTTG	4450
	CCTATTTTGT	CAAGAAAATA	ATAGGTCAAG	TCCTGTTCTC	ACTTATCTCC	4500
	TGCCTAGCAT	GGCTTAGATG	CACGTTGTAC	ATTCAAGAAG	GATCAAATGA	4550
	AACAGACTTC	TGGTCTGTTA	CAACAACCAT	AGTAATAAAC	AGACTAACTA	4600
	ATAATTGCTA	ATTATGTTTT	CCATCTCTAA	GGTTCCCAAC	TTTTTCTGTT	4650
60	TTAAGATCCC	ATTATCTGGT	TGTAACGTAA	GCTCAATGGA	ACATGAACAG	4700
	TATTTCTCAG	TCTTTTCTCC	AGCAATCCTG	ACGGATTAGA	AGAAGTGGCA	4750

	GAAAACTT	TGTTACCCAG	AATTAATAAC	TAATATTTGC	TCTCCCTTCA	4800
	ATCCAAAATG	GACCTATTGA	AACTAAAATC	TGACCCAATC	CCATTAAATT	4850
	ATTTCTATGG	CGTCAAAGGT	CAAACTTTGT	AAGGGAACCT	GTGGGTGGGT	4900
	CCCAATTGAG	GCTATATATT	CCCCAGGGCT	CAGCCAGTGG	ATCCATGGGC	4950
5	TCCATCGGTG	CAGCAAGCAT	GGAATTTTGT	TTTGATGTAT	TCAAGGAGCT	5000
	CAAAGTCCAC	CATGCCAATG	ACAACATGCT	CTACTCCCCC	TTTGCCATCT	5050
	TGTCAACTCT	GGCCATGGTC	TTCTTAGGTG	CAAAAGACAG	CACCAGGACC	5100
	CAGATAAATA	AGGTTGTTC	CTTTGATAAA	CTTCCAGGAT	TCGGAGACAG	5150
	TATTGAAGCT	CAGTGTGGCA	CATCTGTAAA	TGTTCACTCT	TCACTTAGAG	5200
10	ACATACTCAA	CCAAATCACC	AAACAAAATG	ATGCTTATTC	GTTTCAGCCTT	5250
	GCCAGTAGAC	TTTATGCTCA	AGAGACATAC	ACAGTCGTGC	CGGAATACTT	5300
	GCAATGTGTG	AAGGAACTGT	ATAGAGGAGG	CTTAGAATCC	GTCAACTTTC	5350
	AAACAGCTGC	AGATCAAGCC	AGAGGCCTCA	TCAATGCCTG	GGTAGAAAGT	5400
	CAGACAAACG	GAATTATCAG	AAACATCCTT	CAGCCAAGCT	CCGTGGATTG	5450
15	TCAAACCTGCA	ATGGTCCTGG	TTAATGCCAT	TGCCTTCAAG	GGACTGTGGG	5500
	AGAAAGCATT	TAAGGCTGAA	GACACGCAAA	CAATACCTTT	CAGAGTGACT	5550
	GAGCAAGAAA	GCAAACCTGT	CAGATGATG	TACCAGATTG	GTTCAATTAA	5600
	AGTGCATCA	ATGGCTTCTG	AGAAAATGAA	GATCCTGGAG	CTTCCATTG	5650
	CCAGTGGAAC	AATGAGCATG	TTGGTGCTGT	TGCCTGATGA	TGTCTCAGGC	5700
20	CTTGAGCAGC	TTGAGAGTAT	AATCAGCTTT	GAAAACTGA	CTGAATGGAC	5750
	CAGTTCTAGT	ATTATGGAAG	AGAGGAAGGT	CAAAGTGTAC	TTACCTCGCA	5800
	TGAAGATGGA	GGAGAAATAC	AACCTCACAT	CTCTCTTAAT	GGCTATGGGA	5850
	ATTACTGACC	TGTTCACTCT	TTCAGCCAAT	CTGTCTGGCA	TCTCCTCAGT	5900
	AGGGAGCCTG	AAGATATCTC	AGCTGTCCA	TGCAGCACAT	GCAGAAATCA	5950
25	ATGAAGCGGG	CAGAGATGTG	GTAGGCTCAG	CAGAGCTGG	AGTGGATGCT	6000
	ACTGAAGAAT	TTAGGGCTGA	CCATCCATTC	CTCTTCTGTG	TCAAGCACAT	6050
	CGAAACCAAC	GCCATTCTCC	TCTTTGGCAG	ATGTGTTTCT	CCGCGGCCAG	6100
	CAGATGACGC	ACCAGCAGAT	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	6150
	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	GACGCAACAA	CATGTATCCT	6200
30	GAAAGGCTCT	TGTGGCTGGA	TCGGCCTGCT	GGATGACGAT	GACAAAAAAT	6250
	ACAAAAAAGC	ACTGAAAAAA	CTGGCAAAAC	TGCTGTAATG	AGGGCGCCTG	6300
	GATCCAGATC	ACTTCTGGCT	AATAAAAGAT	CAGAGCTCTA	GAGATCTGTG	6350
	TGTTGGTTTT	TTGTGGATCT	GCTGTGCCCT	CTAGTTGCCA	GCCATCTGTT	6400
	GTTTGCCCTT	CCCCCGTGCC	TTCCTTGACC	CTGGAAGGTG	CCACTCCCAC	6450
35	TGTCCTTTCC	TAATAAAATG	AGGAAATTGC	ATCGCATTGT	CTGAGTAGGT	6500
	GTCATTCTAT	TCTGGGGGGT	GGGGTGGGGC	AGCACAGCAA	GGGGGAGGAT	6550
	TGGGAAGACA	ATAGCAGGCA	TGCTGGGGAT	GCGGTGGGCT	CTATGGGTAC	6600
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCTCT	6650
	CTCGAGGGGG	GGCCCGGTAC	CCAATTCGCC	CTATAGTGAG	TCGTATTACG	6700
40	CGCGCTCACT	GGCCGTGCTT	TTACAACGTC	GTGACTGGGA	AAACCCTGGC	6750
	GTTACCCAAC	TTAATCGCCT	TTCAGCACAT	CCCCCTCTCG	CCAGCTGGCG	6800
	TAATAGCGAA	GAGGCCCGCA	CCGATCGCCC	TTCCCAACAG	TTGCGCAGCC	6850
	TGAATGGCGA	ATGGAAATG	TAAGCGTTAA	TATTTTGTGA	AAATTCGCGT	6900
	TAAATTTTTG	TTAAATCAGC	TCATTTTTTA	ACCAATAGGC	CGAAATCGGC	6950
45	AAAATCCCTT	ATAAATCAAA	AGAATAGACC	GAGATAGGGT	TGAGTGTGTT	7000
	TCCAGTTTGG	AACAAGAGTC	CACTATTAAA	GAACGTGGAC	TCCAACGTCA	7050
	AAGGGCGAAA	AACCGTCTAT	CAGGGCGATG	GCCCACTACT	CCGGGATCAT	7100
	ATGACAAGAT	GTGTATCCAC	CTTAACTTAA	TGATTTTTAC	CAAAATCATT	7150
	AGGGGATTCA	TCAGTGCTCA	GGGTCAACGA	GAATTAACAT	TCCGTCAGGA	7200
50	AAGCTTATGA	TGATGATGTG	CTTAAAAACT	TACTCAATGG	CTGGTTATGC	7250
	ATATCGCAAT	ACATGCGAAA	AACCTAAAAG	AGCTTGCCGA	TAAAAAAGGC	7300
	CAATTTATTG	CTATTTACCG	CGGCTTTTTA	TTGAGCTTGA	AAGATAAATA	7350
	AAATAGATAG	GTTTTATTGT	AAGCTAAATC	TTCTTTATCG	TAAAAAATGC	7400
	CCTCTGGGGT	TATCAAGAGG	GTCATTATAT	TTGCGGGAAT	AACATCATT	7450
55	GGTGACGAAA	TAACTAAGCA	CTTGCTCTCT	GTTTACTCCC	CTGAGCTTGA	7500
	GGGGTTAACA	TGAAGGTCAT	CGATAGCAGG	ATAATAATAC	AGTAAAACGC	7550
	TAAACCAATA	ATCCAAATCC	AGCCATCCCA	AATTGGTAGT	GAATGATTAT	7600
	AAATAACAGC	AAACAGTAAT	GGGCCAATAA	CACCGGTTGC	ATTGGTAAGG	7650
	CTCACCAATA	ATCCCTGTAA	AGCACCTTGC	TGATGACTCT	TTGTTTGGAT	7700
60	AGACATCACT	CCCTGTAATG	CAGGTAAAGC	GATCCACCA	CCAGCCAATA	7750
	AAATTAATAAC	AGGAAAAACT	AACCAACCTT	CAGATATAAA	CGCTAAAAAG	7800



5 GCAAAATGCAC TACTATCTGC AATAAAATCCG AGCAGTACTG CCGTTTTTTTC 7850  
 GCCCCATTTA GTGGCTATTG TTCCCTGCCAC AAAGGCTTGG AATACTGAGT 7900  
 GTAAAAGACC AAGACCCGCT AATGAAAAGC CAACCATCAT GCTATTCCAT 7950  
 CCAAAACGAT TTTCGGTAAA TAGCACCAC ACCGTTGCGG GAATTTGGCC 8000  
 TATCAATTGC GCTGAAAAAT AAATAATCAA CAAAATGGCA TCGTTTTTAA 8050  
 TAAAGTGATG TATACCGAAT TCAGCTTTTG TTCCCTTTAG TGAGGGTTAA 8100  
 TTGCGCGCTT GGCCTAATCA TGGTCATAGC TGTTCCTGT GTGAAATTGT 8150  
 TATCCGCTCA CAATTCCACA CAACATACGA GCCGGAAGCA TAAAGTGTA 8200  
 AGCCTGGGGT GCCTAATGAG TGAGCTAACT CACATTAATT GCGTTGCGCT 8250  
 10 CACTGCCCCG TTTCCAGTCG GGAAACCTGT CGTGCCAGCT GCATTAATGA 8300  
 ATCGGCCAAC GCGCGGGGAG AGGCGGTTTG CGTATTGGGC GCTCTTCCGC 8350  
 TTCTCGCTC ACTGACTCGC TGCGCTCGGT CGTTCGGCTG CGGCGAGCGG 8400  
 TATCAGCTCA CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT 8450  
 AACCGCAGGAA AGAACATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG 8500  
 15 TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCTTGACG 8550  
 AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA CCCGACAGGA 8600  
 CTATAAGAT ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TCGCTCTCC 8650  
 TGTTCGACCC CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCCTTCGG 8700  
 GAAGCGTGGC GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTGCGTG 8750  
 20 TAGGTCGTTT GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC 8800  
 CGACCGCTGC GCCTTATCCG GTAACATCG TCTTGAGTCC AACCCGGTAA 8850  
 GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG GATTAGCAGA 8900  
 GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA 8950  
 CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG 9000  
 25 TTACCTTCGG AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAAACCACC 9050  
 CCTGGTAGCG GTGGTTTTT TGTTCGCAAG CAGCAGATTA CGCGCAGAAA 9100  
 AAAAGGATCT CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC 9150  
 AGTGGAACGA AAATCACGT TAAGGGATT TGGTCATGAG ATTATCAAAA 9200  
 AGGATCTTCA CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT 9250  
 30 CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA 9300  
 GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTTATC CATAGTTGCC 9350  
 TGACTCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG 9400  
 CCCCAGTGCT GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT 9450  
 TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT 9500  
 35 GCAACTTTAT CCGCTCCAT CCAGTCTATT AATTGTTGCC GGAAGCTAG 9550  
 AGTAAGTAGT TCGCCAGTTA ATAGTTTGGC CAACGTTGTT GCCATTGCTA 9600  
 CAGGCATCGT GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC 9650  
 GGTTCCTAAC GATCAAGGCG AGTTACATGA TCCCCATGT TGTGCAAAA 9700  
 AGCGGTTAGC TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG 9750  
 40 CAGTGTATC ACTCATGGTT ATGGCAGCAC TGCATAATC TCTTACTGTC 9800  
 ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC 9850  
 ATCTGTAGAA TAGTGTATGC GGCGACCGAG TTGCTCTTGC CCGCGTCAA 9900  
 TACGGGATAA TACCGCGCCA CATAGCAGAA CTTTAAAGT GCTCATCATT 9950  
 GGAACCGTT CTTGCGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG 10000  
 45 ATCCAGTTCG ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT 10050  
 TTACTTTTAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAAATGCC 10100  
 GCAAAAAGG GAATAAGGCG GACACGGAAA TGTGAATAC TCATACTCTT 10150  
 CCTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG 10200  
 GATACATATT TGAATGTATT TAGAAAAATA AACAAATAGG GGTCCGCGC 10250  
 50 ACATTTCCCC GAAAAGTGCC AC 10272

SEQ ID NO:47 pTnMCS (CMV-CHOVg-ent-ProInsulin-synPA)

55 1 ctgacgcgcc ctgtacggcg gcattaagcg cggcggggtgt ggtgggttacg cgcagcgtga  
 61 ccgctacact tgccagcgcc ctacgcccgc ctcccttcgc ttcttccct tcctttctcg  
 121 ccacgttcgc oggcatcaga ttggtatttg gccattgcat acgttgatc catatcataa  
 181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac  
 241 tagttattaa tagtaataa ttacgggggc attagttcat agcccatata tggagttccg  
 301 cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt  
 60 361 gacgtcaata atgacgtatg ttcccatagt aacgcccaata gggactttcc attgacgtca  
 421 atgggtggag tatttacggt aaactgccca cttggcagta catcaagtg atcatatgcc  
 481 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta

541 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tgcctattac  
 601 catgggtgatg cgggttttggc agtacatcaa tgggctgtga tagcggtttg actcaccggg  
 661 atttccaagt ctcaccccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg  
 721 ggactttcca aaatgtcgtg acaactccgc cccattgacg caaatgggag gtaggcgtgt  
 781 acgggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg  
 841 ccatccacgc tgttttgacc tccatagaag acaccgggac cgtccagcc tccgcgcccg  
 901 ggaacgggtgc attggaacgc ggattccccc tgccaagagt gacgtaagta ccgcctatag  
 961 actctatagg cacaccocct tggctcttat gcatgctata ctgttttttg cttggggcct  
 1021 atacaccccc gcttccttat gctatagggt atgggtatag ttgacctata ggtgtgggtt  
 1081 attgaccatt attgaccact cccctattgg tgacgatact ttccattact aatccataac  
 1141 atggctcttt gccacaacta tctctattgg ctatatgcca atactctgtc cttcagagac  
 1201 tgacacggac tctgtatatt tacaggatgg ggtcccatat attatttaca aattcacata  
 1261 tacaacaacg ccgtcccccgc tgcccgcagt ttttattaaa catagcgttg gatctccacg  
 1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctccg gtacggcgcg agcttccaca  
 1381 tccgagccct ggtcccatgc ctccagcggc tcatggctgc tcggcagctc cttgtctcta  
 1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gcgcgacaag  
 1501 gccgtggcgg taggggtatgt gtctgaaaat gagcgtggag attgggctcg cacggctgac  
 1561 gcagatggaa gacttaaggg agcggcagaa gaagatgcag gcagctgagt tgttgtattc  
 1621 tgataagagt cagaggtaac tcccgttggc gtgctgttaa cgggtggagg cagtgtagt  
 1681 tgagcagtag tctgtgtcgc cgcgcgcgc accagacata atagctgaca gactaacaga  
 1741 ctgttccctt ccatgggtct tttctgcagt caccgtcgga ccatgtgcga actcgatatt  
 1801 ttacacgact ctctttacca attctgcccc gaattacact taaaacgact caacagctta  
 1861 acgttggctt gccacgcatt acttgactgt aaaactctca ctcttaccga acttggccgt  
 1921 aacctgccaa ccaaaagcag aacaaaacat aacatcaaac gaatcgaccg attgttaggt  
 1981 aatcgtccac tccacaagaa gcgactcgct gtataccgtt ggcattgtag ctttatctgt  
 2041 tccggcaata cgtatgccat tgtacttgtt gactggtctg atattcgtga gcaaaaacga  
 2101 cttatgggtat tgcgagcttc agtcgcaacta caccgtcgtt ctgttactct ttatgagaaa  
 2161 gcgttccccc tttcagagca atgttcaaag aaagctcatg accaatctct agccgacctt  
 2221 gcgagcattc taccagtaga caccacaccg ctcatgttca gtgatgctgg ctttaaagt  
 2281 ccatgggtata aatccgttga gaagctgggt tggtagctgt taagtgcagt aagaggaaaa  
 2341 gtacaatatg cagacctagg agcggaaaac tggaaaacct tcagcaactt acatgatag  
 2401 tcatctagtc actcaaaagc ttttaggtat aagaggctga ctaaaagcaa tccaatctca  
 2461 tgccaaattc tattgtataa atctcgtctt aaaggccgaa aaaatcagcg ctgcacacgg  
 2521 actcattgtc accaccgctt acctaaaatc tactcagcgt cggcaaaagg gccatgggtt  
 2581 ctagcaacta acttacctgt tgaaattcga acaccocaaac aacttgttaa tatctattcg  
 2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtccctgcta cggactaggc  
 2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg  
 2761 atgcttcaac taacatgttg gcttgccggc gttcatgctc agaaaacagg ttgggacaag  
 2821 cacttccagg ctaacacagt cagaaatcga aacgtactct caacagttcg cttaggcatg  
 2881 gaagttttgc ggcattcttg ctacacaata acaagggaag acttactcgt ggcctgcaacc  
 2941 ctactagctc aaaatttatt cacacatggg tacgctttgg ggaaattatg aggggatcgc  
 3001 tctagagcga tccgggatct cgggaaaagc gttgtgtgacc aaagggtgct tttatcatca  
 3061 ctttaaaaat aaaaaacaat tactcagtgc ctgttataag cagcaattaa ttatgattga  
 3121 tgcctacatc acaacaaaaa ctgatttaac aaatgggttg tctgccttag aatgattatt  
 3181 tgaacattat cttgattata ttattgataa taataaaaaa cttatcccta tccaagaagt  
 3241 gatgcctatc attggttgga atgaacttga aaaaaattag ccttgaatac attactggta  
 3301 aggtaaacgc cattgtcagc aaattgatcc aagagaacca acttaaaagt ttctgacgg  
 3361 aatgtttaatt ctogttgacc ctgagcactg atgaatcccc taatgatttt ggtaaaaatc  
 3421 attaaagttta ggtggataca catcttgtca tatgatcccg gtaattgtga ttactcact  
 3481 cattaggcac cccaggcttt acactttatg ctccggctc gtatgttgtg tggaaattgtg  
 3541 agcggataac aatttcacac aggaacacgc tatgaccatg attacgcaa gcgcgcaatt  
 3601 aaccctcact aaagggaaca aaagctggag ctccaccgag gtggcgcccg ctctagaact  
 3661 agtggatccc ccgggcatac gattggctat tggccattgc atacgttgta tccatcatc  
 3721 aatatgtaca tttatattgg ctcatgtcca acattaccgc catgttgaca ttgattattg  
 3781 actagttatt aatagtaatc aattacgggg tcattagttc atagcccata tatggagttc  
 3841 cgcgttacat aacttacggt aaatggcccg cctggctgac cgcccaacga ccccgccca  
 3901 ttgacgtcaa taatgacgta tgttcccata gtaacgcaa tagggacttt ccattgacgt  
 3961 caatgggttg agtatttacg gtaaacgtgc cacttggcag tacatcaagt gtatcatatg  
 4021 ccaagtacgc cccctattga cgtcaatgac ggtaaattgg ccgcctggca ttatgccag  
 4081 tacatgacct tatgggactt tctacttggc cagtacatct acgtattagt catcgctatt  
 4141 accatggtga tgcggttttg gcagtacatc aatgggctgt gatagcgtt tgaactacgg  
 4201 ggatttccaa gtctccaccc cattgacgtc aatgggagtt tgttttggca ccaaaatcaa  
 4261 cgggactttc caaaatgtcg taacaactcc gccccattga cgcaaatggg cggtaggcgt  
 4321 gtacgggtggg aggtctatataaacagagct cgtttagtga accgtcagat cgcctggaga  
 4381 cgccatccac gctgttttga cctccataga agacaccggg accgatccag cctccgccc  
 4441 cgggaacggt gcattggaac gcggtattcc cgtgccaaga gtgacgtaag taccgcctat  
 4501 agactctata ggcacacccc tttggctctt atgcatgcta tactgttttt ggcttggggc  
 4561 ctatacacccc ccgcttccct atgctatagg tgatggtata gcttagccta taggtgtggg

4621 ttattgacca ttattgacca ctcccttatt ggtgacgata ctttccatta ctaatccata  
 4681 acatggctct ttgccacaac tatctctatt ggctatatgc caatactctg tccctcagag  
 4741 actgacacgg actctgtatt ttacacggat ggggtcccat ttattattha caaattcaca  
 4801 tatacaacaa cgccgtcccc cgtgcccga gtttttatta aacatagcgt gggatctcca  
 4861 cgcgaaatctc gggtagctgt tccggacatg ggctcttctc cggtagcgtc ggtgcttcca  
 4921 catccgagcc ctgggtcccat gcctccagcg gctcatggtc gctcggcagc tccctgtctc  
 4981 taacagtggg ggcagactt aggcacagca caatgcccac caccaccagt gtgcccagca  
 5041 aggcctgtgg ggtagggtat gtgtctgaaa atgagcgtgg agattgggct cgcacggctg  
 5101 acgcagatgg aagacttaag gcagcggcag aagaagatgc aggcagctga gttgtgtat  
 5161 tctgataaga gtcagaggta actcccgttg cgggtgctgtt aacgggtggag ggcagtgtag  
 5221 tctgagcagt actcgttgct gccgcgcgcg ccaccagaca taatagctga cagactaaca  
 5281 gactgttccct tcccatgggt cttttctgca gtcaccgtcg gatcaatggg cccatcgggt  
 5341 gcagcaagca tgggaattttg ttttgatgta ttcaaggagc tcaaagtcca ccatgccaat  
 5401 gagaacatct tctactgccc cattgcccac atgtcagctc tagccatgggt ataccctgggt  
 5461 gcaaaaagaca gcaccaggag acaataaata aaggttggtc gotttgataa acttccagga  
 5521 ttcggagaca gtattgaagc tcagtgtggc acatctgtaa acgttccactc ttcacttaga  
 5581 gacatcctca accaaatcac caaaccacaa gatgtttatt cgttcagcct tgccagttaga  
 5641 ctttatgctg aagagagata cccaatcctg ccagaatact tgcagtgtgt gaaggaactg  
 5701 tatagaggag gcttggaaac tatcaacttt caaacagctg cagatcaagc cagagagctc  
 5761 atcaattcct gggtagaaag tcagacaaat ggaattatca gaaatgtcct tcagccaagc  
 5821 tccgtggatt ctcaaactgc aatgggtctg gttaatgcca ttgtcttcaa aggactgtgg  
 5881 gagaaagcat ttaaggatga agacacacaa gcaatgcctt tcagagtgcac tgagcaagaa  
 5941 agcaaacctg tgcagatgat gtaccagatt ggtttattha gagtggcatc aatgcttct  
 6001 gagaaaatga agatcctgga gcttccattt gccagtggga caatgagcat gttgggtctg  
 6061 ttgctgatg aagtctcagg ccttgagcag cttgagagta taatcaactt tgaaaaactg  
 6121 actgaatgga ccagttctaa tggtaggaa gagagaagat caaagtgtac ttacctcgca  
 6181 tgaagatgga ggaataatc aacctcacat ctgtcttaat ggctatgggc attactgagc  
 6241 tgtttagctc ttcagccaat ctgtctggca atgaagcagg cagagaggtg gtagggtcag  
 6301 aagctgtcca tgcagcacat gcagaaaatca ctgaagcagg tagggctgac catccattcc  
 6361 cagaggctgg agtggatgct gcaagcgtct cgttctctct cttttggcag atgtgttcc  
 6421 tcttctgtat caagcacatc gcaaccacag ccggtctctt cttttggcag atgtgttcc  
 6481 cgccggccagc agatgacgca ccagcagatg acgcaccagc agatgacgca ccagcagatg  
 6541 acgcaccagc agatgacgca acaacatgta tcttgaaagg ctcttggtgc tggatcgggc  
 6601 tgcgtggatga cgtgacaaa tttgtgaacc aacacctgtg cggctcacac ctggtggaag  
 6661 ctctctacct agtgtgcggg gaacgaggct tcttctacac acccaagacc cgcggggagg  
 6721 cagaggacct gcaggtgggg caggtgggagc tggggcgggg ccctgggtgca ggcagcctgc  
 6781 agcccttggc cctggagggg tccctgcaga agcgtggcat tgtggaacaa tgcgtacca  
 6841 ccatctgctc cctctaccag ctggagaact actgcaacta gggcgccctaa agggcggaatt  
 6901 atcgcggccg ctctagacca ggcgcctgga tccagatcac ttctggctaa taaaagatca  
 6961 gagctctaga gatctgtgtg ttggtttttt gtggatctgc tgtgccttct agttgccagc  
 7021 catctgttgt ttgcccctcc cccgtgcctt ccttgacctt ggaaggtgoc actcccactg  
 7081 tcccttcccta ataaaatgag gaaattgcat cgcattgtct gagttaggtc cattctattc  
 7141 tgggggggtg ggtggggcag cacagcaagg gggaggattg ggaagacaat agcaggcatg  
 7201 ctggggatgc ggtgggctct atgggtacct ctctctctct ctctctctct ctcactctct  
 7261 ctctctctcg gtacctctcc tcgagggggg gcccggtacc caattcgccc tatagttagt  
 7321 cgtattacgc gcgctcactg gccgtcggtt tacaacgtcg tgactgggaa aaccctggcg  
 7381 ttacccaact taatcgctt gcagcacatc ccccttctgc cagctggcgt aatagcgaa  
 7441 aggcgcgcac cgtatcgccct tcccaacagt tgcgcagcct gaatggcgaa tggaaattgt  
 7501 aagcgttaat attttgttaa aattcgcggt aaatttttgt taaatcagct cattttttaa  
 7561 ccaataggcc gaaatcgga aaatccctta taaatcaaaa gaatagaccg agatagggtt  
 7621 gagtgttgtt ccagtttggg acaagagtcc actattaaag aacgtggact ccaacgtcaa  
 7681 agggcgaaaa accgtctatc agggcgatgg ccactactc cgggatcata tgacaagatg  
 7741 tgtatccacc ttaacttaat gatttttacc aaaatcatta ggggattcat cagtgtcag  
 7801 ggtcaacgag aattaacatt ccgtcaggaa agcttatgat gatgatgtgc ttaaaaaactt  
 7861 actcaatggc tggttatgca tatcgcaata catgcgaaaa acctaaaaaga gcttgccgat  
 7921 aaaaaaggcc aatttattgc tatttaccgc ggctttttat tgagcttgaa agataaataa  
 7981 aatagatagg ttttatttga agctaaatct tctttatcgt aaaaaatgcc ctcttgggtt  
 8041 atcaagaggg tcattatatt tcgcggaata acatcatttg gtgacgaaat aactaagcac  
 8101 ttgtctctcg tttactcccc tgagcttgag gggtaacat gaaggtcatc gatagcagga  
 8161 taataatata gtaaaacgct aaaccaataa tccaaatcca gccatcccaa attggtagtg  
 8221 aatgattata aataacagca aacagtaatg ggccaataac accggttgca ttggttaaggc  
 8281 tcaccaataa tccctgtaaa gcaocttgct gatgactctt tgtttggcta gacatcactc  
 8341 cctgtaatgc aggtaaagcg atcccaccac cagccaataa aattaaaaca gggaaaacta  
 8401 accaaccttc agatataaac gctaaaaagg caaatgcact actatctgca ataaatccga  
 8461 gcagtactgc cgtttttctg cccatttagt ggctattctt cctgccacaa aggcttgga  
 8521 tactgagtgt aaaagaccaa gaccgtaat gaaaagccaa ccatatgctc attcatcctc  
 8581 acgatttctg taatagcacc acaccgtgct ggattggcta tcaatgcgct gaaataataa  
 8641 tcaacaaatg gcatcgtaa ataagttagt tataccgata agcttttgtt ccccttagtg

5 8701 aggggttaatt gcgcgcttgg cgtaatcatg gtcataagctg tttcctgtgt gaaattgtta  
 8761 tccgctcaca attccacaca acatacagagc cggaagcata aagtgtaaag cctgggggtgc  
 8821 ctaatgagtg agctaactca cattaattgc gttgcgctca ctgcccgctt tccagtcggg  
 8881 aaacctgtcg tgccagctgc attaatgaat cggccaacgc ggggggagag gcgggttgcg  
 8941 tattggggcgc tcttcgcgctt cctcgtcac tgactcgtg cgctcggtcg ttcggctgcg  
 9001 gcgagcggtg tcagctcact caaaggcggt aatacgggta tccacagaat caggggataa  
 9061 cgagggaaag aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta aaaaggccgc  
 9121 gttgctggcg tttttccata ggctccgccc ccctgacgag catcacaaaa atcgacgctc  
 9181 aagtcagagg tggcgaaacc cgacaggact ataaagatac caggcgtttc ccctggaaag  
 10 9241 ctccctcgtg cgctctcctg ttccgaccct gccgcttacc ggatacctgt ccgctttct  
 9301 cccttcggga agcgtggcgc tttctcatag ctacgctgt aggtatctca gttcgggtga  
 9361 ggtcgcttcgc tccaagctgg gctgtgtgca cgaaccccc gtccagcccg accgctgcgc  
 9421 cttatccggt aactatcgtc ttgagtcctaa ccgggtaaga cagcacttat cggcactggc  
 9481 agcagccact ggtaacagga ttagcagagc gaggtatgta ggcggtgcta cagagttctt  
 15 9541 gaagtgggtg cctaactacg gctacactag aaggacagta ttgggtatct gcgctcgtc  
 9601 gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac aaaccaccgc  
 9661 tggtagcggg ggtttttttg tttgcaagca gcagattacg cgagaaaaa aaggtatcta  
 9721 agaagatcct ttgatctttt ctacggggtc tgacgctcag tggaaacgaaa actcacgtta  
 9781 agggattttg gtcatgagat tatcaaaaag gatcttcacc tagatccttt taaattaaaa  
 20 9841 atgaagtttt aaatcaatct aaagtatata tgagtaaaact tggcttgaca gttaccaatg  
 9901 cttaatcagt gaggcaccta tctcagcgat ctgtctatct cgttcatcca tagttgcctg  
 9961 actccccgtc gtgtagataa ctacgatagc ggagggtcta ccatctggcc ccagtgctgc  
 10021 aatgataccg cgagacccac gctcacccgc tccagattta tcagcaataa accagccagc  
 10081 cggaaggggc gagcgagaa gtggtcctgc aactttatcc gcctccatcc agtctattaa  
 25 10141 ttgttgccgg gaagctagag taagtagttc gccagttaat agtttgcgca acgttggtgc  
 10201 cattgctaca ggcacgtgg tgacacgtc gtggtttgg atggcttcat tcagctccgg  
 10261 tccccacga tcaaggcgag ttacatgac cccatgttg tgcaaaaaa cgggttagctc  
 10321 cttcggctct ccgatcgttg tcagaagtaa gttggccgca gtgttatcac tcatggttat  
 10381 ggcagcactg cataattctc ttactgtcat gccatccgta agatgctttt ctgtgactgg  
 30 10441 tgagtactca accaagtcac tctgagaata gtgtatgcgg cgaccgagtt gctcttgccc  
 10501 ggcgtcaata cgggataata ccgcgccaca tagcagaact ttaaaagtgc tcatcattgg  
 10561 aaaacgttct tcggggcgaa aactctcaag gatcttacg ctgttgagat ccagttcgat  
 10621 gtaaccact cgtgcacca actgatcttc agcatctttt actttcacca gcgtttctgg  
 10681 gtgagcaaaa acagggaagg aaaaagggc aaaaagggga ataaggcgca cagggaatg  
 35 10741 ttgaatactc atactcttcc tttttcaata ttattgaagc atttatcagg gttattgtct  
 10801 catgagcgga tacatatttg aatgtattta gaaaaataaa caaatagggg ttccgcgcac  
 10861 atttcccgga aaagtgcac

40 SEQ ID NO:48 (cecropin prepro)

AAT TTC TCA AGG ATA TTT  
 TTC TTC GTG TTC GCT TTG  
 GTT CTG GCT TTG TCA ACA  
 GTT TCG GCT GCG CCA GAG  
 45 CCG AAA

SEQ ID NO:49 (cecropin prepro extended)

AAT TTC TCA AGG ATA TTT  
 50 TTC TTC GTG TTC GCT TTG  
 GTT CTG GCT TTG TCA ACA  
 GTT TCG GCT GCG CCA GAG  
 CCG AAA TGG AAA GTC TTC  
 AAG

55

SEQ ID NO:50 (cecropin pro)

GCG CCA GAG CCG AAA

60

SEQ ID NO:51 (cecropin pro extended)  
 GCG CCA GAG CCG AAA TGG AAA GTC TTC AAG

65 SEQ ID NO:52 (a Kozak sequence)  
 ACCATGT

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/41335

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/00, 15/63; C12P 21/00; A01K 67/027

US CL : 435/320.1, 455; 800/4, 7, 13, 14, 19, 21

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1, 455; 800/4, 7, 13, 14, 19, 21

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
WEST, STN, MEDLINE, CAPLUS BIOSIS, SCISEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HORN et al. A Versatile Vector Set for Animal Transgenesis. Development Genes and Evolution. 2000, Vol. 210, No. 12, pages 630-637, especially abstract, introduction.	1-20, 23-28
A	EGGLESTON et al. A sensitive and Rapid Assay for Homologous Recombination in Mosquito Cells: Impact of Vector Topology and Implications for Gene Targeting. BMC Genetics. 17 December 2001, Vol. 2, No. 21, <a href="http://www.biomedcentral.com/1471-2156">http://www.biomedcentral.com/1471-2156</a> , online, pages 1-9, especially background, materials and methods.	1-20, 23-28
A	WO 01/71019 A1 (SAVAKIS et al.) 27 September 2001 (27.09.2001), especially, pages 10, 11, 27, 31.	1-20, 23-28

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

07 October 2004 (07.10.2004)

Date of mailing of the international search report

03 NOV 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Shin-Lin Chen  
Telephone No. 571-272-1600

## INTERNATIONAL SEARCH REPORT

PCT/US03/41335

**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim Nos.: 21, 22  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest** ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.